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General introduction
1
GEnErAl inTrODUcTiOn
Worldwide, there has been a remarkable increase in the incidence of esophageal cancer, 
and presently it is the eight most common cancer and the sixth most common cancer 
related death in the world.1 Primarily esophageal cancer is composed of two histological 
subtypes, esophageal adenocarcinoma (EAC) and squamous cell carcinoma (SCC). The 
increase in incidence is mainly attributed to an increase in EAC, especially in Western 
countries. 2-5 For example, in the Netherlands the incidence of EAC has increased from 
819 new patients in 1990 to 1,740 new patients in 2014, while the incidence of SCC has 
roughly remained stable (www.cijfersoverkanker.nl) (Figure 1). 
It is generally accepted that the premalignant lesion Barrett’s esophagus (BE) is the major 
risk factor for EAC, in addition to age, male gender, Caucasian ethnicity, smoking, and obe-
sity.6-8 As a consequence of chronic gastroesophageal reflux (GER), the normal squamous 
epithelium of the lower esophagus can be replaced by columnar intestinal cells, including 
goblet cells, representing BE. The risk of developing EAC from BE is estimated at 0.12-0.5% 
per year9,10 and follows a multimorphological sequence, in which metaplasia evolves to 
low-grade dysplasia (LGD), high-grade dysplasia (HGD) and ultimately into invasive adeno-
carcinoma.11 (Figure 2) 
EACs are typically diagnosed in white males with a median age of 70 years.4 The most 
common symptom patients present with is dysphagia. Since dysphagia generally ap-
pears when the tumor has obtained already a significant size, patients frequently pres-
ent with an advanced stage of disease. Hence, less than half of the newly diagnosed 
figure 1: Incidence of esophageal cancer in the Netherlands (1990-2014)
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patients, with limited locally advanced disease, are qualified for curative therapy, i.e. 
neoadjuvant chemoradiation (nCRT) followed by surgery. This combined treatment 
with curative intent results in a 5-year overall survival of approximately 50%.12,13 A small 
proportion of patients with curable disease, however unfit for surgery are treated with 
definitive chemoradiation.14 The remaining patients are not eligible for curative therapy 
and are therefore indicated for palliative treatment with chemotherapy, radiotherapy, 
endoscopic interventions (stent placement) and/or best supportive care,14-16 resulting in 
a 2-year relative survival of nine percent.4 Tumor staging is based on the tumor-node-
metastasis (TNM) classification developed by the American Joint Committee on Cancer 
(AJCC), which takes into account the depth of tumor invasion, lymph node status, and 
the presence or absence of distant metastatic disease.17
Since the prognosis of advanced EAC is poor, patients diagnosed with BE are subjected to 
intensive endoscopic surveillance to identify patients with neoplastic progression in an 
early and curable stage. Current guidelines recommend endoscopic surveillance every 
3-5 years in patients with non-dysplastic BE, every 6-12 months in patients with LGD and 
(endoscopic) treatment in patients with established HGD.18 The histological diagnosis 
of LGD is currently the only accepted predictor for neoplastic progression, although 
it is hampered by sampling error and considerable interobserver variation. The cost-
effectiveness of BE surveillance is under discussion given the relatively high prevalence 
of BE in the general population estimated at two percent,19,20 the overall low incidence 
of neoplastic progression,9,10 and the lack of discriminative tests for risk stratification. The 
figure 2: Multimorphological sequence of the development of esophageal adenocarcinoma
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1identification of additional risk factors, such as oncological biomarkers, might support the rationale for a BE surveillance program. 
To identify oncological biomarkers that could serve as markers for risk stratification or 
as a target for therapy, an improved understanding of the molecular signature of BE and 
EAC is required. Therefore, there is a great urgency to clarify the genetic landscape of 
EAC. The availability of next-generation sequencing (NGS) has enabled examination of 
the genomes of human cancers at an exceptional scale. Large NGS studies on BE and 
EAC identified a broad mutational spectrum, with mutations most frequently discovered 
in the genes: TP53, SYNE1,21-24 CDKN2A, SMAD4, PIK3CA,23 ARID1A.21,23,24 While, alterations 
in the TP53 gene occur in the majority (approximately 75%) of EAC cases, and even an 
association between TP53 overexpression and an increased risk of developing EAC has 
been suggested,25,26 only few other somatic alterations are shared between patients with 
EAC, representing substantial intertumor heterogeneity, which makes the discovering 
of a set of ubiquitous oncological biomarkers for EAC challenging. In addition, other 
studies suggest that even an extensive molecular variation is present within individual 
tumors, termed intratumor heterogeneity. For example, multiregion sequencing of 
clear-cell renal cell carcinomas revealed that 63-69% of the somatic mutations were 
heterogeneous and thus not detectable in every sequenced tumor region. Conceivably, 
intratumor heterogeneity may lead to an underestimation of the mutational spectrum 
of a tumor when using a single biopsy procedure and may present major challenges to 
personalized medicine and biomarker development.27 Although the extent of intratumor 
heterogeneity in EAC has to be resolved, it might explain the difficulties in finding and 
validating clinically valuable oncological biomarkers.
To avoid the possible consequence of inter- and intratumor heterogeneity in the search 
for oncological biomarkers, patient specific biomarkers can be considered. Assessing the 
individual genetic susceptibility can help identifying high risk patients for malignant 
progression. From this perspective, the identification of single nucleotide polymor-
phisms (SNPs) is promising for identifying patients susceptible for invasive carcinoma. 
Recently, few genome-wide association studies (GWAS) were performed on BE and EAC 
samples. These studies revealed several SNPs to be associated with BE: rs9936833 (FOXF1), 
rs9257809 (MHC),28 rs3072 (GDF7), and rs2701108 (TBX5).29 Three SNPs were also found to 
be associated with EAC: rs10419226 (CRTC1), rs11789015 (BARX1), and rs2687201 (FOXP1). 
In addition, rs9936833 (FOXF1), previously associated with BE, was also associated with 
EAC, as well as the SNPs: rs2178146 and rs3111601 also located in FOXF1.30 The identi-
fication of these SNPs provide evidence that the etiology of BE and EAC has a genetic 
component, although the exact role for SNPs has remained undisclosed. Inference of the 
underlying genes must be undertaken cautiously, and validation studies are required. 
Chapter 1
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Another observation supporting the application of genetics in clinical decision-making 
is the reportedly increased risk for BE and EAC in patients with a positive family history. 
Although the vast majority of BE and EAC cases are sporadic and caused by somatic 
mutations, several families have been identified with clustering of BE and EAC. Previous 
studies introduced the definition familial BE (FBE), i.e. two or more first- or second-degree 
family members diagnosed with BE or EAC. It has been estimated that approximately 
seven percent of BE and EAC cases are considered familial.31-33 Of all cancer types approxi-
mately five percent is caused by inherited factors. Regarding the concepts of inheritance, 
these familial cancer syndromes can be categorized as follows:
a) Autosomal dominant inheritance, in which a heterozygous germline mutation in-
herited from one of the parents, causes the cancer syndrome. For example, Multiple 
Endocrine Neoplasia Type 2 (MEN2) syndrome caused by a heterozygous germline 
mutation in the proto-oncogene RET.34  
b) Autosomal recessive inheritance, which requires biallelic germline mutations inher-
ited from both parents. For instance, biallelic germline mutations in MMR genes lead 
to constitutional mismatch repair-deficiency (CMMR-D).35,36
c) Biallelic inactivation of a tumor suppressor gene caused by one germline mutation 
inherited from one parent followed by a somatic second inactivating mutation in the 
wild type allele, based on the concept of the “Knudsons two hit” hypothesis (Figure 
3) as described e.g. Lynch Syndrome (mismatch repair genes MLH1, MSH2, MSH6, 
PMS2)37,38 in familial adenomatous polyposis (APC),39-41 hereditary breast and ovarian 
cancer (BRCA1/BRCA2),42,43 familial atypical multiple mole melanoma (P16),44  and Li-
Fraumeni syndrome (TP53).45,46
It can be hypothesized that the initiation of BE and EAC in several members of one family 
is caused by the presence of one or more inherited factors. The pattern of inheritance of 
most familial cancer syndromes is based on the concept of “Knudsons two hit” hypoth-
esis, causing a phenotypic dominant inheritance pattern. It is likely that development of 
familial BE is caused by an inherited germline mutation in a (unknown) tumor suppressor 
gene followed by a somatic second inactivating mutation in the wild type allele causing 
biallelic inactivation. 
Familial patients with BE and EAC are mostly diagnosed at a younger age,32,33,47 which is in 
line with the presence of a germline mutation in a cancer-predisposing gene. However, of 
all patients diagnosed with EAC, regardless of the family history, a certain proportion of 
the patients are also diagnosed at a younger age, and since the rise in incidence has oc-
curred among all age groups, EAC is no longer a disease exclusively of the elderly (www.
cijfersoverkanker.nl), while the treating protocols are still based on the average cohort of 
EAC patients aged 70 years.3 The effect of age on disease stage and survival of patients 
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1with EAC is controversial 
48-54 probably due to use of different definitions of young age, 
as well as the restriction of surgically treated EAC patients included in the studies. It can 
be anticipated that young EAC patients have a different clinical presentation as well as a 
different etiology of their tumor.
Aims of the thesis
Esophageal cancer has traditionally been considered a sporadic disease of the elderly. 
However, recently it has become increasingly clear that this type of cancer comprises 
a relatively heterogeneous population of patients, including sporadic, hereditary or 
exceptionally young aged EAC cases. For these subgroups of patients with EAC, informa-
tion regarding the clinicopathological characteristics, patient-tailored treatments and 
prognosis is currently lacking. It can be hypothesized that the molecular biology of these 
subgroups is distinct from a “conventional” EAC patient. Hence, the aim of this thesis was 
to elucidate the molecular biology of EAC by performing standard molecular analysis, 
i.e. whole-exome sequencing, targeted sequencing and Sanger sequencing on sporadic, 
familial and young EAC cases. As well as to describe the clinicopathological features of 
the familial and young subpopulations of EAC.
figure 3: “Knudsons two hit” hypothesis
A) Most hereditary cancer syndromes are caused by an inherited germline mutation in a tumor suppressor 
gene followed by a somatic second inactivating mutation in the wild type allele. B) Most of the non-heredi-
tary cancers are caused by two successive somatic mutations in a tumor suppressor gene.
Chapter 1
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Outline of the thesis
Besides a general introduction (Part I, chapter 1) and a general discussion (Part V, chapter 
10) this thesis is divided into three major parts: Part II: Molecular analysis of sporadic 
esophageal adenocarcinoma. Part III: Familial clustering of esophageal adenocarcinoma. 
Part IV: Young patients with esophageal adenocarcinoma.
Part II: Molecular analysis of sporadic esophageal adenocarcinoma
Besides the substantial intertumor heterogeneity identified in EACs by NGS, intratumor 
heterogeneity has been noticed in several other cancer types. In chapter 2 the extent of 
intratumor heterogeneity in EACs is investigated. Based on the results of previous NGS 
studies on EACs, a panel of frequently mutated genes is designed and multiregional, tar-
geted sequencing is performed on multiple tumor regions obtained from several EACs. 
As a consequence of intratumor heterogeneity the mutational spectrum of a tumor will 
be underrepresented, challenging the discovery of oncological biomarkers in EACs even 
more. Hotspot mutations in the promoter region of the TERT gene have been described 
in several cancer types. In chapter 3 the occurrence of TERT promoter mutations in EAC 
is evaluated. Besides tumor specific biomarkers, patient specific biomarkers can be 
promising as well. SNPs, for example, can be helpful by identifying high risk patients 
for developing EAC from BE. In chapter 4 the results of a validation study are presented, 
and the association between SNPs and the risk of EAC is studied in an independent 
case–control study. 
Part III: Familial clustering of esophageal adenocarcinoma
Although the vast majority of BE and EAC cases are sporadic and caused by somatic 
mutations, over the last decades several families have been identified with clustering of 
BE and EAC. In chapter 5 an overview is given of the occurrence and characteristics of 
patients from families with clustering of EAC. It can be hypothesized that the develop-
ment of BE and EAC in more than two members of one family is caused by the presence 
of a germline defect. In chapter 6 a family is described with clustering of BE and EAC, in 
which the germline DNA of an indicated index-patient is investigated by whole-exome 
sequencing and SNP array. In addition, potential germline variants are validated on 
germline and tumor DNA of the affected family members on a NGS platform.
Part IV: Young patients with esophageal adenocarcinoma.
Although EACs were previously thought to be a disease of the elderly, a small but clini-
cally relevant group of younger patients suffering from EAC exists. The effect of age on 
disease stage and prognosis is controversial. In chapter 7 and chapter 8 the differences 
in clinicopathological characteristics, treatment and outcome between esophageal 
cancer patients (EAC and SCC) aged 50 years or younger and patients older than 
21
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150 years are evaluated in a retrospective analysis of a single center cohort study and a population-based study, respectively. Since it has been generally accepted that the 
transformation of a normal cell into a malignant cell and subsequently the outgrowth 
into a clinically manifest lesion takes several decades, it can be anticipated that cancers in 
young patients have gone through an accelerated transformation process. Hence, it can 
be hypothesized that esophageal cancer in young patients is a disease distinct from that 
in older patients. In chapter 9 the differences in molecular biology, i.e. mutational load 
and profile, between young and older EAC patients aredescribed.
Finally, chapter 10 includes a general discussion and the future perspectives, chapter 11 
is a summary of this thesis.
Chapter 1
22
rEfErEncEs
 1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
 2. Bosetti C, Levi F, Ferlay J, et al: Trends in oesophageal cancer incidence and mortality in Europe. Int 
J Cancer 122:1118-29, 2008
 3. Brown LM, Devesa SS, Chow WH: Incidence of adenocarcinoma of the esophagus among white 
Americans by sex, stage, and age. J Natl Cancer Inst 100:1184-7, 2008
 4. Dikken JL, Lemmens VE, Wouters MW, et al: Increased incidence and survival for oesophageal 
cancer but not for gastric cardia cancer in the Netherlands. Eur J Cancer 48:1624-32, 2012
 5. Thrift AP, Whiteman DC: The incidence of esophageal adenocarcinoma continues to rise: analysis 
of period and birth cohort effects on recent trends. Ann Oncol 23:3155-62, 2012
 6. Cameron AJ: Epidemiology of columnar-lined esophagus and adenocarcinoma. Gastroenterol 
Clin North Am 26:487-94, 1997
 7. Falk GW: Risk factors for esophageal cancer development. Surg Oncol Clin N Am 18:469-85, 2009
 8. Kubo A, Corley DA: Body mass index and adenocarcinomas of the esophagus or gastric cardia: a 
systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 15:872-8, 2006
 9. Bhat S, Coleman HG, Yousef F, et al: Risk of malignant progression in Barrett’s esophagus patients: 
results from a large population-based study. J Natl Cancer Inst 103:1049-57, 2011
 10. Hvid-Jensen F, Pedersen L, Drewes AM, et al: Incidence of adenocarcinoma among patients with 
Barrett’s esophagus. N Engl J Med 365:1375-83, 2011
 11. Jankowski JA, Wright NA, Meltzer SJ, et al: Molecular evolution of the metaplasia-dysplasia-
adenocarcinoma sequence in the esophagus. Am J Pathol 154:965-73, 1999
 12. Shapiro J, van Lanschot JJ, Hulshof MC, et al: Neoadjuvant chemoradiotherapy plus surgery versus 
surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised 
controlled trial. Lancet Oncol 16:1090-8, 2015
 13. van Hagen P, Hulshof MC, van Lanschot JJ, et al: Preoperative chemoradiotherapy for esophageal 
or junctional cancer. N Engl J Med 366:2074-84, 2012
 14. Wong RK, Malthaner RA, Zuraw L, et al: Combined modality radiotherapy and chemotherapy in 
nonsurgical management of localized carcinoma of the esophagus: a practice guideline. Int J 
Radiat Oncol Biol Phys 55:930-42, 2003
 15. Sreedharan A, Harris K, Crellin A, et al: Interventions for dysphagia in oesophageal cancer. Co-
chrane Database Syst Rev:CD005048, 2009
 16. Yakoub D, Fahmy R, Athanasiou T, et al: Evidence-based choice of esophageal stent for the pallia-
tive management of malignant dysphagia. World J Surg 32:1996-2009, 2008
 17. Edge SB, Compton CC: The American Joint Committee on Cancer: the 7th edition of the AJCC 
cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471-4, 2010
 18. Wang KK, Sampliner RE, Practice Parameters Committee of the American College of G: Updated 
guidelines 2008 for the diagnosis, surveillance and therapy of Barrett’s esophagus. Am J Gastroen-
terol 103:788-97, 2008
 19. Rex DK, Cummings OW, Shaw M, et al: Screening for Barrett’s esophagus in colonoscopy patients 
with and without heartburn. Gastroenterology 125:1670-7, 2003
 20. Ronkainen J, Aro P, Storskrubb T, et al: Prevalence of Barrett’s esophagus in the general population: 
an endoscopic study. Gastroenterology 129:1825-31, 2005
 21. Agrawal N, Jiao Y, Bettegowda C, et al: Comparative genomic analysis of esophageal adenocarci-
noma and squamous cell carcinoma. Cancer Discov 2:899-905, 2012
23
General introduction
1
 22. Chong IY, Cunningham D, Barber LJ, et al: The genomic landscape of oesophagogastric junctional 
adenocarcinoma. J Pathol 231:301-10, 2013
 23. Dulak AM, Stojanov P, Peng S, et al: Exome and whole-genome sequencing of esophageal ad-
enocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 45:478-86, 
2013
 24. Streppel MM, Lata S, DelaBastide M, et al: Next-generation sequencing of endoscopic biopsies 
identifies ARID1A as a tumor-suppressor gene in Barrett’s esophagus. Oncogene 33:347-57, 2014
 25. Kastelein F, Biermann K, Steyerberg EW, et al: Aberrant p53 protein expression is associated with 
an increased risk of neoplastic progression in patients with Barrett’s oesophagus. Gut 62:1676-83, 
2013
 26. Sikkema M, Kerkhof M, Steyerberg EW, et al: Aneuploidy and overexpression of Ki67 and p53 as 
markers for neoplastic progression in Barrett’s esophagus: a case-control study. Am J Gastroen-
terol 104:2673-80, 2009
 27. Gerlinger M, Rowan AJ, Horswell S, et al: Intratumor heterogeneity and branched evolution re-
vealed by multiregion sequencing. N Engl J Med 366:883-92, 2012
 28. Su Z, Gay LJ, Strange A, et al: Common variants at the MHC locus and at chromosome 16q24.1 
predispose to Barrett’s esophagus. Nat Genet 44:1131-6, 2012
 29. Palles C, Chegwidden L, Li X, et al: Polymorphisms near TBX5 and GDF7 are associated with in-
creased risk for Barrett’s esophagus. Gastroenterology 148:367-78, 2015
 30. Levine DM, Ek WE, Zhang R, et al: A genome-wide association study identifies new susceptibility 
loci for esophageal adenocarcinoma and Barrett’s esophagus. Nat Genet 45:1487-93, 2013
 31. Ash S, Vaccaro BJ, Dabney MK, et al: Comparison of endoscopic and clinical characteristics of 
patients with familial and sporadic Barrett’s esophagus. Dig Dis Sci 56:1702-6, 2011
 32. Chak A, Ochs-Balcom H, Falk G, et al: Familiality in Barrett’s esophagus, adenocarcinoma of the 
esophagus, and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers 
Prev 15:1668-73, 2006
 33. Verbeek RE, Spittuler LF, Peute A, et al: Familial clustering of Barrett’s esophagus and esophageal 
adenocarcinoma in a European cohort. Clin Gastroenterol Hepatol 12:1656-63 e1, 2014
 34. Mulligan LM, Kwok JB, Healey CS, et al: Germ-line mutations of the RET proto-oncogene in mul-
tiple endocrine neoplasia type 2A. Nature 363:458-60, 1993
 35. Ricciardone MD, Ozcelik T, Cevher B, et al: Human MLH1 deficiency predisposes to hematological 
malignancy and neurofibromatosis type 1. Cancer Res 59:290-3, 1999
 36. Wang Q, Lasset C, Desseigne F, et al: Neurofibromatosis and early onset of cancers in hMLH1-
deficient children. Cancer Res 59:294-7, 1999
 37. Aaltonen LA, Peltomaki P, Leach FS, et al: Clues to the pathogenesis of familial colorectal cancer. 
Science 260:812-6, 1993
 38. Ionov Y, Peinado MA, Malkhosyan S, et al: Ubiquitous somatic mutations in simple repeated 
sequences reveal a new mechanism for colonic carcinogenesis. Nature 363:558-61, 1993
 39. Groden J, Thliveris A, Samowitz W, et al: Identification and characterization of the familial adeno-
matous polyposis coli gene. Cell 66:589-600, 1991
 40. Kinzler KW, Nilbert MC, Su LK, et al: Identification of FAP locus genes from chromosome 5q21. 
Science 253:661-5, 1991
 41. Nishisho I, Nakamura Y, Miyoshi Y, et al: Mutations of chromosome 5q21 genes in FAP and colorec-
tal cancer patients. Science 253:665-9, 1991
 42. Hall JM, Lee MK, Newman B, et al: Linkage of early-onset familial breast cancer to chromosome 
17q21. Science 250:1684-9, 1990
Chapter 1
24
 43. Wooster R, Neuhausen SL, Mangion J, et al: Localization of a breast cancer susceptibility gene, 
BRCA2, to chromosome 13q12-13. Science 265:2088-90, 1994
 44. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al: Assignment of a locus for familial melanoma, 
MLM, to chromosome 9p13-p22. Science 258:1148-52, 1992
 45. Malkin D, Li FP, Strong LC, et al: Germ line p53 mutations in a familial syndrome of breast cancer, 
sarcomas, and other neoplasms. Science 250:1233-8, 1990
 46. Srivastava S, Zou ZQ, Pirollo K, et al: Germ-line transmission of a mutated p53 gene in a cancer-
prone family with Li-Fraumeni syndrome. Nature 348:747-9, 1990
 47. Drovdlic CM, Goddard KA, Chak A, et al: Demographic and phenotypic features of 70 families 
segregating Barrett’s oesophagus and oesophageal adenocarcinoma. J Med Genet 40:651-6, 2003
 48. Cen P, Banki F, Cheng L, et al: Changes in age, stage distribution, and survival of patients with 
esophageal adenocarcinoma over three decades in the United States. Ann Surg Oncol 19:1685-91, 
2012
 49. Hashemi N, Loren D, DiMarino AJ, et al: Presentation and prognosis of esophageal adenocarci-
noma in patients below age 50. Dig Dis Sci 54:1708-12, 2009
 50. Markar SR, Karthikesalingam A, Low DE: Outcomes assessment of the surgical management of 
esophageal cancer in younger and older patients. Ann Thorac Surg 94:1652-8, 2012
 51. Mehta SP, Bailey D, Davies N: Comparative outcome of oesophagogastric cancer in younger pa-
tients. Ann R Coll Surg Engl 92:515-8, 2010
 52. Oezcelik A, Ayazi S, DeMeester SR, et al: Adenocarcinoma of the esophagus in the young. J Gastro-
intest Surg 17:1032-5, 2013
 53. Portale G, Peters JH, Hsieh CC, et al: Esophageal adenocarcinoma in patients < or = 50 years old: 
delayed diagnosis and advanced disease at presentation. Am Surg 70:954-8, 2004
 54. Yoon HY, Kim CB: Gastroesophageal junction adenocarcinoma of young patients who underwent 
curative surgery: a comparative analysis with older group. Surg Today 41:203-9, 2011


parT ii
MOLECULAR ANALYSIS OF SPORADIC 
ESOPHAGEAL ADENOCARCINOMA

Chapter 2
Molecular clonality analysis of 
esophageal adenocarcinoma 
by multiregion sequencing 
of tumor samples
Anna M.J. van Nistelrooij
Ronald van Marion
Linetta B. Koppert
Katharina Biermann
Manon C.W. Spaander
Hugo W. Tilanus
J. Jan B. van Lanschot
Bas P.L. Wijnhoven
Winand N.M. Dinjens
Submitted for publication
Chapter 2
30
AbsTrAcT
background: Intratumor heterogeneity has been demonstrated in several cancer types, 
following a model of branched evolution. It is unknown to which extent intratumor het-
erogeneity is applicable to esophageal adenocarcinoma. Therefore, the aim of this study 
was to characterise intratumor heterogeneity in esophageal adenocarcinoma.
Methods: Multiregional targeted sequencing of four commonly altered genes was per-
formed on 19 tumor regions collected from five esophageal adenocarcinomas. Altera-
tions were classified as homogeneous or heterogeneous based on mutational and loss 
of heterozygosity analysis.
results: Identical TP53 mutations and homogeneously loss of heterozygosity of the TP53 
locus were identified in all separated tumor regions in each of five adenocarcinomas, and 
in the corresponding Barrett’s esophagus and tumor positive lymph node of one primary 
tumor.  Loss of heterozygosity of the P16 locus was homogeneous among all tumor 
regions in four adenocarcinomas, and an identical pattern of loss of heterozygosity was 
present in the Barrett’s esophagus. Loss of heterozygosity of the SMAD4 and APC loci was 
observed in a heterogeneous pattern.
conclusion: Known driver alterations, such as TP53 and P16 are homogeneously pres-
ent within each adenocarcinoma, and therefore occur early during carcinogenesis and 
subsequently clonally expand throughout the entire tumor. However, loss of heterozy-
gosity of the SMAD4 and APC loci shows a heterogeneous pattern, indicating intratumor 
heterogeneity of esophageal adenocarcinoma.
31
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2
inTrODUcTiOn
The incidence of esophageal adenocarcinoma (EAC) has been rising rapidly in Western 
countries over the last decades.1-3 The major risk factor for EAC is Barrett’s esophagus 
(BE),4 a premalignant condition, in which the normal squamous epithelium of the distal 
esophagus has been replaced by columnar epithelium, including goblet cells. The risk of 
developing EAC from BE is estimated at 0.12-0.5% per year and follows a multimorpho-
logical sequence, in which metaplasia evolves into low-grade dysplasia (LGD), high-grade 
dysplasia (HGD) and ultimately into EAC.5-7 
Previous results from whole-exome/genome sequencing of EACs demonstrated that 
these tumors bear a broad mutational spectrum, genes frequently altered are e.g. TP53, 
P16, SMAD4 and APC.8-10  Alterations in the TP53 gene occur in the majority of EAC cases, 
however, only few other somatic alterations are shared between EACs, representing sub-
stantial intertumor heterogeneity. In addition, emerging evidence suggests that even 
an extensive molecular variation is present within individual tumors, termed intratumor 
heterogeneity.11-13 
With the use of next-generation sequencing, intratumor heterogeneity has been dem-
onstrated in several cancer types and even a model of branched evolution leading to 
intratumor heterogeneity has been advocated.12,14 This model implicates that a single 
biopsy may not represent the total mutational burden of a tumor, which can explain the 
heterogeneous mutational spectrum described in EACs.8 Conceivably, intratumor het-
erogeneity may lead to an underestimation of the mutational spectrum of a tumor using 
a single biopsy procedure, which might clarify the difficulties in finding and validating 
clinically valuable oncological biomarkers.
To date it is unknown to which extent this model of branched evolution for intratumor 
heterogeneity is applicable to EAC. Therefore, the aim of this study was to characterize 
intratumor heterogeneity in EAC, by multiregional targeted sequencing on a total of 19 
tumor regions collected from five EAC patients, including adjacent BE in one of them, 
who underwent primary surgical resection with curative intent. To evaluate intratumor 
heterogeneity, DNA alterations were classified as homogeneous, i.e. present in all regions 
of the tumor, or heterogeneous defined as present in some regions or in only one region 
of the tumor.
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METHODs
Patients and specimens
Resection specimens of distal esophageal or gastroesophageal junction adenocarcino-
mas were obtained from five patients treated between December 2001 and April 2002 
at the Department of Surgery, Erasmus MC Cancer Institute, University Medical Center 
Rotterdam, The Netherlands. All patients underwent a transhiatal esophagectomy, and 
none of them received neoadjuvant chemo- and/or radiation therapy, which is part of 
the current standard treatment of EAC.15
Tissue samples, DnA isolation and immunohistochemistry 
Tissue samples were derived from non-malignant and malignant areas in the fresh re-
section specimens and used according to the Code of Proper Secondary Use of Human 
Tissue in the Netherlands, as established by the Dutch Federation of Medical Scientific 
Societies (http://www.federa.org). In addition the study was approved by The Medical 
Ethical Committee of the Erasmus MC, University Medical Center, Rotterdam. 
From each of the five EACs, multiple, macroscopically separated tumor regions were 
collected (Figure 1). In addition, from one resection specimen, samples from an area of 
premalignant BE (HGD) and from a tumor positive lymph node (TPLN) were available 
for study. Tumor tissue areas composed of at least 50% neoplastic cells (confirmed by a 
GI-pathologist) were manually microdissected from 10 to 15 hematoxylin-stained sec-
tions (4µm) of formalin-fixed paraffin-embedded tissue blocks. DNA was extracted using 
proteinase K and 5% Chelex 100 resin. TP53 immunohistochemistry was performed with 
the mouse monoclonal antibody Do-7 (Dako, Glostrup, Denmark), according to standard 
protocols.
ion Torrent Personal Genome Machine
Ion semiconductor sequencing was performed on the Ion Torrent Personal Genome 
Machine (PGM) with a custom-made cancer panel on DNAs extracted from the macro-
scopically separated tumor regions according to the manufacturer’s protocols. In short, 
libraries were made using the Ion AmpliSeq Library Preparation Kit. A template was 
prepared using the Ion OneTouch Template Kit and sequencing was performed with the 
Ion Sequencing Kit v2.0 on an Ion 316 chip. Data were analyzed with the Variant Caller 
v2.2.3-31149 (Life Technologies, Carlsbad, CA, USA). Variants were called when the posi-
tion was covered at least 100 times. Sequences of all primers and probes are available on 
request. 
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Mutation analysis 
The custom-made cancer panel contained the genes: APC, P16, SMAD4 and TP53. Of all 
genes the total coding regions and the exon-intron boundaries were covered. Nonsyn-
onymous somatic point mutations, insertions and deletions that change the protein 
amino acid sequence and splice site alterations were selected. In addition, variants pres-
ent in the ESP6500si or 1000genomes databases in ≥1% were excluded. Variants present 
in at least 30% of the called reads were considered reliable and were validated by Sanger 
sequencing according to standard protocols. 
loss of heterozygosity analysis
To demonstrate loss of heterozygosity (LOH) of the genes of interest (APC, P16, SMAD4, 
TP53) amplicons for single nucleotide polymorphisms (SNPs, selected from dbSNP137) 
in these loci were added to the custom-made cancer panel. Per locus nine SNPs were 
selected, all with a minor allele frequency of ≥0.45 and located within the gene (three 
SNPs) and at positions ~300, ~600 and ~900 kb centromeric and telomeric of the gene. 
The SNPs were considered heterozygous if the percentage of the variant in the normal 
figure 1: Macroscopically separated tumor regions from resection specimen
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DNA was within the range of 40-60%. When at least one SNP was present heterozygous 
in the normal DNA it was considered informative for LOH analysis. Variants present in 
the normal DNA in <10% were considered homozygous reference and therefore not 
informative for LOH analysis, as well as variants present in >90%, which were considered 
homozygous variant. 
For tumor DNAs, of which the normal DNA was considered heterozygous, all SNPs with 
variants <40% or >60% were denoted as indicative for LOH. A sample was evaluated as 
having locus LOH when ≥50% of the informative SNPs in that locus demonstrated LOH 
(variant in tumor DNA <40% or >60%)16. In addition, identified tumor suppressor gene 
mutations also supplied information about possible LOH (loss of the wild type allele) by 
the relative frequency of the mutant DNA sequence compared to the normal wild type 
sequence in the tumor samples.
intratumor heterogeneity analysis
Analysis of intratumor heterogeneity could be determined through mutation and LOH 
analysis. Homogeneity was signified by an identical mutation or the same pattern of 
LOH at a given gene identified in different tumor regions of the same tumor, whereas 
heterogeneity was signified by different mutations or various LOH patterns of a given 
gene in different regions of the same tumor.
rEsUlTs
Targeted sequencing with a custom-made cancer panel was performed on DNA isolated 
from 19 tumor regions derived from the resection specimen of five EAC patients, all male, 
with a median age at the time of diagnosis of 70 years (range 51-78 years). Two tumors 
were localised at the gastroesophageal junction and three in the distal esophagus within 
the background of BE. Four tumors were moderately differentiated, and one tumor was 
poorly differentiated. All resection margins were free of tumor cells. Three patients had 
tumor positive lymph nodes, without distant metastasis. Patient and tumor characteris-
tics are listed in Table 1.
From one resection specimen, a region of BE (HGD) and a TPLN were analyzed with 
the custom-made cancer panel as well. Next-generation sequencing on the PGM and 
conventional Sanger sequencing revealed 21 mutations in the TP53 gene, no mutations 
were identified in APC, P16, and SMAD4. Reliable data for the LOH analysis of TP53, P16, 
SMAD4 and APC were obtained in 92%, 92%, 81% and 73% of the samples, respectively.
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All five EACs showed homogeneous TP53 mutations: in each EAC the same TP53 
mutations (nonsynonymous somatic point mutations or splice site alterations) were 
identified in all investigated tumor regions, all mutations were previous described in 
esophageal cancer samples in the COSMIC database. In addition, the TP53 mutation 
found in a primary EAC was also identified in the adjacent BE and TPLN samples. LOH of 
TP53 occurred homogeneously in all informative regions of the EACs and in the paired 
EAC and BE samples with identical LOH patterns observed by SNP and/or mutation 
analysis (Figure 2). TP53 immunohistochemistry showed homogeneous and strong 
nuclear expression in all tumor regions and the BE sample of the four patients with 
TP53 somatic missense mutations (Figure 3). The tumor cells of the four regions derived 
from the EAC with a TP53 splice site mutation were all homogeneously negative for 
TP53 expression (EAC2).
LOH of P16 occurred homogeneously in all regions of four informative tumors (EAC1, 
2, 4, 5), and an identical LOH pattern of P16 was observed in the paired tumor and BE 
samples (Figure 4). EAC1 and EAC3 showed homogeneous LOH of SMAD4 in all tumor 
regions, two tumors showed different subclones with LOH or without LOH of SMAD4 
(EAC2 and 5), while in EAC4 no LOH of SMAD4 was identified. Homogeneous LOH of APC 
was observed in two tumors (EAC1 and 2), different subclones with and without LOH of 
APC were observed in EAC3 and EAC4, whereas one tumor (EAC5) was not informative for 
the APC locus (Figure 2).
Table 1: Patient and tumor characteristics
Patient 
Age
(years) Gender
Tumor
type
Differentiation 
grade
resection 
marge
TnM
stage$
Tumor 
regions
EAc1 77 Male GEJAC* Moderate R0# pT3N1Mx 5
EAc2 62 Male GEJAC Moderate/Poor R0 pT3N3Mx 4
EAc3 78 Male BAC^ Moderate R0 pT1N0Mx 3
EAc4 51 Male BAC Moderate R0 pT3N1M0 3
EAc5 70 Male BAC Poor R0 pT2N0Mx 4
*  GEJAC = Gastroesophageal junction adenocarcinoma 
^  BAC = Adenocarcinoma in Barrett’s epithelium
#  R0 = Tumor free resection margin
$  According to the classification of the American Joint Committee on Cancer (AJCC) Staging Manual 7th 
edition. 
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figure 3: TP53 immunohistochemistry
TP53 immunohistochemistry showing strong and diff use expression of TP53 in the premalignant Barrett 
epithelium (A) and the tumor region T3 (B) of EAC4, both samples bearing a nonsynonymous mutation: 
p.R248Q.
figure 4: P16 LOH analysis by the means 
of SNPs, which are represented as num-
bered dots.
On the horizontal axis the base position at 
chromosome 9 is denoted, and on the ver-
tical axis the percentage of base variant. 
The SNPs in the normal sample (A) num-
bered with 2 and 3 have variant frequen-
cies between 40-60% and are therefore 
considered heterozygous, the remaining 
SNPs with variant frequencies of <10% or 
>90% are considered homozygous, and 
not informative. In the premalignant Bar-
rett epithelium (B) and the tumor region 
T5 (C) the SNPs 2,3 and 9 have variant fre-
quencies between 10-40% and 60-90% 
and are therefore indicative for LOH. In ad-
dition, the pattern of LOH in the premalig-
nant Barrett epithelium (B) and the tumor 
region T5 (C) is identical.
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DiscUssiOn
Recent data on next-generation sequencing of several tumor DNAs were supportive for 
the model of branched tumor evolution leading to intratumor heterogeneity.11,13 This 
model describes a tumor as a tree structure, with the trunk representing early molecular 
alterations, which clonally expand and therefore are homogeneously present through-
out the entire tumor, reflecting a process involved before and during tumor initiation 
and early development. The branches of the tree represent later molecular alterations, 
which as a result are only present in different subclones of the tumor, contributing to 
intratumor heterogeneity and shaping the genome during tumor maintenance and 
progression.12,14 The extent of this branched evolution model leading to intratumor 
heterogeneity in EACs is as yet unknown. 
Therefore, the aim of the current study was to characterize intratumor heterogeneity 
in EACs, by performing multiregion, targeted sequencing on 19 tumor regions derived 
from five surgical resected EACs. Targeted sequencing of the commonly altered genes 
TP53, P16, SMAD4 and APC was performed. This analysis revealed a clonal origin of TP53 
alterations: all five EACs where homogeneous with regard to TP53 mutations and LOH of 
the TP53 locus, in addition the same mutation and pattern of LOH in TP53 was observed 
in a paired TPLN of one EAC. These results indicate that TP53 mutation and LOH of the 
TP53 locus are relatively early events in EAC tumorigenesis and clonally expand through-
out the entire tumor. In concordance with this is the finding of the same TP53 mutation, 
identical pattern of LOH, and comparable strong nuclear TP53 expression in the paired 
primary tumor and BE case.
Mutations in the P16 gene were not observed in this study, however LOH of the P16 locus 
was identified in all EACs. Four EACs had a homogeneous P16 locus LOH pattern, while 
one EAC was heterogeneous for P16 LOH. In addition, an identical pattern of P16 locus 
LOH was present in the paired primary EAC and BE case, suggesting that LOH of P16 is an 
early alteration, clonally expanding throughout the tumor. No mutations were identified 
in SMAD4 and APC, but LOH of these genes was observed in a heterogeneous pattern 
within the EACs. Some EACs showed homogeneous LOH of SMAD4 and/or APC, one EAC 
showed no LOH of SMAD4 at all, while the remaining EACs showed different subclones: 
some with LOH of SMAD4 and/or APC and others without LOH of these loci. In addition, 
no LOH of SMAD4 and APC was found in the BE sample, indicating a late occurrence of 
these alterations, reflecting intratumor heterogeneity of EACs. 
Taken together, the results of the current study suggest that both homogeneous and 
heterogeneous intratumoral molecular alterations are present in EACs. A homogeneously 
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present TP53 mutation and LOH of the TP53 locus as well as LOH of the P16 locus in the 
primary tumor were also found in the adjacent BE sample, indicating that the earliest 
molecular alterations can already be present in the premalignant lesion (BE) and from 
there on clonally expand throughout the entire tumor. Temporarily, no multiregion se-
quencing of EACs was performed before. Alterations in TP53 were described previously in 
the sequential of BE (HGD) and EAC, and in addition were found to be present in a major 
clone, which also indicates clonal expansion of TP53 as an early alteration.17 
The presence of alterations in BE is in accordance with previous studies, showing that mul-
tiple BE crypts contain different clones with alterations competing with each other,18,19 of 
which one progenitor clone with a selective growth advantage will expand clonally and 
will create a field in which other (pre)malignant alterations might arise.19 Several studies 
on P16 have reported clonal expansion of P16 alterations in all regions of BE segments, 
and it has been suggested that expansion of TP53 alterations occur only in a background 
of P16 altered clones.20 However, others described progenitor clones containing TP53 
alterations alone or in combination with P16 alterations present at many levels of BE 
segments.21 Leedham et al.18 concluded that BE was genetically heterogeneous, however 
they observed identical TP53 mutations in multiple BE crypts, indicating widespread and 
far-reaching clonal expansion as a consequence of the strong selective advantage that 
absence of TP53 function supposedly provide. Recently, a study on cytochrome c oxidase 
(CCO) deficient cells in BE confirmed the concept of clonal expansion of BE, probably by 
fission of BE glands.22
Conceivably, intratumor heterogeneity can cause tumor sample bias using single biopsy 
approaches, since it may underestimate the mutation spectrum of a tumor. This could 
contribute to difficulties in identifying and validating biomarkers, which are desirable to 
identify BE patients with a high risk for neoplastic progression. Furthermore, intratumor 
heterogeneity may contribute to therapy resistance: if the actionable target of treatment 
is only present in a subclone of the tumor, than targeting this genetic alteration may not 
have an impact on the entire tumor. This concept might explain the diversity in respond-
ers and non-responders after neoadjuvant chemoradiotherapy (nCRT) in EACs.23  
cOnclUsiOns
Recent studies on EAC reveal extensive intertumor heterogeneity concerning molecular 
alterations with different studies showing different recurrently mutated genes. There-
fore, the genes found frequently mutated in several studies were investigated in the 
current study.8-10,17 Even though the sample size is small, and targeted sequencing of 
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only commonly mutated genes was performed, the current study provides evidence that 
although intratumor heterogeneity is present in EACs, known driver alterations in TP53 
and P16 were homogeneously present in all five primary EACs, indicating clonal cellular 
expansion. Studies with larger cohorts and extensive genome sequencing are needed 
to fully characterize intratumor heterogeneity in EACs and in addition, to understand 
the impact of intratumor heterogeneity on current clinical outcome of both BE and EAC 
patients. 
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DEAr EDiTOrs:
Telomerase reverse transcriptase (TERT) is the catalytic subunit of telomerase, which 
maintains the telomere length at the end of the chromosomes.1 Recently, promoter 
mutations in the TERT gene have been described in melanomas, bladder cancer, gliomas, 
and thyroid cancers.2 The two most common mutations, 1,295,228 C>T (C228T) and 
1,295,250 C>T (C250T), have been demonstrated to confer increased transcriptional 
activity on the TERT promoter and probably represent a novel mechanism of telomerase 
activation in human tumorigenesis.3 Three additional mutations: 1,295,228 C>A (C228A), 
1,295,228/1,295,229 CC>TT (C228T/C229T) and 1,295,242/1,295,243 CC>TT (C242T/
C243T) have been rarely described.2,4
Zhoa et al. reported a very low frequency (1.6%) of TERT promoter mutations in esopha-
geal squamous cell carcinomas (ESCC),5 which is the most common histological type 
of esophageal cancer in East Asian countries.  Conversely, the incidence of ESCC in the 
Western world is declining while that of esophageal adenocarcinoma (EAC) is remark-
ably increasing. This rising incidence together with a poor prognosis of EAC represents a 
growing health concern.6 Hence, there is great urgency to clarify the genomic alterations 
underlying EAC to better comprehend the pathogenesis of these tumors and to encour-
age development of new diagnostic, prognostic, therapeutic and prevention strategies. 
Previous studies have identified frequent mutations in TP53 and somatic mutations in 
CDKN2A, ARID1A, PIK3CA and SMAD4,7 but widespread use of these markers in clinical 
practice has not taken place. To investigate whether mutations in the TERT promoter 
play a role in EAC tumorigenesis, the occurrence of TERT promoter mutations in EAC was 
evaluated.
This study included 90 EAC samples. The tumor tissue samples were obtained from the 
resection specimens of patients with distal EAC or gastroesophageal junction adenocar-
cinoma and were used according to the Code of Proper Secondary Use of Human Tissue 
in the Netherlands established by the Dutch Federation of Medical Scientific Societies. Of 
each patient the clinical information was accessible (Table 1). Ten to fifteen hematoxylin-
stained sections (4 μm) from formalin-fixed paraffin-embedded tissue blocks were used 
for manual microdissection of tissue areas composed of a high percentage (at least 60%) 
of neoplastic cells. DNA was extracted using proteinase K and 5% Chelex 100 resin. In ad-
dition, ten human EAC cell lines, which were authenticated by DNA short tandem repeat 
profiling, were included in the study,8 as well as four bladder tumor samples, which were 
previously tested positive for the mutations C228T, C228A, C242T/C243T and C250T.4
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Primers were used to amplify the regions of the previously described TERT promoter 
mutations: C228T, C228A, C242T/C243T, and C250T (Hg19). The amplified fragments of 
the tumors were analyzed by SNaPshot using the ABI Prism SNaPshot Multiplex Kit (Life 
Technologies).4 Data analysis was performed using GeneMarker Analysis Software ver-
sion 2.4.0 (Softgenetics). TERT promoter mutations were successfully evaluated in 90 EAC 
samples, ten verified human EAC cell lines, and four positive bladder tumor samples, the 
TERT promoter mutations C228T, C228A, C242T/C243T, and C250T were not identified in 
the 90 EAC samples and neither in the ten verified human EAC cell lines. However, the 
mutations C228T, C228A, C242T/C243T and C250T were verified properly in the positive 
bladder tumor samples (Figure 1).
Previous studies support the hypothesis that TERT mutations are mainly associated to 
tumors derived from tissues with relative low rates of self-renewal under normal circum-
stances, such as melanomas, bladder cancer, gliomas and thyroid cancers.2,9 Cancers 
that originate from tissues that constantly self-renew, such as cancers of the epithelia of 
the gastrointestinal tract, would be unlikely to harbor telomere-maintaining mutations, 
since telomerase is already activated in their precursor cells.9 In addition, it has been 
suggested that these TERT mutations can result from environmental factors such as ultra-
violet radiation and chemical carcinogens, which also could explain the high frequency 
of TERT mutations in melanoma, bladder cancers and squamous cell carcinoma of the 
tongue.2
Table 1: Patients characteristics
Patients characteristics Total (%)
All cases
Mean Age (sd)
sex
Male
Female
Tumor grade
Well
Moderate
Poor / undifferentiated
TnM-stage
IA
IB
IIA
IIB
IIIA
IIIB
IIIC 
IV
90
63.23 
75 
15 
4 
48 
38 
13 
4 
1 
22 
18 
14 
16 
2 
(11.21)
(83.3)
(16.7)
(4.4)
(53.3)
(42.2)
(14.4)
(4.4)
(1.1)
(24.4)
(20.0)
(15.6)
(17.8)
(2.2)
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figure 1: Results of SNaPshot analysis
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In summary, our results demonstrate that TERT promoter mutations do not occur in EAC. 
Obviously, these tumors have alternative mechanisms to maintain telomere lengthen-
ing, and therefore would be less likely to benefit from activating mutations in TERT. This 
suggests that TERT promoter mutations are not likely to play a crucial role in the develop-
ment and progression of EAC. 
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AbsTrAcT
Objective: Recently, single nucleotide polymorphisms (SNPs) associated with esopha-
geal adenocarcinoma (EAC) and Barrett’s esophagus (BE) were identified: rs10419226 
(CRTC1), rs11789015 (BARX1), rs2687201 (FOXP1), rs2178146 (FOXF1), rs3111601 (FOXF1), 
and rs9936833 (FOXF1). These findings indicate that genetic susceptibility could play a 
role in the initiation of EAC in BE patients. The aim of this study was to validate the asso-
ciation between these previously identified SNPs and the risk of EAC in an independent 
and large case–control study. 
Design: Six SNPs found to be associated with EAC and BE were genotyped by a multiplex 
SNaPshot analysis in 1,071 EAC patients diagnosed and treated in the Netherlands. Al-
lele frequencies were compared to a control group derived from the Rotterdam Study, a 
population-based prospective cohort study (n = 6,206). Logistic regression analysis and 
meta-analysis were performed to calculate odds ratios (OR). 
results: Rs10419226 (CRTC1) showed a significantly increased EAC risk for the minor 
allele (OR = 1.17, p= 0.001), and rs11789015 (BARX1) showed a significantly decreased 
risk for the minor allele (OR = 0.85, p= 0.004) in the logistic regression analysis. The 
meta-analysis of the original GWAS and the current study revealed an improved level of 
significance for rs10419226 (CRTC1) (OR = 1.18, p= 6.66 × 10−10) and rs11789015 (BARX1) 
(OR = 0.83, p= 1.13 × 10−8). 
conclusions: This independent and large Dutch case–control study confirms the associa-
tion of rs10419226 (CRTC1) and rs11789015 (BARX1) with the risk of EAC. These findings 
suggest a contribution of the patient genetic make-up to the development of EAC and 
might contribute to gain more insight in the etiology of this cancer.
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inTrODUcTiOn
Esophageal adenocarcinoma (EAC) is one of the rapidly rising cancers in the Western 
world.1-3 Despite improvements in multimodality treatment, the prognosis for EAC re-
mains disconcerting.4 The major risk factor for EAC is the premalignant lesion Barrett’s 
esophagus (BE), in addition to age, male gender, and Caucasian ethnicity.5 As a conse-
quence of gastroesophageal reflux (GER), the normal squamous epithelium of the lower 
esophagus can be replaced by columnar intestinal cells, including goblet cells, represent-
ing BE. Per year 0.12–0.5% of the patients diagnosed with BE will develop EAC, following 
a multimorphological sequence, in which intestinal metaplasia evolves to low-grade dys-
plasia (LGD), high-grade dysplasia (HGD) and ultimately to invasive adenocarcinoma.6-8
The prevalence of BE in the general population is estimated at two percent,9 and among 
patients with GER even at ten percent.10 Since the prognosis of advanced EAC is relatively 
poor,3 patients with BE are subjected to intensive endoscopic surveillance with biopsy 
sampling to identify those patients with neoplastic progression at an early stage.11 How-
ever, because the annual risk of developing EAC from BE is relatively low, most BE patients 
will not progress to cancer and do not benefit from this surveillance.6,7
It can be anticipated that genetic susceptibility could play a role in the initiation of EAC in 
BE patients. From this perspective the identification of single nucleotide polymorphisms 
(SNPs), which identifies high risk patients, could make the surveillance of BE patients 
more cost-effective and could be helpful by diagnosing patients with EAC in an early and 
curable stage, which will increase the prognosis remarkably.
Recently, the first Genome-wide association study (GWAS) on EAC and the premalignant 
lesion BE was published. This study revealed three SNPs associated with EAC: rs10419226 
(CRTC1), rs11789015 (BARX1), and rs2687201 (FOXP1).12 In addition, evidence was found 
that rs9936833 (FOXF1), previously associated with BE,13 was also associated with EAC 
and that the SNPs: rs2178146 and rs3111601 near rs9936833 had even a stronger as-
sociation with EAC.12 Rs9936833 was first identified in a GWAS on BE performed by Su et 
al. in 2012, simultaneously rs9257809 (MHC) was found to be associated with BE.13 The 
aim of the present study was to validate the association between these six previously 
identified SNPs and the risk of EAC in an independent and large case–control study.
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MATEriAls AnD METHODs
study population
Patients diagnosed with an adenocarcinoma of the distal esophagus or esophagogastric 
junction (EGJ) and treated at the Department of Surgery, Erasmus MC Cancer institute, 
University Medical Centre, Rotterdam, between January 1996 and December 2013 
(n = 761) were selected for the study. In addition, patients treated in the Academic Medi-
cal Centre at the university of Amsterdam, between 1994 and 2004 were included as well 
(n = 310). All patients underwent an esophagectomy with curative intention.
The control group was derived from the Rotterdam Study, a population-based prospec-
tive cohort study. In brief, this is an ongoing large population-based cohort study, which 
started in January 1990.14 All inhabitants, who were aged 55 years and older, living in 
Ommoord, a district in Rotterdam, The Netherlands, were invited to participate. This 
population-based control group provided reference groups of allele frequencies, which 
reflect the local general European population. Individuals in the control group diagnosed 
with EAC were excluded. Patients and controls were of European descent.
DnA isolation
For cases, the tissue samples were obtained from the resection specimens and used 
according to the Code of Proper Secondary Use of Human Tissue in the Netherlands 
established by the Dutch Federation of Medical Scientific Societies (http://www.federa.
org). Non-malignant tissue from the resection specimen; tumor negative lymph nodes 
or tumor negative resection margins, confirmed by an experienced GI-pathologist, were 
macrodissected from microscopic sections of fresh frozen-or formalin-fixed paraffin 
-embedded tissues. DNA was extracted using proteinase K and 5% Chelex 100 resin. 
For controls, genomic DNA was extracted from whole blood samples using standard 
methods.15
Genotyping
For cases, a multiplex SNaPshot assay was designed: multiplex polymerase chain reaction 
was used to amplify the regions of the SNPs: rs2178146 (FOXF1), rs10419226 (CRTC1), 
rs9936833 (FOXF1), rs2687201 (FOXP1), rs11789015 (BARX1), and rs3111601 (FOXF1) 
(Hg19). The amplified fragments of the normal DNAs were analyzed by SNaPshot using 
the ABI Prism SNaPshot Multiplex Kit (Life Technologies, Carlsbad, CA, USA). Data analysis 
was performed using GeneMarker Analysis Software version 2.4.0 (Softgenetics, State 
College, PA, USA) (Figure 1).16 Primers and probes sequences are listed in Supplementary 
Table 1.
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For controls, genome-wide SNP genotyping was performed using Infinium II assay on the 
HumanHap550 and Human 660-quad Genotyping BeadChips (IlluminaInc, San Diego, 
CA, USA). Approximately 30 million SNPs were imputed using 1000G Phase 1 v3 popula-
tions as reference.17 The imputations were performed using MACH software (http://www.
sph.umich.edu/csg/abecasis/MACH/). All variants tested here had an imputation quality 
of 0.9 or higher, suggesting near perfect imputation. Best-guess genotypes were used 
for the analyses.
statistical analysis
Departures from Hardy–Weinberg equilibrium were tested for using the goodness-of-
fit χ2 test. Logistic regression analysis were used to calculate odds ratios (OR) with 95% 
confidence intervals (95% CI). The major allele homozygous was set as a reference and 
was compared with the minor allele. P values were corrected for multiple testing using 
Bonferroni correction (p = 0.05/6 = 0.008) before considered significant. Logistic regres-
sion was performed with SPSS version 20.0 (SPSS, Chicago, IL, USA) and meta-analysis 
of the original GWAS,12 and the current study was performed using R library rmeta.18 A 
fixed-effects inverse-variance meta-analysis was performed.
figure 1: Results of SNaPshot analysis
Results of SNaPshot analysis of DNA from a patient with esophageal adenocarcinoma: SNPs rs2178146, 
rs2687201, and rs11789015 are heterozygous, all other SNPs are homozygous for the major allele. 
* Reverse probes used.
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rEsUlTs
study population
A total of 1,071 cases were initially analyzed, due to technical failure of 972 cases reliable 
data were obtained that was compared with 6,206 controls regarding the six previously 
mentioned SNPs. Clinical data were available of 550 cases from Rotterdam. The median 
age of these patients was 63 years (Range: 19–84 years) and 80% was male. Almost half 
of the patients received some form of neoadjuvant therapy and all patients underwent 
esophagectomy. Ninety percent was diagnosed with an invasive adenocarcinoma, of 
which 35% arose clearly from BE. Most tumors were located in the distal esophagus 
(41.3%) or at the EGJ (40.5%). The majority of the tumors were moderately or poorly 
differentiated (36.5% and 45.1%, respectively). The most common pathological tumor 
stage (pT) was pT3 (53.8%) and half of the patients appeared to have positive lymph 
nodes (pN1-3), whereas four patients had distant metastasis (pM) according to the TNM-
classification of the American Joint Committee on Cancer Staging Manual 7th edition. 
After surgery, 40.4% of the cases developed recurrence of disease (locoregional disease 
or distant metastasis). The mean overall survival of the 550 cases was 53.8 months (95%CI: 
49.5–58.2) and the 5-year overall survival was estimated at 38.2%.
Allelic association analysis
The distribution of genotype frequencies for the investigated SNPs was consistent with 
Hardy–Weinberg equilibrium (p > 0.05), except for FOXF1 rs3111601 (p = 0.013). The al-
lelic association of the six SNPs with EAC showed significantly increased risk for the minor 
allele of rs10419226 (CRTC1) (OR = 1.17, p = 0.001) and significantly decreased risk for the 
minor allele of rs11789015 (BARX1) (OR = 0.85, p = 0.004). None of the other four SNPs were 
significant in the currently studied population, although direction and effect size were 
consistent with previous GWAS results. The meta-analysis of the original GWAS and the 
current study revealed more accurate effect estimate and improved level of significance 
for rs10419226 (CRTC1) (OR = 1.18, p = 6.66 × 10−10) and rs11789015 (BARX1) (OR = 0.83, p= 
1.13 × 10−8), and in addition for rs2178146 (FOXF1) (OR = 0.87, p = 9.37 × 10−7), while there 
was no significant allelic association with EAC in the currently studied population (Table 1).
Genotypic association analysis
Genotypic association analysis showed a dose effect for the significantly associated SNPs. 
The GT genotype for rs10419226 (CRTC1) increased the risk of EAC in comparison with 
the GG genotype (OR = 1.07, p = 0.428), which became significant for the TT genotype 
(OR = 1.39, p = 0.001). The rs11789015 (BARX1) AG genotype decreased the risk of EAC 
in comparison with the AA genotype (OR = 0.95, p= 0.456), this decrease in risk became 
significant for the genotype GG (OR = 0.57, p= 3.68 × 10−4) (Supplementary Table 2). 
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DiscUssiOn
In this study two SNPs, rs10419226 (CRTC1) and rs11789015 (BARX1), were replicated to 
be associated with EAC. In the performed meta-analysis including the data of the EAC 
cohort from the original GWAS,12 the level of significance was improved compared with 
the original findings of the GWAS, confirming the association of CRTC1 and BARX1 with 
EAC. This was expected, since the present case–control study revealed a significantly 
increased risk of EAC for the minor allele T of rs10419226 (CRTC1) and a significantly 
decreased risk of EAC for the minor allele G of rs11789015 (BARX1). Both SNPs showed a 
dose-effect in the genotypic analysis:two minor alleles gave a stronger effect than one 
minor allele.
In addition, rs2178146 (FOXF1) showed an improved level of significance in the meta-
analysis while it did not reach significance in the allelic analysis of the present study co-
hort. This could be explained by a smaller sample size compared to the population used 
for the original GWAS resulting in a decreased power to detect the association. However, 
because all cases were retrieved clinically, and controls with EAC were excluded, no 
attenuation had taken place. Only two of the six previously identified SNPs, appeared 
to be significantly associated with EAC in the current study, however, a consistency of 
the direction of effect and effect size was seen for all variants, suggesting that all these 
variants may play a role in EAC.
Rs10419226 is an intronic variant in the CRTC1 gene, which is encoding for CREB-reg-
ulated transcription co-activator that has been found previously to be associated with 
the oncogenic activity. The down-regulation or loss of LKB1, a tumor suppressor kinase, 
activates CRTC1 signaling and the transcriptional activity of the downstream targets of 
CRTC1. In addition, altered LKB1/CRTC1 signaling has been demonstrated to induce a 
migratory and invasive phenotype in esophageal cancer cell lines.19,20
Rs11789015 is located in an intron of BARX1, a homeobox transcription factor. The homo-
log of BARX1 has been found to be associated with the differentiation of the esophagus 
and trachea in developing mouse embryos and in addition to be associated with the 
down-regulation of the Wnt pathway in stomach morphogenesis and differentiation.21
Identifying these SNPs associated with EAC suggests that genetic susceptibility might 
play a role in the initiation of EAC and could be of importance for the surveillance of 
BE patients. Since the prevalence of BE patients is valued at two percent in the general 
population,9 and the annual risk of developing EAC from BE is estimated at 0.12–0.5%,6,7 
most patients with BE will not benefit from endoscopy surveillance. However because of 
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the relatively poor prognosis of EAC,3 it is of utmost importance to diagnose EAC patients 
in an early and curable stage of the disease. Therefore, it could be of additional value to 
incorporate SNPs associated with EAC in the surveillance program of BE, in order to only 
select the high risk patients for developing EAC.
cOnclUsiOns
This independent and large Dutch case–control study replicated the association of 
rs10419226 (CRTC1) and rs11789015 (BARX1) with the risk of EAC. These findings indicate 
a possible genetic contribution to the development of EAC and might contribute to gain 
more insight in the etiology of this cancer. In addition, SNPs associated with EAC could be 
helpful by identifying patients at increased risk for malignant progression during surveil-
lance and/or screening programs aimed to improving the survival of these patients by 
diagnosing EAC in an early and curable stage.
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supplementary Table 2: Genotypic association analysis
EAC 
N=972 (%)
Controls
 N=6,206(%) 
SNPID OR (95%CI) p-value
rs2178146
TT
TC
CC
351
459
162
(36.1)
(47.2)
(16.7)
2,054
3,022
1,130
(33.1)
(48.7)
(18.2)
1
0.89 (0.765-1.033)
0.84 (0.687-1.024)
0.123
0.085
rs10419226
GG
GT
TT
260
469
243
(26.7)
(48.3)
(25.0)
1,845
3,117
1,244
(29.7)
(50.2)
(20.0)
1
1.07 (0.908-1.256)
1.39 (1.147-1.675)
0.428
0.001
rs9936833
TT
TC
CC
399
453
120
(41.0)
(46.6)
(12.3)
2,609
2,847
750
(42.0)
(45.9)
(12.1)
1
1.04 (0.900-1.202)
1.05 (0.840-1.303)
0.591
0.687
rs2687201
CC
CA
AA
426
437
109
(43.8)
(45.0)
(11.2)
2,847
2,720
639
(45.9)
(43.8)
(10.3)
1
1.07 (0.930-1.239)
1.14 (0.908-1.431)
0.331
0.258
rs11789015
AA
AG
GG
521
403
48
(53.9)
(41.5)
(4.9)
3,138
2,560
508
(50.6)
(41.3)
(8.2)
1
0.95 (0.824-1.091)
0.57 (0.417-0.776)
0.456
3.68*10-4
rs3111601
TT
TC
CC
484
401
87
(49.8)
(41.3)
(9.0)
3,060
2,653
493
(49.3)
(42.7)
(7.9)
1
0.96 (0.829-1.102)
1.12 (0.871-1.429)
0.531
0.385
EAC: Esophageal adenocarcinoma, OR (95% CI): odds ratio (95% confidence interval).

parT iii
FAMILIAL CLUSTERING OF 
ESOPHAGEAL ADENOCARCINOMA

Chapter 5
Hereditary factors in esophageal 
adenocarcinoma
Anna M.J. van Nistelrooij
Winand N.M. Dinjens
Anja Wagner
Manon C.W. Spaander
J. Jan B. van Lanschot
Bas P.L. Wijnhoven
Gastrointest Tumors. 2014 Jun;1(2):93-8
Chapter 5
70
AbsTrAcT
background: The vast majority of Barrett’s esophagus (BE) and esophageal adenocarci-
noma (EAC) cases are sporadic and caused by somatic mutations. However, over the last 
decades several families have been identified with clustering of EAC. Here, we review 
data from the published literature in order to address the current knowledge on familial 
EAC.
summary: Although familial EAC comprises a relatively small group of patients, it is a 
clinically relevant category due to the poor prognosis of this type of cancer. Efforts should 
be made to identify specific genetic risk factors for familial EAC to enable identification 
of relatives at risk, since endoscopic surveillance can diagnose preneoplastic or early 
neoplastic lesions leading to early treatment, with improved outcome.
key Message: Although familial EAC comprises a relatively small group of patients, this 
is a clinically relevant category due to the poor prognosis. Efforts should be made to 
identify specific genetic risk factors for familial EAC in order to facilitate the identification 
of other family members with a predisposition for this type of cancer.
Practical implications: Approximately seven percent of BE and EAC cases are considered 
familial. Age at diagnosis is generally lower for patients with familial EAC as compared to 
sporadic cases, while other known risk factors for EAC, such as male gender and Cauca-
sian ethnicity, do not differ between the two groups. In several described families with 
clustering of EAC the pattern of inheritance seems to be consistent with a rare autosomal 
dominant genetic trait. However, some association has been found with (attenuated) 
familial adenomatous polyposis, mismatch repair deficiency and recently with the genes 
MSR1, ASCC1 and CTHRC1. Nevertheless, no specific genetic predisposition has yet been 
identified.
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inTrODUcTiOn
During the last decades there has been a dramatic increase in the incidence of esophageal 
adenocarcinoma (EAC) in Western countries.1-3 Despite improvements in multimodality 
therapy, the prognosis of patients with EAC remains poor.4 Barrett’s esophagus (BE) is the 
predominant risk factor for EAC in addition to age, male gender and Caucasian ethnicity.5 
BE is a premalignant condition in which the normal squamous epithelial lining in the 
lower esophagus is replaced by columnar intestinal cells.6 BE is considered a long-term 
complication of severe chronic gastroesophageal reflux (GER). The susceptibility for GER 
may in turn be influenced by factors such as obesity, alcohol consumption and nicotine 
abuse.7
The vast majority of BE and EAC cases are sporadic and caused by somatic mutations,8 
i.e. mutations that may occur in any cell of the body except for germ cells. However, 
over the last decades several families have been identified with clustering of EAC.9-14 This 
observation suggests that one or more inherited factors might play a role in the initiation 
of EAC in these families.  Familial clustering of cancer is important thanks to the suc-
cess of implementing genetic testing and screening methods for cancer syndromes.15-17 
However, for cancers that are not covered in familial risk management guidelines, such 
as EAC, awareness of the true familial risk is needed to provide rational advice.17 In terms 
of clinical genetics, for a true familial risk, the number of affected family members needs 
to be higher than is to be expected by chance alone.18
The purpose of the present study was to review the literature on the occurrence and 
characteristics of familial EAC. Previous studies introduced and persevered the definition 
familial BE, i.e. two or more first- or second-degree family members diagnosed with BE, 
EAC or gastroesophageal junction adenocarcinoma (GEJAC).19 These studies considered 
familial BE and familial EAC to be part of the same genetic trait, because EAC appears 
to arise from BE and both conditions share the same epidemiological risk factors. We 
hypothesize that familial EAC can be distinct from most familial BE. Since BE is much 
more prevalent among the common population, familial BE does not necessarily have to 
be the underlying condition of familial EAC. If two or more first-degree family members 
are diagnosed with EAC, it is unlikely that this can be explained by chance alone, based 
on the absolute risk of 0.12-0.5% for malignant transition of BE into EAC.20,21 Therefore, 
familial EAC might be the result of accelerated malignant progression from familial BE, or 
familial EAC might arise without familial BE as the premalignant condition. In both sce-
narios involvement of specific germline mutations driving familial EAC can be envisaged.
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Prevalence of familial EAc
In the literature familial EAC has been grouped with familial BE and has been termed 
familial BE, which is defined as two or more family members diagnosed with BE, EAC or 
GEJAC.19 Two studies estimated the prevalence of familial BE by reporting the proportion 
of patients diagnosed with BE, EAC or GEJAC that had at least one other family member 
diagnosed with BE, EAC or GEJAC. Chak et al.22 reported that about seven percent fulfill 
the criteria of familial BE, which is in line with the six percent reported by Ash et al.23 
Including GEJAC in familial BE can be criticized, since a tumor present on the gastro-
esophageal junction can be originated either from the esophagus or the gastric cardia. 
In the last instance the tumor probably did not arose from BE.
risk of GEr, bE and EAc for familial EAc
BE is generally accepted as the premalignant lesion for EAC. BE is a complication of chronic 
GER. The prevalence of BE in the common population is estimated at two percent,24 while 
the prevalence of BE among patients with GER is approximately ten percent.25 The annual 
risk of developing EAC from BE is estimated to be between 0.12 and 0.5%.20,21 Two case-
control studies about the prevalence of GER among relatives of BE patients suggested a 
familial predisposition for GER in these families.26,27 Among 27 and 47 relatives of patients 
diagnosed with BE or EAC, the prevalence of BE was reported to be 18% (n=5) and 28% 
(n=13), respectively.28,29 More importantly, the prevalence of EAC described among 20 
families with a strong familial expression of GER, BE, and EAC was estimated at 31%.14 
This finding suggests a true familial risk of EAC in these families. In contrast, a Swedish 
population-based, nationwide case-control study did not find an association between a 
positive history of esophageal cancer among first-degree relatives and the risk of EAC.30 
In addition, an Italian case-control study revealed no difference in prevalence of cancer 
in general between patients diagnosed with BE and patients with reflux esophagitis plus 
healthy controls. However, relatives of patients diagnosed with esophageal or gastric 
cancer had an increased risk of BE, particularly if the affected relative was younger 
than 50 years at time of diagnosis.31 It should be noted that the prevalence of familial 
BE is relatively low, hence in a randomly taken cohort of patients with BE only a few 
patients will be part of family with clustering of BE and/or EAC. Although the previously 
mentioned studies are based on relatively small samples sizes, the prevalence of EAC in 
these families with clustering of EAC appears to be distinctly higher than in the common 
population, and this also accounts for the prevalence of BE. 
risk factors and patient characteristics
Known risk factors for the malignant transition of BE into EAC are increasing age, male 
gender and Caucasian ethnicity.7 No differences in gender, ethnicity, and in addition in 
nicotine abuse and alcohol consumption were reported between patients with familial 
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BE and/or EAC and sporadic cases.22,23,28,32 Contradictory results were observed regarding 
the prevalence of obesity, with some studies reporting no difference in prevalence,28,32 
while others reported a lower body mass index for patients with familial BE and/or EAC 
compared to sporadic cases.22,23
Several studies reported a lower age at diagnosis for patients with familial BE and/or EAC 
compared with sporadic cases.12,13,23,33,34 Other studies could not confirm these observa-
tions.22,28,32 In a study on 20 families with a strong familial expression of GER, BE, and EAC, 
the age at diagnosis of EAC appeared to be five to ten years younger when compared to 
sporadic cases.14 This finding is consistent with the concept of the presence of a germline 
mutation, which generally results in a lower age at disease onset when compared with 
sporadic cases. This concept is based on the “Knudsons two hit” hypothesis for the com-
plete (biallelic) inactivation of tumor suppressor genes, i.e. individuals born with already 
one inactivating germline mutation are likely to develop the second somatic inactivat-
ing hit earlier in life than individuals without an inherited predisposition, who have to 
develop both somatic hits during life in the same cell before tumorigenesis occurs. The 
second hit may be influenced by environmental factors and/or by other genetic factors.35 
Pattern of inheritance
Since 1978 there have been several case reports on families with clustering of BE and 
EAC.9-14,34 All studies suggest a pattern of inheritance consistent with an autosomal 
dominant genetic trait,10-14 which likely reflects genetic predisposition to the disease. 
Nevertheless, it can be anticipated that familial EAC can also be caused by common 
environmental exposures in family members or by a combination of both. However, the 
segregation analysis (i.e. an analysis to determine whether a certain gene is involved 
in the distribution of a phenotypic trait) of Sun et al.36 provided the first epidemiologic 
evidence in support of a genetic etiology for familial BE, EAC or GEJAC. The pattern of 
inheritance was found to be consistent with a rare autosomal dominant genetic trait.
Genetic alterations and molecular markers
Hereditary tumors are generally caused by the presence of germline mutations, which are 
present in the reproductive cells of one or both of the parents of the affected offspring. 
Germline mutations are therefore present in all the cells of the affected offspring and 
can be transmitted from one generation to the next. Colorectal cancer has well-defined 
familial syndromes due to specific gene mutations. For example, patients with Lynch syn-
drome have germline mutations in mismatch repair (MMR) genes and attenuated familial 
adenomatous polyposis, familial adenomatous polyposis (FAP) and Gardner’s syndromes 
are all caused by germline mutations in the adenomatous polyposis coli (APC) gene.37
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Esophageal lesions are rarely described in these hereditary colorectal cancer syndromes. 
However, several studies reported the occurrence of BE and/or EAC in patients with (at-
tenuated) FAP or Gardner’s syndrome, which are both caused by mutations in the APC 
gene. Gupta et al.38 described a family with a father who tested positive for exon 4 dele-
tion in APC. All three of his sons were diagnosed with attenuated familial adenomatous 
polyposis based on the presence of multiple polyps (<100) throughout the entire colon. 
The middle son (41 year old) was additionally diagnosed with EAC in the background of 
BE. A biopsy of the father revealed BE with low-grade dysplasia. In the youngest son BE 
was also confirmed in histopathological biopsies. The oldest son had endoscopic findings 
compatible with esophagitis without metaplastic changes. Although the simultaneous 
occurrence of these two potentially inherited disorders in a single family may be due to 
chance alone, it is also possible that the disorders are linked. This suggests that deletions 
of the APC gene could play a role in the pathogenesis of familial BE and subsequently 
familial EAC. In another study with 36 FAP patients, six patients were additionally diag-
nosed with BE (16.7%); interestingly, the average age at diagnosis of BE was 20 years 
younger than that in the non-FAP patients with BE.39 In (attenuated) FAP, APC gene muta-
tions lead to increased nuclear β-catenin levels and activation of the Wnt pathway. In 
EAC, although through a different mechanism of Wnt activation, nuclear β-catenin is also 
frequently increased.40 It can be anticipated that the mutation in APC in patients with 
(attenuated) FAP might increase the chance of developing EAC.
EAC has not been associated with Lynch syndrome. However, three to five percent of EAC 
appears to have MMR deficiency.41 It is unknown, however, whether these tumors arise as 
part of Lynch syndrome or whether they are due to somatic MMR gene mutations. 
Orloff et al.42 sought to identify genes associated with BE and EAC predisposition. Germ-
line mutations in three candidate genes were identified in approximately 11% of patients 
diagnosed with BE and EAC, the most commonly affected gene being macrophage scav-
enger receptor 1 (MSR1), followed by activating signal cointegrator 1 complex subunit 1 
(ASCC1) and collagen triple helix repeat containing 1 (CTHRC1). However, further studies 
are needed to determine the role of these genes in the development of familial EAC.
cOnclUsiOns
Clustering of EAC in a family is rare but may be caused by an autosomal dominant genetic 
trait. In view of the poor prognosis of EAC, efforts should be made to identify a genetic 
predisposition for EAC in these families. Finding a genetic predisposition in familial EAC 
would facilitate identifying non-affected family members with the predisposition for this 
type of cancer. Endoscopic surveillance of relatives with the predisposition may lead to 
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the detection of preneoplastic or early neoplastic stages of EAC. Because patients diag-
nosed with earlier stages of EAC have a better chance for definite cure, this strategy could 
probably improve outcome.4
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AbsTrAcT
introduction: The vast majority of esophageal adenocarcinoma cases are sporadic 
and caused by somatic mutations. However, over the last decades several families have 
been identified with clustering of Barrett’s esophagus and esophageal adenocarcinoma, 
defined as familial Barrett’s esophagus. This observation suggests that one or more 
hereditary factors may play a role in the initiation of Barrett’s esophagus and esophageal 
adenocarcinoma in these families.  
Methods: A Dutch family with clustering of Barrett’s esophagus and esophageal adeno-
carcinoma was identified. Normal DNA obtained from an indicated proband diagnosed 
with Barrett’s esophagus was analyzed with SNP array and exome sequencing. A custom-
made panel consisting off potential germline variants was verified in the normal DNA 
of the affected family members. In addition, the respective tumors were analyzed for 
somatic loss of the wild type allele or the presence of an inactivating somatic mutation 
in the wild type allele.
results: Exome sequencing revealed 244 candidate variants in the normal DNA of the 
proband, of which 206 variants were verified successfully on the Ion Torrent Personal 
Genome Machine and six variants by Sanger sequencing. After the normal DNA of the 
affected family members was analyzed for the presence of the 212 potential germline 
variants and subsequently the respective tumors, only one potential germline variant in 
MSX1 showed loss of the wild type allele in both the tumor DNAs of the affected family 
members.
conclusion: A germline variant in MSX1 was identified in a Dutch family with clustering 
of Barrett’s esophagus and esophageal adenocarcinoma. This finding indicates that the 
germline defect in MSX1 may be associated with Barrett’s esophagus and cancer in this 
particular family.
6Germline variant in MSX1 in Dutch family with FBE
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inTrODUcTiOn
Esophageal adenocarcinoma (EAC) is a histopathological subtype of esophageal cancer, 
of which the incidence is rising rapidly over the last decades in Western countries.1-3 The 
presence of Barrett’s esophagus (BE), as a consequence of chronic gastroesophageal re-
flux (GER), is generally accepted as the predominant risk factor of EAC. Other risk factors 
are high age, male gender, Caucasian ethnicity,4 and obesity.5 The risk of developing EAC 
from BE is estimated at 0.12-0.5% per year6,7 and follows a multimorphological sequence, 
in which metaplasia evolves to low-grade dysplasia (LGD), high-grade dysplasia (HGD) 
and ultimately into invasive adenocarcinoma.8 
Although the vast majority of BE and EAC cases are sporadic and caused by somatic 
mutations, over the last decades several families have been identified with clustering 
of BE and EAC.9-12 Previous studies introduced the definition familial BE (FBE), i.e. two or 
more first- or second-degree family members diagnosed with BE or EAC. It has been esti-
mated that approximately seven percent of BE and EAC cases are considered familial.13-15 
When compared to sporadic cases, familial cases of BE and EAC are mostly diagnosed at a 
younger age.14-16 These findings are consistent with the presence of a germline mutation 
in a cancer-predisposing gene. Theoretically, a germline mutation can be present in a 
proto-oncogene or in a tumor suppressor gene. The pattern of inheritance suggested for 
FBE17 and for most familial cancer syndromes (familial adenomatous polyposis, heredi-
tary breast and ovarian cancer, familial atypical multiple mole melanoma, Li-Fraumeni 
syndrome) is consistent with the concept of “Knudsons two hit” hypothesis, and is caused 
by biallelic inactivation of a tumor suppressor gene. 
It can be anticipated that the development of BE and EAC in several members of one family 
is caused by the presence of a germline defect. Orloff et al.18 identified germline mutations 
in the genes MSR1, ASCC1, and CTHRC1 with the use of a linkage analysis on affected siblings 
diagnosed with BE or EAC. However, information about the presence of identical germline 
mutations in affected siblings is lacking and the role of these genes in the development 
of FBE is unknown. Extensive candidate gene and linkage researches have to date been 
unsuccessful in identifying genetic variants that are associated with the risk of FBE.
Here, we describe a family, of whom two members were diagnosed with BE and three 
with EAC. To identify a possible germline defect in the affected family members, we 
investigated the normal DNA of a proband with a SNP array and exome sequencing. 
Subsequently, we validated the potential germline variants identified in the proband in 
the normal and tumor DNA of the other affected family members on a next-generation 
sequencing platform. 
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METHODs
This study was approved by the Erasmus MC – University Medical Center Rotterdam In-
stitutional Review Board. Formal written informed consent was obtained from the living 
family members, whom are therefore included in the study. All tissues investigated in 
this study were used in accordance with the code for adequate secondary use of tissue, 
code of conduct: “Proper Secondary Use of Human Tissue” as established by the Dutch 
Federation of Medical Scientifi c Societies (http://www.federa.org).  
family presentation
The fi rst family member (further referred to as proband), who came to our attention is a 
male patient of 45 years (Figure 1: II-3). He has been suff ering from pyrosis for several years 
and was diagnosed with BE (LGD) based on histopathological examination of multiple bi-
opsies obtained during upper gastrointestinal endoscopy. In addition, in his family there 
is a high incidence of BE and EAC (Figure 1). His father (I-1) was diagnosed with EAC at the 
age of 50 years and died in the same year of the consequences of the disease (no further 
information available). The oldest brother of the proband (II-1) was diagnosed with EAC 
at the age of 49 years. He underwent neoadjuvant chemoradiotherapy followed by an 
figure 1: Pedigree of investigated family
Black symbols indicate esophageal adenocarcinoma. Partly blocked symbols indicate Barrett’s esophagus 
and/or gastroesophageal refl ux (GER). The proband is indicated by a red arrow.
6Germline variant in MSX1 in Dutch family with FBE
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esophagectomy. Pathological examination of the resection specimen revealed a vital 
adenocarcinoma within the background of BE located at the distal esophagus, Mandard 
score III-IV, pT3N0. He died one month later at the age of 50 years due to postopera-
tive complications. At autopsy, liver metastases were identified. Furthermore, the older 
sister of the proband (II-2) was diagnosed with a poorly differentiated adenocarcinoma 
at the gastroesophageal junction at the age of 45 years and died one year later of the 
consequences of the disease. The younger brother of the proband (II-4) has been suffer-
ing from pyrosis for several years, and was diagnosed with BE (intestinal metaplasia, no 
dysplasia) based on histopathological examination of multiple biopsies obtained during 
upper gastrointestinal endoscopy at the age of 40 years. He was prescribed proton pump 
inhibitors and included in the surveillance program for BE, in the biopsies taken during 
the latest control no intestinal metaplasia was observed any longer. The youngest sister 
of the proband (II-5) did not give informed consent, and was therefore not included in 
the study.
snP array and exome sequencing
The proband (II-3) was subjected to genetic testing, i.e. SNP array and exome sequenc-
ing performed at the Erasmus MC Center for Biomics, Rotterdam, the Netherlands. 
After informed consent was obtained during a counselling session at the Department 
of Clinical Genetics, blood was drawn and DNA was isolated using a Chemagic DNA 
Blood Kit according to standard procedures. To identify copy number variations (CNVs) 
in the germline DNA of the proband (II-3), the Genome-wide human SNP array 6.0 was 
performed according to the manufacturer’s protocol (Affymetrix, Santa Clara, CA, USA). 
Data were analyzed using Nexus Copy Number tm V4 software (Biodiscovery, Hawthorne, 
CA, USA). Exome sequencing was performed on the Hiseq2000, using the Agilent version 
4 capture kit, according to the Illumina TruSeq v3 protocol. Reads were aligned against 
the human reference genome build 19 (hg19) using Burrows-Wheeler Aligner,19 and the 
NARWHAL pipeline.20 Subsequently, genetic variants were called using tools from the 
genome analysis toolkit.21 The resulting VCF files were processed with a custom variant 
annotation tool that determines the variant effects. Germline variants identified by 
exome sequencing were selected to cause amino-acid changes or splice site alterations, 
in addition variants present in the dbSNP135 database or with a frequency of >1% in 
ESP6500 and the 1000 Genomes databases were excluded. To confirm these data on a 
different platform, a custom-made panel was designed by the Ion AmpliSeq Designer 
V2.0 for targeted sequencing on the Ion Torrent Personal Genome Machine (PGM) (Life 
Technologies, Carlsbad, CA, USA). In short, libraries were made using the Ion AmpliSeq 
Library Preparation Kit. A template was prepared using the Ion OneTouch Template Kit 
and sequencing was performed with the Ion Sequencing Kit v2.0 on an Ion 316 chip. 
Data were analyzed with the Variant Caller v2.2.3-31149 (Life Technologies, Carlsbad, CA, 
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USA). For the variants that could not be validated by the PGM, primers were designed for 
PCR amplification and Sanger sequencing on an ABI 3730 sequencer (Life Technologies, 
Carlsbad, CA, USA) according to the BigDye Terminator v3.1 Cycle Sequencing Kit Proto-
col. DNA sequences were visualized using the Mutation Surveyor software (Softgenetics, 
State College, PA, USA), which aligned the sequences to annotated GenBank reference 
files.
Tissue samples 
To test whether the validated germline variants in the proband (II-3) could also be 
identified in the normal and tumor DNA of the family members, formalin-fixed paraffin-
embedded (FFPE) tissue blocks were reclaimed from several pathology archives in the 
Netherlands. Tumor tissue (II-1, II-2) composed of at least 50% neoplastic cells (confirmed 
by a GI-pathologist) and areas of non-malignant esophageal cells (II-1, II-2, II-4) were 
manually microdissected from 10 to 15 hematoxylin-stained sections (4µm). Subse-
quently, DNA was extracted using proteinase K and 5% Chelex 100 resin.
rEsUlTs
The SNP array revealed a known CNV with no clinical relevance and a CNV in an unknown 
gene (data not shown). Exome sequencing performed on the normal DNA of the proband 
(II-3) revealed after the selection procedure 244 candidate germline variants (Table 1). For 
228 variants custom-made primers could be designed to confirm the data on a different 
platform. After sequencing on the PGM, 206 variants were verified successfully in the nor-
mal DNA of the proband (II-3). The remaining 22 variants obtained either low sequencing 
depth or poor coverage and therefore did not qualify for further analysis on the PGM. For 
the 38 variants, which could not be validated by the PGM, primers were designed for PCR 
amplification and Sanger sequencing. Of the 38 variants, six were validated in the normal 
DNA of the proband (II-3) by Sanger sequencing. Leaving 212 potential germline variants 
of interest, which were validated in the family members (Figure 2).
Table 1: Mutations identified in normal DNA of the proband by exome sequencing.
Amount
n=244 (%)
Nonsynonymous
Stop gains
Frameshift indels*
Non-frameshift indels*
Splice site variants
Unknown
164
3
14
44
12
7
(67.2)
(1.2)
(5.7)
(18.0)
(4.9)
(2.9)
* Indels = insertions and deletions
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The custom-made panel for the PGM, containing the germline variants identifi ed in the 
proband (II-3), was extended to two other aff ected members of the family (II-1, II-2). 
Normal DNA of the aff ected family members (II-1, II-2) was analyzed for the presence 
of the 212 potential germline variants identifi ed in the proband (II-3). In addition, the 
respective tumors of the family members (II-1, II-2) were analyzed for somatic loss of 
the wild type allele or the presence of an inactivating somatic mutation in the wild type 
allele. Twenty-four of the potential germline variants were also identifi ed in the normal 
figure 2: Flowchart of sequencing pipeline
WES: Whole-exome sequencing
PGM: Ion Torrent Personal Genome Machine
Sanger: Sanger Sequencing
G: Germline DNA
T: Tumor DNA
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DNA of the family members II-1 and II-2.  Only one potential germline variant, MSX1 (chr4: 
4861985 T>G, c.359T>G, p.V120G, NM_002448), showed loss of the wild type allele in 
both the tumor DNA of family members II-1 and II-2. In the normal and metaplastic DNA 
of the youngest brother (II-4) no variant in MSX1 was identified (Figure 3).
DiscUssiOn
For the first time a germline variant in the MSX1 gene was identified in a family with 
clustering of BE and EAC with the aid of exome sequencing. In addition, the investigated 
tumors of two affected family members showed somatic loss of the wild type allele. The 
germline variant in MSX1 changed codon 120 from Valine into Glycine.  Although not 
reported in the Cosmic database and in dbSNP135, the variant was described before on 
a very low frequency (allele frequency: 0.00052),22 suggesting that this is a rare variant. 
This finding indicates that the germline defect in MSX1 may be associated with the high 
occurrence of BE and EAC in this Dutch family.
figure 3: Sanger sequencing results of MSX1
(A) Sanger sequencing of normal DNA of the proband (II-3) confirmed the presence of the heterozygote 
variant (c.359T>G) in MSX1.
(B) Sanger sequencing of normal DNA of youngest brother of the proband (II-4) 
 reveal no variant in MSX1.
(C) Sanger sequencing of normal DNA (upper panel) and tumor DNA (lower panel) of the oldest brother 
of the proband (II-2) confirmed the presence of the heterozygote variant (c.359T>G) in MSX1 in normal 
DNA and loss of the wild type allele in tumor DNA, which changed the codon 120 from Valine into Gly-
cine (p.V120G).
(D) Sanger sequencing of normal DNA (upper panel) and tumor DNA (lower panel) of the oldest sister of the 
proband (II-2) confirmed the presence of the heterozygote variant (c.359T>G) in MSX1 in normal DNA 
and loss of the wild type allele in tumor DNA, which changed the codon 120 from Valine into Glycine 
(p.V120G).
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MSX1 encodes a homeobox protein and is involved in multiple epithelial-mesenchymal 
interactions. In addition, MSX homeobox genes are able to interact with bone morphoge-
netic proteins (BMPs), in particular to the closely related BMP-2 and BMP-4.  Recent stud-
ies established e.g. BMP-4 signaling as important interconnected regulatory pathways 
that contribute to the early stage of the transformation of the epithelial cells of the distal 
esophagus from the normal stratified squamous mucosa to an intestinal columnar cell 
type. BMP-4 was found to be present in inflamed squamous epithelium but not in normal 
squamous mucosa.23 MSX1 may be involved in the malignant progression of BE into EAC 
for familial cases as well as for sporadic cases, however somatic mutations in MSX1 were 
identified in a very low frequency by Dulak et al.24 (p.R158W, p.F151L, p.P153P), suggest-
ing a prominent role of this germline defect in the development of BE and EAC in this 
particular family. In addition, mutations in MSX1 have also been reported in families with 
dominantly inherited congenital absence of several permanent teeth, called oligodontia 
or hypodontia, with or without cleft lip and/or palate,25-28 no oligodontia or hypodontia 
was observed in the proband.
In one of the family members (II-4) the MSX1 variant was not observed, although he 
did suffer from pyrosis and was diagnosed with intestinal metaplasia at the first his-
topathological examination.  However, the most recent biopsies taken during upper 
gastro-intestinal endoscopy revealed no signs of intestinal metaplasia. It can therefore 
be hypothesized that family member II-4 is a phenocopy. Since the prevalence of BE in 
the common population is estimated at two percent,29,30 it can be anticipated that the ini-
tial metaplasia in this family member developed as a consequence of an environmental 
factor, instead of within the context of an inherited genetic defect.
Family member II-3 was indicated as the proband and since he was only diagnosed with 
BE without invasive carcinoma, it has to be taken into account that MSX1 may only be 
associated with the development of BE and not necessarily with EAC. In addition, it was 
not possible to test the presence of the MSX1 variant in the father of proband (I-1), also 
diagnosed with EAC, since no tissues blocks were present. 
In conclusion, a germline variant in MSX1 was identified in the normal DNA of three af-
fected members of a family with clustering of BE and EAC, in addition the investigated 
tumors showed somatic loss of the wild type allele, consistent with biallelic inactivation 
of a tumor suppressor gene. This germline defect may be associated with the develop-
ment of BE and EAC in this family. However, functional studies have to be performed to 
prove any effect of this germline defect.
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AbsTrAcT
background: The incidence of esophageal cancer has risen among all age groups. Con-
troversy exists about the clinical presentation and prognosis of young patients. The aim 
of this study was to compare the clinicopathological characteristics and outcome after 
surgery between patients with esophageal cancer, who were ≤50 years of age and those 
>50 years of age.
Methods: Patients diagnosed with esophageal carcinoma, who underwent esophagec-
tomy between January 1990 to January 2011 in a single institution were selected from 
a prospective database. Patients aged ≤50 years at diagnosis (n=163) were compared 
with those >50 years (n=1,151) with respect to clinicopathological stage and oncological 
outcome.
results: Younger patients had less co-morbidities (p<0.001). There were no signifi-
cantly differences in tumor localization, histology, differentiation or TNM stage in the 
two groups. In both groups, 37% of the patients underwent neoadjuvant chemo(radio)
therapy. One or more nonsurgical complications developed in 53% of the older group 
versus 42% in the younger group (p=0.012). In-hospital mortality was 6.3% for patients 
>50 years compared to 1.8% for younger patients (p=0.021). The 5 -year overall survival 
was significantly better for the younger patients than for those <50 years (41 vs. 31%, 
p<0.001), but median disease-specific and disease-free survival did not differ between 
the groups (37 vs. 30 months, p=0.140 and 49 vs. 28 months, p=0.079 respectively). 
Multivariate analysis identified moderate, poorly, and undifferentiated tumors; tumor-
positive resection margins (pR1-2) and TNM stage IIB- IV as independent predictors of 
disease-specific survival.
conclusion: A considerable proportion (12%) of patients diagnosed with resectable 
esophageal carcinoma were ≤50 years. Phenotypic tumor characteristics and disease-
specific survival were comparable for the two age groups.
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inTrODUcTiOn
Over the last decades there has been a marked increase in the incidence of esophageal 
cancer, which is mainly attributed to an increase in esophageal adenocarcinoma (EAC) 
in developed countries.1-3 This rise has occurred among all age groups, which makes 
esophageal cancer no longer a disease of the elderly,4 although esophageal cancer is still 
relatively rare in patients ≤50 years of age.
Controversy exists about the biological behaviour and prognosis of young patients with 
EAC. Some studies suggest that younger patients present with more advanced disease 
but receive more aggressive treatment and therefore attain a survival comparable to that 
of their older counterparts.5-7 Others found that younger patients did not differ from their 
older counterparts with regard to clinicopathological characteristics or survival.8-11 The 
aim of this retrospective analysis was to compare clinicopathological characteristics and 
short- and long-term follow-up of patients with esophageal cancer, who were ≤50 years 
of age and those >50 years. 
METHODs
Patients
All patients who were diagnosed with cancer of the esophagus or gastroesophageal 
junction (GEJ) and underwent esophagectomy with curative intent between January 
1990 and January 2011 were included in the study. Patients with an unresectable tumor 
and those with a tumor of the GEJ, who underwent a total gastrectomy were excluded. 
Neoadjuvant chemotherapy was given to a cohort of patients with squamous cell 
carcinoma (SCC) of cT1-3N0-1M0, who participated in a randomized controlled trial.12 
Preoperative and postoperative chemotherapy was given to patients with proximal 
gastric cancer infiltrating into the distale esophagus after the results of the MAGIC-trial 
became available.13 None of the patients received adjuvant chemoradiationtherapy. In-
duction chemotherapy was used in patients with gross celiac lymph node involvement, 
who were not eligible for primary surgical therapy.14 From 2003 untill 2009, a number of 
patients with an operable tumor received neoadjuvant chemoradiation as participants in 
a randomized controlled trial.15 Neoadjuvant chemoradiation has become our preferred 
treatment since early 2010.
Clinicopathological characteristics of patients, treatment, and follow-up were prospec-
tively collected by a dedicated database manager, who closely collaborated with the 
medical team and attended the weekly multidisciplinary conferences. Also attending 
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the meetings were one or more surgeons, a gastroenterologist, a medical oncologist, a 
radiation therapist and a pathologist. At these meetings, patient characteristics, clinical 
staging, details on treatment, postoperative morbidity and mortality, and pathological 
staging were discussed. They were reported thereafter in the database.16
The young aged group was defined as patients ≤50 years of age at the time of diagnosis. 
This group was compared with patients >50 years of age. The cut-off point of 50 years was 
arbitrary chosen and based on data in other articles.6,8 The 7th edition of the American 
Joint Committee on Cancer (AJCC) Staging Manual was used for describing the tumor, 
the node and metastasis classifications, and staging.17  
surgery
Most of the patients underwent transhiatal esophagectomy. The primary tumor and its 
adjacent lymph nodes were dissected under direct vision through the widened hiatus 
of the diaphragm up to the level of the inferior pulmonary vein. All adjacent fatty tissue 
surrounding the tumor was removed simultaneously until the lateral resection margins 
were reached (diaphragm, pleura, pericardium, aorta). Subsequently, a gastric tube was 
created. The left gastric artery was transected at its origin, with local resection of celiac 
trunk lymph nodes. After mobilization and transection of the cervical esophagus, the 
normal intrathoracic esophagus proximal to the primary tumor was mobilized from the 
neck to the abdomen with a vein stripper. No formal cervical or mediastinal lymph node 
dissection was carried out. Esophagogastrostomy (hand-sewn or by using a circular 
stapler) was performed in the neck. 
Right posterolateral thoracotomy was the first step in transthoracic resection with 
extended lymphadenectomy. The thoracic duct, azygos vein, ipsilateral pleura, and 
all periesophageal tissue in the posterior mediastinum were dissected en bloc. The 
resection specimen included the lower and middle mediastinal, subcarinal, and right-
sided paratracheal lymph nodes. The aortopulmonary window nodes were dissected 
separately. Through a midline laparotomy, the paracardial, lesser curvature, left gastric 
artery, celiac trunk, common hepatic artery, and splenic artery nodes were dissected; 
and a gastric tube was constructed. The cervical part of the transthoracic procedure was 
identical to that of the transhiatal procedure.
statistical analysis
Data analysis was performed with SPSS version 18.0 (SPSS, Chicago, IL, USA). Two-sided 
p-values <0.05 were considered significant. Categorical variables were summarized using 
frequencies and percentages. Proportions were compared using χ2 test or Fisher’s exact 
tests for the categorical variables. Survival estimates were calculated using Kaplan-Meier 
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curves, and differences were tested with a log-rank test. Survival time was measured from 
the date of surgery to the date of an event (defined as death or recurrence of disease). 
The cause of death was obtained from the database. When it was unknown, the patient’s 
general practitioner was contacted to retrieve the information. Patients were censored 
at the date of last follow-up. Survival data are expressed as medians with interquartile 
ranges (IQR). Separate models for overall survival (OS), disease-specific survival (DSS) (ex-
cluded: in-hospital mortality and 30 day mortality), and disease-free survival (DFS) were 
created. Univariate analysis were performed to identify prognostic variables associated 
with DSS and OS after esophagectomy. Cox proportional hazard models were used to 
identify independent predictors of DSS and OS. Variables were entered in the multivariate 
Cox proportional hazard model if they reached p-value of <0.10 in the univariate analysis. 
rEsUlTs
Patients
A total of 1,589 patients with cancer of the esophagus or cancer of the GEJ were re-
trieved from the database. Patients with the bulk of the tumor being located in the cardia 
(n=37), patients with proof of local irresectability and/or distant dissemination [n=192: 
25 (13.0%) ≤50 years, 167 (86.9%) >50 years], patients who underwent total gastrectomy 
with distal esophagectomy (n=43), and patients who did not undergo esophagectomy 
because of intraoperative complications (n=3) were excluded. The remaining 1,314 pa-
tients underwent esophagectomy with curative intent. 
The mean ± SD age of the study population was 62.2 ± SD 9.824 years. Some 1,019 
patients (77.5%) were men and 295 (22.5%) were women. Among these patients, 163 
(12.4%) were ≤50 years of age (median: 47 years, range: 19-50 years), and 1,151 (87.6%) 
were >50 years (median: 64 years, range: 51-90 years).
Patient characteristics are shown in Table 1. Patients >50 years had significantly more 
co-morbidities, in particular cardiac, respiratory, and vascular diseases. Localization of 
the tumor did not differ between the younger and older patients.
Tumor characteristics are shown in Table 2.  Among the patients, adenocarcinoma was 
the most prevalent histologic type (67.8%) and was found to be more common among 
the patients ≤50 years of age. There were no differences between the two groups with 
regard to grade of differentiation, pTNM stage and radicality of the resection.
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Table 1: Patients characteristics
Age≤ 50 years 
n=163 (%)
Age> 50 years 
n= 1,151 (%)
p-value
Age (median) 47 (19-50) 64 (51-90)
sex 
  Male
  Female
133 (81.6)
  30 (18.4)
886 (77.0)
265 (23.0)
0.186
co-morbidity 
  Cardiac
  Respiratory
  Vascular
  Neurological
  Diabetes Mellitus
  Mental
  Other malignancy
  Other
  50 (30.7)
  14 (8.6)
  14 (8.6)
    5 (3.1)
    5 (3.1)
    6 (3.7)
    3 (1.8)
    8 (4.9)
  10 (6.1)
675 (58.6)
322 (27.9)
199 (17.3)
167 (14.5)
  63 (5.5)
110 (9.6)
    6 (0.5)
101 (8.8)
  98 (8.5)
<0.001
localisation tumor 
  Cervical
  Upper 1/3 thoracic
  Middle 1/3 thoracic
  Lower 1/3 thoracic
  Gastroesophageal junction
  Unknown
    1 (0.6)
    4 (2.5)
  15 (9.2)
  67 (41.1)
  75 (46.0)
    1 (0.6)
    3 (0.3)
  16 (1.4)
163 (14.2)
484 (42.1)
481 (41.8)
    4 (0.3)
0.400
Table 2: Tumor characteristics
Age≤ 50 years 
n=163 (%)
Age> 50 years 
n= 1,151 (%)
p-value
Tumor type 
  Squamous cell carcinoma
  Adenocarcinoma
  High-grade dysplasia
  Other
  39 (23.9)
116 (71.2)
    6 (3.7)
    2 (1.2)
346 (30.1)
775 (67.3)
  15 (1.3)
  15 (1.3)
0.066
Differentiation 
  Unknown
  Good
  Moderate
  Poor/Undifferentiated
pT*
  0
  is
  1
  2
  3
  4
pn* 
  0
  1
  2
  3
pM* 
  0
  1
  21 (12.9)
  13 (8.0)
  69 (42.3)
  60 (36.8)
  
  10 (6.1)
  10 (6.1)
  28 (17.2)
  23 (14.1)
  91 (55.8)
    1 (0.6)
69 (42.3)
32 (19.6)
31 (19.0)
21 (12.9)
152 (93.3)
 1 (0.6)
106 (9.2)
  78 (6.8)
487 (42.3)
480 (41.7)
    
  75 (6.5)
  29 (2.5)
167 (14.5)
186 (16.2)
687 (59.7)
    7 (0.6)
454 (39.4)
274 (23.8)
183 (15.9)
165 (14.3)
1062 (92.3)
 14 (1.2)
0.373
0.171
0.651
0.778
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Treatment
Treatment details are summarized in Table 3. In both groups, 37% of the patients under-
went neoadjuvant therapy. The percentage of transhiatal esophagectomy was higher in 
the younger patients than in the older patients (82.8 vs. 75.2%, p=0.032).  In 89.2% of 
all patients who underwent transhiatal esophagectomy, the tumor was localized in the 
lower one-third of the esophagus or at the GEJ, and 73.7% of the tumors were EACs. 
Adjuvant therapy was rarely used. It was applied more often in the younger patients 
(chemotherapy 1.8 vs. 1.2%, radiotherapy 8.0 vs. 1.9%; p<0.001).
Table 2: Tumor characteristics (continued)
Age≤ 50 years 
n=163 (%)
Age> 50 years 
n= 1,151 (%)
p-value
stage grouping* 
  No evidence of primary      
  tumor
  0 (HGD)
  IA
  IB
  IIA
  IIB
  IIIA
  IIIB
  IIIC
  IV
11 (6.7)
  
    7 (4.3)
  14 (8.6)
  17 (10.4)
    5 (3.1)
  38 (23.3)
  24 (14.7)
  24 (14.7)
  22 (13.5)
    1 (0.6)
  
 74 (6.4)
  
  25 (2.2)
  84 (7.3)
  94 (8.2)
  74 (6.4)
260 (22.6)
226 (19.6)
138 (12.0)
162 (14.1)
  14 (1.2)
0.373
resection**
  R0
  R1
  R2
124 (76.1)
  36 (22.1)
    3 (1.8)
842 (73.2)
284 (24.7)
  25 (2.2)
  0.729
* According to AJCC, American Joint Committee on Cancer 7th edition17
** R0 = tumor free resection margin, R1= vital tumor present at 1 mm from the proximal, distal or circumfer-
ential resection margin, R2= residual macroscopic tumor
Table 3: Treatment details
 Age≤ 50 years
n=163  (%) 
Age> 50 years 
n= 1151 (%)
p-value
neoadjuvant therapy 
  Chemotherapy only
  Chemoradiation
    36 (25.2)
    20 (12.3)
  262 (25.7)
  127 (11.0)
0.896
0.639
Type of surgery 
  Transthoracic esophagectomyy
  Transhiatal esophagectomy
  28 (17.2)  
135 (82.8)   
286 (24.8)
865 (75.2)   
0.032
 Adjuvant therapy 
  Chemotherapy
  Radiotherapy
      3 (1,8)
    13 (8.0)
    14 (1.2)
    22 (1.9)
<0.001
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Morbidity and mortality
Postoperative complications are shown in Table 4. Surgical complications did not differ 
between the two groups, but nonsurgical complications were seen more often in the 
older patients (p=0.012). In-hospital mortality was 1.8% for the younger patients com-
pared to 6.3% for the older patients (p=0.021).  The 30 day mortality rates for the younger 
and the older patients was 1.0 and 4.3%, respectively (p=0.069). 
survival
The median OS was 33 months (IQR 12-134 months) for patients ≤50 years of age and 23 
months (IQR 9-86 months) for the patients >50 years. The 5-year OS was 40.5% for the 
younger patients versus 31.0% for the older patients (p= 0.001) (Figure 1). The DSS did 
not differ between the two groups, with a median survival for the younger group at 37 
months (IQR 12-134 months) and for the older group at 30 months (IQR 12-185 months). 
The younger group versus older group 5-year survivals were 43.6 and 37.4%, respectively 
(p=0.140) (Figure 2). There was no significant difference between the younger and older 
group in regard to the percentage of patients who developed locoregional and/or distant 
recurrences: 48.5 versus 50.2%, respectively (p= 0.676). The median DFS was 49 months 
(IQR 10-109 months) for the young patients and 28 months (IQR 10-147) for the older 
patients, with corresponding 5-year survival rates of 49.2 and 39.8% (p=0.079) (Figure 3).
Table 4: Morbidity and mortality
Age≤ 50 years 
n=163 (%)
Age> 50 years 
n= 1,151 (%)
p-value
surgical complications 
  Hemorrhage
  Chylothorax
  Suture leak
  Jejunum fistula leak
  Unilateral recurrence nerve palsy
  Bilateral recurrence nerve palsy
  Wound infection
  Graft necrosis
  Other 
67 (41.1)
  4 (2.5)
  8 (4.9)
17 (10.4)
  1 (0.6)
26 (16.0)
  3 (1.8)
11 (6.7)
  2 (1.2)
10 (6.1)
444 (38.6)
  41 (3.6)
  48 (4.2)
106 (9.2)
  10 (0.9)
153 (13.3)
  27 (2.3)
  56 (4.9)
  37 (3.2)
127 (11.0)
0.535
nonsurgical complications 
  Pneumonia or atelectasis
  ARDS
  Myocardial infarction
  Urinary tract infection
  Sepsis
  Thrombosis or pulmonary embolism
  Other
Mortality 
69 (42.3)
50 (30.7)
  4 (2.5)
  0 (0.0)
  0 (0.0)
  4 (2.5)
  4 (2.5)
25 (15.3)
608 (52.8)
384 (33.4)
  56 (4.9)
  15 (1.3)
  24 (2.1)
  44 (3.8)
  40 (3.5)
319 (27.7)
0.012
  In-hospital 
  30 days
  3 (1.8)
  1 (1.0)
  73 (6.3)
  36 (4.3)
0.021
0.069
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figure 1: Overall survival according to age group
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Prognostic factors
Factors predicting OS in the univariate analysis are shown in Table 5. Independent pre-
dictors of OS were age, presence of co-morbidity, occurrence of surgical complications, 
poorly and undifferentiated tumors, tumor-positive resection margins (pR1-2), and TNM 
stage IIB- IV(Table 6).  Multivariate analysis identified moderately, poorly, and undif-
ferentiated tumors, tumor positive resection margins (pR1-2), and TNM stage IIB- IV as 
independent predictors of DSS.
figure 3: Disease-free survival according to age
Disease-free survival                      Age ≤ 50 years  (n= 163)     Age > 50 years (n= 1,151)             
Median survival (IQR)                       49 (10-109)                                28 (10-147)
Mean survival (95% CI)                    119.2 (100.1-138.4)                  99.8 (92.0-107.6)
5-year survival                                    49.2%                                           39.8%
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Table 5: Cox proportional hazard analysis for overall survival (univariate)
factor Hazard ratio (95% ci) p-value
co-morbidity 1.277 (1.122-1.454) <0.001
surgical complications 1.365 (1.198-1.555) <0.001
nonsurgical complications 1.123 (0.987-1.276)   0.078
Differentiation*
  Good
  Moderate 
  Poor/undifferentiated
1.520 (0.993-2.326)
3.083 (2.235-4.249)
4.292 (3.113-5.918)
  0.054
<0.001
<0.001
neoadjuvant chemotherapy 0.949 (0.813-1.108)   0.511
neoadjuvant chemoradiation 0.635 (0.489-0.823)   0.001
r1/2** 2.840 (2.468- 3.268) <0.001
sex: Male 1.146 (0.980-1.340)   0.088
stage***
  0 - IIA
  IIB - IIIB
  IIIC - IV
1.798 (1.152-2.806)
4.527 (2.955-6.936)
9.332 (5.984-14.553)
  0.010
<0.001
<0.001
Age ≤50 years
Transthoracic esophagectomy
0,718 (0,584-0,882)
1.194 (1.021-1.397)
  0.002
  0.026
   * With reference to not differentiated
  ** With reference to R0
*** With reference to Tis (HGD)
Table 6: Cox proportional hazard analysis for overall survival (multivariate)
factor Hazard ratio p-value
Age ≤50 years
co-morbidity
surgicalcomplications
nonsurgical complications
Differentiation*
  Good
  Moderate
  Poor/undifferentiated
r1-2**
stage***
  0-IIA
  IIB-IIIB
  IIIC-IV
sex: Male
neoadjuvant chemoradiation
Transthoracic esophagectomy
0.761 (0.616-0.939)
1.233 (1.079- 1.407)
1.296 (1.133- 1.483)
1.074 (0.940-1.228)
0.973 (0.582-1.627)
1.463 (0.935-2.288)
1.635 (1.037-2.577)
1.988 (1.710-2.311)
1.296 (0.729-2.303)  
2.563 (1.412-4.654)
4.581 (2.475-8.478)
1.049 (0.894-1.232)
1.032 (0.788-1.352)
1.223 (1.079-1.407)
  0.011
  0.002
<0.001
  0.293
 
  0.917
  0.096
  0.034
<0.001
  0.378
  0.002
<0.001
  0.556
  0.819
  0.788
   * With reference to not differentiated
  ** With reference to R0
*** With reference to Tis (HGD)
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DiscUssiOn
There is an on going debate about the relations between patient’s age and the clinical 
presentation and prognosis of esophageal cancer. Because survival is highly correlated 
with tumor stage at presentation, early diagnosis is important. To identify young patients 
at an early stage and to define the best treatment strategy for young patients, more 
insight in the oncological nature and prognosis of young patients is needed. This study 
shows that EAC is by far the most common type of cancer among all age groups. Also, 
there is a trend towards a higher prevalence of EAC in younger patients. These younger 
patients have less co-morbidities than their older counterparts. Contrary to others, there 
was no difference shown between the age groups regarding tumor localization, tumor 
grade, TNM stage, or resection margin. Survival analysis demonstrated a significantly 
better overall 5-year survival for the younger patients. However, DSS and DFS did not 
differ significantly between the two groups.
Another study from our institution showed that the increased incidence of EAC has oc-
curred parallel to the increase of Barrett’s esophagus, the precursor lesion of EAC.18 This 
rise in incidence represents a real increase in the burden of the disease.19 This implies a 
shift in the prevalence of causal exposure. Gastroesophageal reflux  (GER) is thought to 
be the primary causal factor of EAC.20-24 Obesity and overweight are associated with GER 
and show an upward trend in prevalence among all ages.25 Therefore, it is conceivable 
that the downward shift in age at the onset of EAC is due to an increase in the prevalence 
of obesity and overweight among younger individuals. Unfortunately, we do not have 
detailed information on anthropomorphic characteristics of our patients. Donohoe et al. 
reported no difference between patients ≤50 versus >50 years in regard to body mass 
index at the time of diagnoses. They also observed that younger patients were more 
likely to be current smokers.8
The transformation of a normal cell into a tumor cell is caused by 10 to 20 mutations 
in a specific gene, and the time necessary for this to occur is one to several decades. 
Provided that specific inherited predispositions are absent, cancer is a disease that oc-
curs after several decades of human life and is thought to be uncommon before the age 
of 50 years. Moreover, the average age of patients with esophageal cancer is around 72 
years.26 Patient and doctor’s awareness is relatively low at a young age, and therefore 
the diagnosis in young patients with specific symptoms is often delayed.  Previous 
studies concluded that younger patients with esophageal carcinoma present with more 
advanced disease because of a delay in diagnosis, but they attain a survival comparable 
to that of their older counterparts because of more aggressive treatment or the lower 
prevalence in co-morbidities and larger physiological reserve.5-7 Our study also dem-
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onstrated that younger patients present with fewer co-morbidities, undergo adjuvant 
therapy more often, and have a lower in-hospital mortality rate. Contrary to our expecta-
tions, a transhiatal surgical approach was used more often in the younger patients rather 
than transthoracic esophagectomy. Nowadays, we prefer transhiatal esophagectomy for 
tumors at the GEJ,27 but localization of the tumor did not differ between the two groups. 
A higher percentage of the patients >50 years were diagnosed with SCC, which is invari-
ably treated with a transthoracic approach. 
Although OS was significantly better for the younger group, there were no differences 
in clinicopathological characteristics or the DSS rate between the groups. These findings 
suggest that patients >50 years die of causes other than recurrent cancer, such as cardiac, 
respiratory and vascular events. Other studies have reported no difference between 
younger and older patients regarding clinicopathological characteristics or survival,8-11 
which is in line with the results of this study. Taken together, younger patients do not 
present with more aggressive disease than their older counterparts, which suggests no 
difference in biological behaviour of the tumor. Because of excluding patients with an 
unresectable tumor in this study, this conclusion cannot yet be drawn.
A limitation of the study is that the duration of symptoms and disease stage at presenta-
tion were not evaluated in patients who were not eligible for surgery and were treated 
with palliative intent. It could be that a larger or smaller percentage of patients aged 
≤50 years had metastatic disease and did not undergo treatment with curative intent. 
Two studies included operated and non-operated patients with esophageal cancer,6,8 
and showed that younger patients present with TNM stage and tumor grade similar to 
those of their older counterparts. However, younger patients more often underwent 
curative treatment including neoadjuvant therapy. Hashemi et al.6 showed identical OS 
for both age groups, whereas Donohoe et al.8 described improved OS and DSS for the 
younger patients. Interestingly, patients aged ≤35 years had a more advanced TNM stage 
and a poorer survival. Our study included only eight patients aged 35 years. Hence, a 
subgroup analysis was not feasible. Second, tumor grade and TNM stage were based on 
the pathological staging of the resected specimen and resected lymph nodes. In patients 
responding to neoadjuvant therapy, the pathologic TNM stage may be more favourable. 
However, a comparable percentage of patients underwent neoadjuvant treatment in the 
two groups. 
Treatment regimes and peri-and postoperative management certainly have changed 
over the last decades. Improvements made in the diagnosis and treatments of esopha-
geal cancer are likely independent of patient’s age and histological type. We therefore 
think that it does not lead to bias when comparing outcomes of the two age groups. 
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Next, because patients seen in a tertiary hospital mostly have a resectable tumor, there 
may have been referral bias. All patients underwent a curative esophagectomy demon-
strating no differences in TNM stage or resection margins between the two groups. This 
translates into similar DSS and the DFS for the young and old patients.
A considerable proportion (12%) of the patients diagnosed with esophageal carcinoma 
and qualified for curative resection are aged ≤50 years. Younger patients presented with 
fewer co-morbidities, resulting in a lower incidence of morbidity and mortality after 
esophagectomy. Although OS is better compared with their older counterparts, DSS and 
DFS are comparable for both age groups of patients with resectable tumors. 
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AbsTrAcT
background: Esophageal cancer is increasingly recognized in younger patients. We 
compared clinicopathological characteristics, treatment, and survival of patients aged 
≤50 years with patients aged >50 years diagnosed with esophageal cancer in the Neth-
erlands.
Methods: From the nationwide Netherlands Cancer Registry we identified all patients di-
agnosed with esophageal cancer between January 2000 and January 2011. Proportions 
were compared using the χ2 test for categorical variables. Overall and relative survival 
was calculated.
results: Eleven percent of the patients (n=1,466) were aged ≤50 years and adenocar-
cinoma was the most common tumor type (73.6%). Grade of tumor differentiation was 
comparable between both age groups (p=0.460) as well as T-stage (p=0.058). Younger 
patients presented more often with positive lymph nodes (70.1 vs. 66.4 %, p=0.010) and 
distant metastasis (50.5 vs. 44.7 %, p<0.001) but had surgery more often as compared to 
older patients: 40.6 vs. 37.9 %, p=0.047. There was no significant difference in the 5-year 
relative survival between both age groups: 18.1 vs. 17.2%, p>0.05. A subgroup analysis 
among patients diagnosed with adenocarcinoma revealed similar results. 
conclusions: Young patients with esophageal cancer present with more advanced dis-
ease stage and received more often treatment. However, they show comparable relative 
survival rates with their older counterparts.
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inTrODUcTiOn
There has been a remarkable increase in the incidence of esophageal cancer over the last 
decades. This rise is attributed to an increase in adenocarcinomas.1-3 Esophageal cancer 
was thought to be a disease of the elderly, with a peak incidence in patients aged 60-70 
years. 4 However, recent studies have shown a rise in incidence of adenocarcinomas, also 
among patients aged <50 years. 2,3,5 
The effect of age on disease stage and survival of patients with esophageal cancer is 
controversial. Given the rarity of esophageal cancer in young patients, it is reasonable 
to assume that this disease is more easily misdiagnosed, and therefore diagnosis might 
be delayed.6-9 Some studies suggest that patients under 50 years present with more 
advanced disease but at the same time receive more aggressive treatment and have a 
similar prognosis compared to older patients.6-8 Others found that younger patients did 
not differ from their older counterparts with regard to clinicopathological characteristics 
or survival,10-13 which is in agreement with a previous study from our institute.14
Previous studies about age differences used institutional databases and included only 
patients who underwent surgery.8,10,12 However, less than 50% of esophageal cancer 
patients receive a potentially curative treatment and the majority has incurable disease 
at the time of diagnosis. To optimize treatment and to improve survival for younger 
patients, a clearer picture of all patients with esophageal cancer, including those who are 
not eligible for surgery, is needed. 
The aim of this population-based study was to compare the clinicopathological charac-
teristics, treatment, and outcome of esophageal cancer patients aged less than 50 years 
with those older than 50 years.
METHODs
Data collection
Population-based data from the nationwide Netherlands Cancer Registry (NCR), which 
was started in 1989 and is maintained and hosted by the Comprehensive Cancer Center, 
were used4. The NCR is based on notification of all newly diagnosed malignancies in the 
Netherlands by the automated pathological archive (PALGA). Additional data sources 
are the national registry of hospital discharge diagnoses, which accounts for up to eight 
percent of new cases.4 Information on patient characteristics such as gender and date 
of birth, as well as tumor characteristics such as date of diagnosis, subsite (International 
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Classification of Diseases for Oncology (ICD-O-3),15 histology, stage (Tumor Lymph Node 
Metastasis (TNM) classification)16 and grade are obtained routinely from the medical 
records about nine months after diagnosis. The quality of the data is high, thanks to 
thorough training of the specialized registrars and computerized consistency checks at 
regional and national levels. Completeness is estimated to be at least 95%.17 Follow-up 
of vital status of all patients was complete up to January 2012.  In addition to passive 
follow-up via the hospitals, date of death is also retrieved from the Municipal Personal 
Records Database.4
For the present study we selected all patients diagnosed with invasive primary esopha-
geal carcinoma or gastroesophageal junction carcinoma (C15-C16) between January 
2000 and January 2011. Patients diagnosed with a tumor of the esophagus defined as 
epithelial neoplasm (ICD-O codes: 8010-8033) or not otherwise specified neoplasms 
(ICD-O codes: 8046, 8082-8084, 8123) were excluded from the study. Patients diagnosed 
with a tumor of the esophagus defined as squamous cell carcinoma (ICD-O codes: 
8051, 8052, 8070-8078), adenoma or adenocarcinoma (ICD-O codes: 8140-8145, 8200, 
8201, 8210, 8211, 8230, 8244, 8246, 8255, 8260, 8263, 8310), cystic, mucinous or serous 
neoplasm (ICD-O codes:  8480,8481,8490), ductal, lobular or medullary neoplasm (ICD-O 
codes: 8510) or complex epithelial neoplasm (ICD-O codes: 8560,8570,8573-8576) were 
included in the study. Patients aged ≥75 years at the time of diagnosis were excluded 
from the study, because of the high prevalence of co-morbidities and complications after 
treatment, which can cause a distortion of the results.14,18-20
The TNM-classification of the American Joint Committee on Cancer (AJCC) Staging 
Manual 6th edition was used for tumor staging.21 For patients who underwent surgery 
TNM stage was based on pathological examination of the resected specimen (pTNM). For 
patients who did not undergo a resection, TNM stage was based on the clinical staging 
(cTNM).
statistical analysis
The young group was defined as patients aged ≤50 years at time of diagnosis. This group 
was compared with the group of patients aged >50 years. The cut-off point of 50 years 
was arbitrarily chosen and based on previous studies.9,14,22
Patient- and tumor characteristics as well as details on treatment were first described 
with regard to the whole study population and subsequently for patients diagnosed with 
esophageal adenocarcinoma. Categorical variables were described using frequencies 
and percentages. Proportions were compared using the χ2 test for categorical variables. 
Two-sided p-values <0.05 were considered significant.
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Survival estimates were calculated using Kaplan-Meier curves, and differences were 
tested with a log-rank test. Survival time was measured from the date of surgery or the 
date of diagnose to the date of death. Patients were censored at the time when they were 
lost to follow-up or when they left the study before the end of follow-up time. Survival 
data were expressed as medians with interquartile ranges (IQR). Univariable and multi-
variable Cox proportional hazard models were used to identify independent predictors 
of overall survival. Variables were entered in the multivariable analysis independent of 
the p-value reached in the univariable analysis, since all variables were considered to be 
clinically relevant. 
Relative survival was used as an estimation of disease-specific survival. It reflects survival 
of cancer patients, adjusted for survival in the general population with the same struc-
ture for age and gender. Relative survival was calculated as the ratio of the observed rates 
in cancer patients to the expected rates in the general population. Expected survival was 
calculated from population life tables from the Netherlands, according to the Ederer II 
method.23 Data analysis was performed with SPSS version 20.0 (SPSS, Chicago, IL, USA) 
and SAS system 9.3 (SAS Institute, Cary, NC, USA).
rEsUlTs
study population
A total of 18,118 patients with cancer of the esophagus and the gastroesophageal junc-
tion were identified in the NCR database. Patients diagnosed with a tumor of the esopha-
gus defined as epithelial neoplasm (n=552) or with a tumor not otherwise specified 
(n=66) were excluded, as well as patients aged ≥75 years at time of diagnosis (n=4,169). 
The remaining 13,331 patients were included in this study (Figure 1).
Patient and tumor characteristics
The mean age of the patients was 61.4 ±8.5 years (median age ≤50 years: 47.0 years, range 
18-50 years, median age >50 years: 64.0 years, range 51-74 years). Eleven percent was 
aged ≤50 years and almost 80% of all patients were male. Esophageal adenocarcinoma 
was the most common histological type, especially in the younger age group. Younger 
patients also presented more often with positive regional lymph nodes (N+) and distant 
metastasis (M+) (70.1 vs. 66.4 %, p=0.010 and 50.5 vs. 44.7 %, p<0.001, respectively). 
Tumor grade was comparable between both age groups (p=0.460) (Table 1).
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Table 1: Patient and tumor characteristics of the study population
≤ 50 years
n=1,466 (%)
> 50 years
n=11,865 (%)
Total
n=13,331 (%) p
Gender
Male
Female
1,148
318 
(78.3)
(21.7)
9,277
2,588
(78.2)
(21.8)
10,425
2,906
(78.2)
(21.8)
0.916
Histology
Adenocarcinoma
Squamous cell carcinoma
1,140
326
(77.8)
(22.2)
8,667
3,198
(73.0)
(27.0)
9,807
3,524
(73.6)
(26.4)
<0.001
T stage 
No tumor + HGD*
T1
T2
T3
T4
Unknown
  
    1 
115 
242 
499 
208 
391 
(0.1)
(7.8)
(16.5)
(34.0)
(14.2)
(26.7)
      
25 
987 
2,081 
4,151
1,585
3,033
(0.2)
(8.3)
(17.5)
(35.0)
(13.4)
(25.6)
26
1,102
2,323
4,650
1,793
3,424
(0.2)
(8.3)
(17.4)
(34.9)
(13.4)
(25.7)
0.058
n stage
N0
N+
Unknown
262
1,027
177 
(17.9)
(70.1)
(12.1)
2,499
7,881
1,485 
(21.1)
(66.4)
(12.5)
2,761
8,908
1,661
(20.7)
(66.8)
(12.5)
0.010
M stage
M0
M+
Unknown
634
740
92
(43.2)
(50.5)
(6.3)
5,682
5,300
883
(47.9)
(44.7)
(7.4)
6,316
6,040
975
(47.4)
(45.3)
(7.3)
<0.001
figure 1: Flowchart
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Treatment
Some 5,093 patients underwent surgery. Despite more advanced tumor stage, patients 
aged ≤50 years underwent more often surgery with or without neoadjuvant therapy as 
compared to patients aged >50 years: 40.6 vs. 37.9 %, p=0.047 (Table 2). For patients who 
only received palliative treatment (61.8%), younger patients received chemotherapy 
more often (44.8 vs. 32.7 %, p<0.001). Radiotherapy for palliation was applied more 
frequently in older patients (27.4 vs. 31.2 %, p=0.003) (Table 2).
survival
The median overall survival for patients aged ≤50 years was 12.1 months (IQR: 5.5-32.7 
months) and 11.3 months (IQR: 4.8-29.4 months) for patients aged >50 years. The 5-year 
overall survival was 17.6 % for the younger patients versus 15.8% for the older patients 
(p=0.014) (Figure 2). Multivariate survival analysis showed that male gender, patients 
aged >50 years, squamous cell carcinoma, poorly differentiated tumors and advanced 
T-, N- and M stage and a tumor-positive resection margin were independently associated 
Table 1: Patient and tumor characteristics of the study population (continued)
≤ 50 years
n=1,466 (%)
> 50 years
n=11,865 (%)
Total
n=13,331 (%) p
Grade
Good
Moderate
Poor/
undifferentiated
Unknown
45
379
590
452
(3.1)
(25.9)
(40.2)
(30.8)
363
2,965
4,603
3,934
(3.1)
(25.0)
(38.8)
(33.2)
408
3,344
5,193
4,386
(30.6)
(25.1)
(39.0)
(32.9)
0.460
resection margin
R0#
R1##
R2###
Unknown
382
65
11
1,008
(26.1)
(4.4)
(0.8)
(68.8)
3,196
540
70
8,059
(26.9)
(4.6)
(0.6)
(67.9)
3,578
605
81
9067
(26.8)
(4.5)
(0.6)
(68.0)
0.777
*HGD = High-grade dysplasia 
    #R0 = Tumor free resection margin
  ##R1 = Vital tumor present within 1 mm from the proximal, distal, or circumferential resection margin
###R2 = Residual macroscopic tumor
Table 2: Treatment details of the study population
≤ 50 years
(n=1,466) (%)
> 50 years
(n=11,865) (%)
Total
(n=13,331) (%) p
surgery
Neoadjuvant therapy*
595 
212
(40.6)
(14.5)
4,498
1,441 
(37.9)
(12,1)
5,093
1,653
(38.2)
(12.4)
0.047
Palliative treatment
Chemotherapy
Radiotherapy
657
402 
(44.8)
(27.4)
3,884 
3,705
(32.7)
(31.2)
4,541
4,107
(34.1)
(30.8)
<0.001
  0.003
*Neoadjuvant chemo-, radio- or chemoradiation therapy followed by surgery
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with a higher risk of dying. Patients who underwent surgery had a lower risk of dying 
(Table 3). 
The 5-year relative survival after resection was 37.6% (95%CI: 33.5-41.7) for the younger 
patients versus 34.1% (95%CI: 32.5-35.7) for the older patients (p>0.05). Among patients 
who received palliative treatment; younger patients showed a worse 5-year relative 
survival compared to their older counterparts: 4.5% (95%CI: 2.8-6.1) and 6.7% (95%CI: 
5.9-7.5) respectively. However, this difference was not significant (Figure 3).
subgroup analysis for adenocarcinomas
Some 9,807 (73.6%) patients were diagnosed with an adenocarcinoma. Younger patients 
presented more often with positive regional lymph nodes (N+) (71.9 vs. 67.1 %, p=0.001) 
and distant metastasis (M+) (53.0 vs. 46.3 %, p<0.001) and tumor grade was comparable 
between both age groups (p=0.434). Overall 5-year survival was significantly better 
for younger patients: 18.2% (95%CI: 2.9-6.5) as compared to 16.4% (95%CI: 5.1-6.7) for 
patients aged >50 years (p=0.021). The 5-year relative survival rates after surgery or pal-
liative treatment did not differ significantly between both groups. 
figure 2: Overall survival according to age
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121
Treatment and outcome of young patients with esophageal cancer in the Netherlands
8
Table 3: Cox proportional hazard model 
Univariable analysis
Hazard ratio (95%ci)
Multivariable analysis
Hazard ratio (95% ci)
p
Gender
Female
male
1
1.10 (1.05-1.15)
1
1.10 (1.05-1.16) <0.001
Age (yrs)
≤ 50
>50
1
1.08 (1.02-1.15)
1
1.12 (1.06-1.19) <0.001
Tumor type
Squamous cell carcinoma
Adenocarcinoma
1
0.88 (0.84-0.92)
1
0.95 (0.91-0.99)  0.024
Tumor grade
Good
Moderate
Poor
Undifferentiated
Unknown
1
1.82 (1.57-2.08)
2.35 (2.06-2.68)
3.20 (1.96-5.24)
2.33 (2.04-2.66)
1
 1.77 (1.54-2.02)
2.05 (1.79-2.35)
4.11 (2.51-6.74)
1.69 (1.48-1.94)
<0.001
<0.001
<0.001
<0.001
T
1
2
3
4
Unknown
HGD
1
2.11 (1.85-2.40)
2.39 (2.10-2.70)
4.62 (4.06-5.27)
3.67 (3.24-4.15)
0.25 (0.06-1.00)
1
1.96 (1.72-2.25)
1.94 (1.70-2.35)
2.66 (2.32-3.03)
2.51 (2.20-2.85)
0.31 (0.08-1.23)
<0.001
<0.001
<0.001
<0.001
  0.095
n
N0
N+
Unknown
1
1.93 (1.83-2.03)
3.32 (3.09-3.55)
1
1.46 (1.38-1.54)
1.73 (1.61-1.86)
<0.001
<0.001
M
M0
M+
Unknown
1
3.37 (3.23-3.51)
1.50 (1.39-1.61)
1
1.74 (1.66-1.83)
1.11 (1.03-1.20)
<0.001
  0.008
neoadjuvant crT*
No
Yes
1
0.39 (0.35-0.44)
1
0.93 (0.82-1.05)   0.234
resection
No
Yes
1
0.29 (0.28-0.31)
1
0.52 (0.49-0.55) <0.001
resection margin
R0 #
R1 ##
R2###
Unknown
1
2.12 (1.92-2.33)
1.75 (1.36-2.25)
3.56 (3.39-3.74)
1
1.87 (1.69-2.06)
1.20 (0.93-1.55)
1.61 (1.50-1.72)
<0.001
  0.155
<0.001
* CRT = Chemoradiation therapy, # R0 = Tumor free resection margin,   ## R1= Vital tumor present within 1 mm 
from the proximal, distal, or circumferential resection margin, ###R2 = Residual macroscopic tumor
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DiscUssiOn
The incidence of esophageal cancer is rising among all age groups.1-3 Hence, esophageal 
cancer is increasingly recognized in patients at a younger age. Controversy exists about 
the disease stage at initial presentation and prognosis of young patients with esophageal 
cancer. A previous study from our group based on an institutional database showed that 
clinicopathological characteristics and overall survival after surgery of patients aged ≤50 
years did not differ from patients aged >50 years.24 This is in agreement with previous 
studies,25 and can be explained by the applied selection criteria and homogeneity of a 
cohort of surgical patients, since only patients without distant metastasis and/or local 
resectability plus an adequate performance status are eligible for surgery and included 
in the analysis.
The present study shows that in the Dutch population differences in tumor stage and 
treatment exist between younger and older patients with esophageal cancer. Patients 
aged ≤50 years presented more often with positive regional lymph nodes and distant 
metastasis. However, they attained a similar 5-year relative survival compared with their 
older counterparts. This can be partly explained by the higher percentage of young 
figure 3: Relative survival accoring to age and resection
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patients who underwent multimodal treatment including surgery and neoadjuvant 
chemo- and/or radiotherapy. Also in the palliative setting, young patients were more 
likely to receive chemotherapy, whereas older patients were more frequently treated 
with less toxic radiotherapy schedules. Portale et al.7 also reported that younger patients 
presented with more advanced disease, but with appropriate aggressive treatment, 
reached similar survival rates compared with their older counterparts.
Overall survival rates were significantly higher for younger patients, probably because 
older patients suffer from co-morbidities more frequently, hence might die of other 
causes than recurrent cancer. To adjust for survival in the general population with the 
same structure for age and gender, we calculated relative survival rates. Comparing of 
the relative survival rates between patients aged ≤50 years and patients aged >50 years 
showed no significant differences.
It is reasonable to assume that upper gastrointestinal symptoms in younger patients are 
more likely ascribed to a benign condition, hence diagnosis could be delayed. Whether 
non-reporting of symptoms by the patient, doctor’s delay in referring youngsters for 
endoscopy or both are causative, is unknown. Several studies have reported that young 
patients indeed present with dysphagia that has been present for a longer period of time 
before diagnosis is made, and as such present with a more advanced disease stage as 
compared to older patients.6-9 Clearly, there is room for improvement in recognition and 
timely detection of esophageal cancer in young patients. 
The increased incidence of esophageal adenocarcinoma has occurred parallel to a ris-
ing prevalence of the Barrett’s esophagus.5 This implies an increase in the causal factor 
inducing Barrett’s esophagus and/or esophageal adenocarcinoma, which is thought to 
be gastroesophageal reflux. Obesity and overweight are also independently associated 
with esophageal cancer and show an upward trend in prevalence among all ages.26 
This would suggest that initiation and progression of cancer are uniform for both the 
young and the older patients. On the other hand, one could hypothesize that esophageal 
cancer in young patients has a different etiology than in their older counterparts. It is 
generally accepted that it takes several decades for a normal cell to turn into a cancer 
cell.  Considering their young age, young patients have not had sufficient time to obtain 
enough mutations needed to turn a normal cell into a cancer cell. Therefore, it can be 
anticipated that young patients might develop esophageal cancer through another 
pathway than older patients. More insight into the molecular biology of the tumorigenic 
pathway is required to better understand the tumor initiation and progression of both 
the young and the old patients.
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Young patients are generally treated according to protocols based on the average cohort 
of patients with esophageal cancer, with a peak incidence in age of 60-70 years.4 More-
over, patients aged ≤50 years are likely underrepresented in clinical trials given the lower 
incidence in this age group. Koppert et al.27 reported that the prevalence of co-morbidi-
ties among older cancer patients is high and older patients are treated less aggressively 
compared to younger cancer patients. Young patients suffer from co-morbidity less often 
compared to elderly patients,14,18-20,28 and they generally have a better physical condition, 
which could lead to an improved tolerance for surgical and nonsurgical treatments. It 
can be expected that medical specialists are more eager to treat these young patients 
with more aggressive and potentially toxic therapies. Also an anticipated higher life ex-
pectancy could contribute to the higher rates of surgical treatment in younger patients 
as reported in the present study. 
A limitation of our study is the lack of detailed information on duration of symptoms 
before diagnosis, co-morbidities, (non)surgical complications and causes of death, that 
are not available in the NCR database. Therefore, we were not able to calculate disease-
specific survival or disease-free survival. Another limitation is the use of different editions 
of TNM-staging throughout the study period. For example, patients diagnosed with 
positive celiac axis lymph nodes were classified as stage M1a according to the 6th edi-
tion, however this stage changed into N1-3, depending on the number of positive lymph 
nodes, in the 7th edition.29 However, it is unlikely, that this has had an impact on the 
distribution of tumor stages between the age groups. Improvements in overall survival 
in later-year cohorts could be attributed to improvements in multimodality treatment,6,30 
however these new treatments are considered to be equal managed in both age groups.
In conclusion, this population-based nationwide study revealed that esophageal cancer 
patients aged ≤50 years present with more advanced disease stage, wherefore they 
received more often treatment. This results in a marginal better overall survival rate but 
similar relative survival as compared to patients aged >50 years. Improvement should 
be made in the earlier recognition of alarm symptoms and the detection of esophageal 
cancer in young patients in order to prevent younger patients presenting with more 
advanced disease stages.
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AbsTrAcT
background: Esophageal adenocarcinoma (EAC) is typically diagnosed in elderly with a 
median age of 68 years. The incidence of EAC has been rising over the last decades, also 
among young adults. The aim of the study was to investigate whether early onset EAC is 
a distinct molecular entity. 
Methods: To identify early onset EACs, the nationwide network and registry of histo- 
and cytopathology in the Netherlands (PALGA) was searched. Twenty-eight tumors of 
patients aged ≤40 years were selected and matched with 27 tumors of patients aged ≥68 
years. DNA was isolated from surgically resected specimen and sequenced on the Ion 
Torrent Personal Genome Machine with the Ion AmpliSeq Cancer Panel.
results: No differences in mutational load between early onset and conventional EACs 
were observed (p=0.196). The most frequently mutated genes were TP53 (73%) and 
P16 (16%). Additional mutations in early onset EACs occurred exclusively in: APC, CDH1, 
CTNNB1, FGFR2, and STK11. In the conventional EACs additional mutations were exclu-
sively identified in: ABL1, FBXW7, GNA11, GNAS, KRAS, MET, SMAD4, and VHL.
conclusion: Additional mutations besides TP53 and P16 seem to occur in different genes 
related to cell fate pathways for early onset EACs, while the additional mutations in con-
ventional EACs are related to survival pathways. 
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inTrODUcTiOn
Esophageal adenocarcinoma (EAC) is typically diagnosed in elderly adults with a median 
age of 68 years.1 The incidence of EAC has been rising rapidly over the last decades, also 
among young adults.2,3 The clinicopathological characteristics of these young adults with 
early onset EACs are different compared to the conventional EAC of the older patients: 
those with early onset EAC suffer from less co-morbidities, present with advanced disease 
stages more often, undergo more aggressive treatments, but ultimately obtain the same 
relative 5-year survival rates as their older counterparts.4-6 Individuals can be predisposed 
to early onset EAC through heredity, since seven percent of the patients diagnosed with 
EAC can be considered familial Barrett’s esophagus (FBE), of which the age at diagnosis is 
generally lower compared to sporadic cases,7,8 yet no genetic defects related to FBE have 
been identified. Nevertheless, early onset EAC can be sporadic as well, lacking a genetic 
predisposition. 
It has been accepted that cancer is generally a disease of the elderly population. In addi-
tion, evidence is obtained that the transformation of a normal cell into a malignant cell 
and subsequently the outgrowth to a clinically manifest lesion takes several decades.9 
This transformation process is driven by genomic instability leading to the accumulation 
of mutations. About three mutations in driver genes, which are causally involved in the 
tumorigenic process, have to accumulate to induce this malignant transformation.10 As 
a result of the genomic instability also passenger mutations, which are not involved in 
the tumorigenic process, will accumulate. Hence, it can be anticipated that early onset 
EACs went through an accelerated transformation process and as a result could have a 
lower mutational load of (passenger) mutations, as has been reported for other tumors 
before.11 In addition, it is possible that early onset EAC is a distinct molecular entity as has 
been demonstrated e.g. for colorectal carcinoma.12 
The aim of the present study was to investigate whether early onset EAC is a distinct 
molecular entity. By next-generation sequencing with a standard cancer panel the mu-
tational load and molecular profile of early onset EACs was determined and compared 
with the conventional EACs. 
MATEriAls AnD METHODs
Patient identification
PALGA, the nationwide network and registry of histopathology and cytopathology, con-
tains pathology reports generated in the Netherlands since 1971 and has complete na-
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tional coverage since 1991 encompassing the pathology laboratories from all academic 
and nonacademic hospitals in the Netherlands.13  The PALGA database was searched, 
with approval of their Privacy Commission and Scientific Council, to identify all patients 
diagnosed with an adenocarcinoma of the esophagus or the gastroesophagealjunction 
(GEJ) and aged ≤40 years in the Netherlands. The following search terms were used: “pri-
mary carcinoma,” “esophagus”, “stomach,” and “age ≤40 years”. The search was performed 
from January 1990 to March 2013. Cases were further confirmed or excluded after careful 
evaluation of the individual pathology reports.
The selected early onset EACs were compared with a group of conventional EACs col-
lected from the Pathology archive of the Erasmus MC Cancer Institute, University Medical 
Center, Rotterdam. Patients aged ≥68 years and diagnosed with an adenocarcinoma of 
the esophagus or GEJ for which an esophagectomy was performed were selected and 
matched with the patients with early onset EAC with regard to grade of tumor differen-
tiation and TNM-stage (according to the classification of the American Joint Committee 
on Cancer (AJCC) Staging Manual 7th edition).14
Tissue samples
Formalin-fixed paraffin-embedded (FFPE) tumor tissues were provided by the participat-
ing laboratories of PALGA. The tissue blocks were assessed anonymously according to 
the Proper Secondary Use of Human Tissue code established by the Dutch Federation of 
Medical Scientific Societies (http://www.federa.org). In addition the study was approved 
by The Medical Ethical Committee of the Erasmus MC Cancer institute, University Medical 
Center, Rotterdam.
Tumor tissue areas composed of at least 50% neoplastic cells (indicated by a GI-pathol-
ogist) were manually microdissected from 10 to 15 hematoxylin-stained sections (4µm) 
of FFPE tissue blocks. DNA was extracted using proteinase K and 5% Chelex 100 resin. 
To determine the presence of microsatellite instability analysis were performed with the 
MSI Analysis System, Version 1.2 (Promega, Madison, WI, USA). 
next-generation sequencing
Ion semiconductor sequencing on the Ion Torrent Personal Genome Machine (PGM) 
was performed with the Ion AmpliSeq Cancer Hotspot Panel on tumor DNA according 
to the manufacturer’s protocols. In short, libraries were made using the Ion AmpliSeq 
Library Preparation Kit. A template was prepared using the Ion OneTouch Template Kit 
and sequencing was performed with the Ion Sequencing Kit v2.0 on an Ion 316 chip. 
Data were analyzed with the Variant Caller v2.2.3-31149 (Life Technologies, Carlsbad, CA, 
USA). Variants were called when the position was covered at least 100 times. Variants 
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found in at least 25% of the called reads were considered reliable. Variants present in the 
ESP6500si or 1000genomes databases in ≥1% were excluded. Subsequently nonsynony-
mous somatic point mutations, insertions and deletions that change the protein amino 
acid sequence and splice site alterations were selected as driver mutations.
Data analysis
Early onset EAC was defined as patients diagnosed with EAC at the aged ≤40 years. This 
group was compared with the group of patients aged ≥68 years.  Patient- and tumor 
characteristics were described using frequencies and percentages. Proportions were 
compared using χ2 test for categorical variables. Differences in the mean number of 
mutations between the age groups were tested using independent samples t-test. Two-
sided p-values <0.05 were considered statistically significant for all analysis. Data analysis 
was performed with SPSS version 20.0 (SPSS, Chicago, IL, USA).
results
Thirty-seven patients diagnosed with EAC or adenocarcinoma of the  GEJ and aged ≤40 
years at time of diagnosis were identified in the PALGA database. Twenty-eight samples 
obtained from these patients passed quality controls and were included in the study 
(Mean age: 37.2 years, range 28-40 years, 89% male). Twenty-seven patients diagnosed 
with EAC or adenocarcinoma of the GEJ and aged ≥68 years at time of diagnosis were 
matched with patients aged ≤40 years based on TNM stage and tumor differentiation 
grade (Mean age: 74.6 years, range 68-83 years, 78% male). All tumors were tested micro-
satellite stable. Of the patients aged ≤40 years seven received some form of neoadjuvant 
therapy, while none of the patients aged ≥68 years did.  Patients- and tumor characteris-
tics are listed in Table 1 according to age groups.
Next-generation sequencing with the PGM revealed 83 mutations in 55 EAC samples 
before filtering: 36 mutations in the patients aged ≤40 years and 47 mutations in the 
patients aged ≥68 years (p=0.094). After filtering 78 mutations remained: 35 mutations 
were identified in the patients aged ≤40 years and 43 mutations in the patients aged ≥68 
years. The mean number of mutations for the young adults and the older patients was, 
1.25 (SD 0.844) and 1.59 (SD 1.083) respectively, and not significantly different (p=0.196). 
The most frequently mutated genes were TP53 (73%), P16 (16%), ATM (7%), and RB1 (7%). 
In the early onset EACs TP53 was altered in 75% and P16 in 11%, whereas in the conven-
tional EACs a mutation in TP53 was found in 70% and P16 was mutated in 22%. Except 
for one, all P16 mutations occurred simultaneously with a TP53 mutation. In 43% of the 
early onset EACs and in 33% of the conventional EACs no additional mutations besides a 
TP53 mutations or a P16 mutations were identified. The genes ATM, JAK3, PIK3CA, and RB1 
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were mutated equally between both groups. Additional mutations in five individual early 
onset EACs occurred exclusively in the genes: APC, CDH1, CTNNB1, FGFR2, and STK11. 
In the conventional EACs additional mutations were exclusively identified in the genes: 
ABL1, FBXW7, GNA11, GNAS, KRAS, MET, SMAD4, and VHL (Figure 1 and Table 2).
Table 1: Patient- and tumor characteristics according to age groups
Early onset EAc
n=28 (%)
conventional EAc
n=27 (%) p-value (χ2)
Mean Age (sd) 37.2 (3.023) 74.6 (4.395) <0.001 (t-test)
Gender
  Male
  Female
25 
3
(89.3)
(10.7)
21 
6 
(77.8)
(22.2)
0.249
Tumor type
  EAC
  GEJAC
  Cardia
  Unknown
16 
9 
2
1
(57.1)
(32.1)
(7.1)
(3.6)
17 
9 
1
0
(63.0)
(33.3) 
(3.7)
(0)
0.718
TnM stage*
  IA
  IB
  IIA
  IIB
  IIIA
  IIIB
  IIIC
  IV
5 
3 
0
2 
9 
3
5
1
(17.9)
(10.7)
(0)
(7.1)
(32.1)
(10.7)
(17.9)
(3.6)
3 
0
1
7
7 
2
6
1
(11.1)
(0)
(3.7)
(25.9)
(25.9)
(7.4)
(22.2)
(3.7)
0.350
Differentiation grade
  High-grade dysplasia
  Good
  Moderate
  Poor
  Unknown
0 
4
11 
9 
4 
(3.6)
(14.3)
(39.3)
(32.1)
(14.3)
0
0
16
9
2
 
(0)
(0)
(59.3)
(33.3)
(7.4)
0.233
EAC= esophageal adenocarcinoma
GEJAC= gastroesophageal junction adenocarcinoma
*According to the classification of the American Joint Committee on Cancer (AJCC) Staging Manual 7th edi-
tion.
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DiscUssiOn
For the first time a molecular analysis was performed on an exclusive group of patients 
with early onset EACs, to determine whether this is a distinct entity based on molecular 
spectrum. In comparison with the conventional EACs no difference in the total muta-
tional load, including common driver mutations, was observed in the early onset EACs. 
Although no evidently differences were observed between the two groups with regard 
to molecular profile, the additional mutations, besides mutations in TP53 and P16, 
identified in some individual early onset EACs differed when compared to the additional 
mutations identified in the conventional EACs. 
Presently, there is no accepted clear definition of early onset EACs. Recent publications 
demonstrate that five percent of the patients diagnosed with EAC are aged ≤40 years, 5 
and 10% aged ≤50 years.6 In these studies young adults with EAC were compared with 
the conventional EAC patients, with a median age of 68 years, based on clinicopatho-
logical characteristics, showing that these younger patients present with more advanced 
disease stages, receive more often aggressive treatment regimes, however, ultimately 
obtain relative survival rates comparable with their older counterparts.6  In order to 
ensure a clear segregation of the two entities and to avoid any overlap, a more restrictive 
definition of both early onset EAC and conventional EAC was used and patients between 
41 and 67 years were excluded in the present study.
EAC evolves from the premalignant condition Barrett’s esophagus, following a mul-
timorphological pathway, in which metaplasia evolves to low-grade dysplasia, high-
grade dysplasia and ultimately into invasive adenocarcinoma, during this malignant 
transformation mutations accumulate over time.9,15 The number of mutations in a tumor 
originating from self-renewing tissue, e.g. the esophagus, is directly correlated with age. 
The majority of these mutations are passenger mutations that have no effect on the neo-
plastic progression. Whereas, the minority are the driver mutations, which confer a selec-
tive growth advantage. The passenger mutations occur mostly during the pre-neoplastic 
phase, which is evidently longer for older patients than for the younger ones.16 Based on 
this concept it can be hypothesized that the number of total mutations, i.e. mutational 
load, is lower in early onset EACs as compared to conventional EACs. 
Although it did not reached the level of significance, probably due to the relatively small 
amount of patients, a higher amount of total mutations (i.e. passenger and driver muta-
tions) was observed in the conventional EACs when compared to the early onset EACs, 
which is in line with concept as has been described previously. The current data did not 
revealed a significant difference in the load of driver mutations between the two age 
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groups. Since the use of the Cancer Hotspot panel in this study, by which only 207 gene 
“hot spot” regions are investigated that are frequently mutated in human cancers, not 
all genes were covered. Hence, a complete overview of the total mutation spectrum per 
patient could not be established. An alternative explanation for the comparable load of 
mutations between the early onset EACs and the conventional EACs can be the occur-
rence of an ultramutator phenotype in the young adults resulting in an accelerated ac-
cumulation of mutations. By this phenomenon, young adults with early onset EAC could 
bear a comparable mutational load as compared to their older counterparts despite their 
shorter time of tumorigenesis.17 
At a first glance no evidently differences were observed between the early onset EACs 
and the conventional EACs, with regard to the molecular profiles: the tumor suppres-
sor gene TP53 was altered in approximately 72% of EACs (75% in early onset vs. 70% in 
conventional EACs), which is comparable with other studies.18 Mutations of TP53 have 
been suggested to be an early genetic event in the multimorphological pathway of 
esophageal adenocarcinogenesis and are facilitating the accumulation of mutations.9,19 
Alterations of tumor suppressor gene P16 are additional early events in EAC, and pres-
ent in approximately 12%.18 Here, in 11% of the early onset EACs a P16 mutation was 
identified, whereas in the conventional EACs a P16 mutation was identified in 22%. A 
remarkable observation was made regarding the additional mutational spectrum; the 
genes APC, CDH1, CTNNB1, FGFR2, and STK11 were exclusively mutated in five individual 
early onset EACs. Whereas these mutations were not identified in the conventional EACs, 
that instead, exclusively carried additional mutations in the genes ABL1, FBXW7, GNA11, 
GNAS, KRAS, MET, SMAD4, and VHL. Since the additional mutations were identified in 
five individual early onset EACs it might be based on randomness. In addition, in a large 
whole exome sequencing study on EACs performed by Dulak et al.18 mutations in APC, 
CDH1, CTNNB1, FGFR2, and STK11 were identified in EAC patients, here categorized as 
conventional EAC of older patients (range: 51-85 years), although in very small amounts. 
However, considering the classification of cancer cell signaling pathways i.e. cell fate, cell 
survival, and genome maintenance, it is striking that the additional mutations in the early 
onset EACs occurred mainly in genes classified in cell fate pathways (APC, CDH1, CTNNB1), 
while all additional mutations in conventional EACs were identified in genes classified 
in survival pathways (ABL1, GNA11, KRAS, MET, SMAD4, VHL, GNAS, FBXW7). In addition, 
the shared mutations occurred in genes classified in genome maintenance pathways 
(TP53, ATM) as well as in survival pathways (JAK3, PIK3CA, P16). Mutations classified in 
cell fate pathways disturb the balance between differentiation and division, favoring the 
latter, which causes a selective growth advantage. Mutations categorized in cell survival 
pathways allow cancer cells to proliferate under limiting nutrient concentrations, making 
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them survive in environments in which sister cells cannot.9 Different biological pathways 
for patients with early onset cancers have been described earlier, for example in breast 
cancer, colorectal cancer, melanoma, and tongue cancer.20
Taken together, these findings indicate that the development of EAC requires, regardless 
of the age of onset, a TP53 mutation mostly accompanied by a P16 mutation. However, 
the additional mutations needed to probably induce the malignant transformation10 in 
some early onset EACs seem to occur in different genes, related to different pathways, 
as compared to the additional mutated genes in conventional EACs. From a treatment 
perspective, different pathways could indicate different inhibitors in the means of tar-
geting treatment as has been established for metastatic colorectal cancer.21 The current 
study gives a clue for a distinct molecular biology for early onset EAC. More extensive 
sequencing of larger cohorts of young adults and older patients with EAC have to be 
performed to determine whether early onset EAC is truly a distinct molecular entity that 
needs probably a different targeting therapy in the future. 
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GEnErAl DiscUssiOn 
Norman Barrett wrote in 1957: ‘This paper concerns a condition whose existence is de-
nied by some, misunderstood by others, and ignored by the majority of surgeons. It has 
been called a variety of names which have confused the story because they have sug-
gested incorrect explanations.’ Norman Barrett was an Australian-born British thoracic 
surgeon, after which the Barrett’s esophagus (BE) was named to in 1950,1 although it was 
Phillip Allison who proved the columnar-lined segment is esophagus and not stomach.2 
In 1953 the association between BE and gastroesophageal reflux (GER) was observed.3 
Subsequently in 1975, the relation between BE and esophageal adenocarcinoma (EAC) 
was suggested.4 Over the past years endoscopic detection and surveillance of BE have 
gained insight in the morphological changes occurring during the transformation of BE 
towards EAC. Almost 60 years later however, there still is a real need to improve the un-
derstanding of this malignant transformation at a molecular level. In addition, although 
EAC has been considered a sporadic disease of the elderly, recently it has become clear 
that the population of EAC patients appeared to be relatively heterogeneous, including 
patients with sporadic cancers, patients with a positive family history for EAC and BE, and 
exceptionally young aged patients. This thesis aimed to elucidate the molecular biol-
ogy of EAC by performing standard molecular analysis, i.e. whole-exome sequencing, 
targeted sequencing and Sanger sequencing on sporadic, familial and young patients 
with EAC. In addition, clinicopathological features of families with clustering of EAC and 
BE and young individuals with EAC were studied.
Molecular analysis of sporadic EAc
The assessment of oncological biomarkers in BE and EAC is based on the examination 
of small biopsy samples, which may not represent the entire molecular heterogeneity of 
a tumor. Genetic intratumor heterogeneity has been identified in several other cancer 
types e.g. clear cell renal cell carcinoma5 and non-small cell lung cancer6 and is thought 
to contribute to treatment failure and drug resistance. The model of branched tumor 
evolution leading to intratumor heterogeneity describes a tumor as a tree structure, with 
the trunk representing early molecular alterations, which clonally expand and therefore 
are homogeneously present throughout the entire tumor, reflecting a process involved 
before and during tumor initiation and early development. The branches of the tree 
represent later molecular alterations, which as a result are only present in different sub-
clones of the tumor, contributing to intratumor heterogeneity and shaping the genome 
during tumor maintenance and progression.7 In chapter 2 of this thesis, the extent of 
intratumor heterogeneity was studied in EACs with the use of multiregional targeted 
sequencing. A panel of frequently mutated genes in EAC (APC, P16, SMAD4, TP53) was 
created based on the results of previous NGS studies.8-10 This panel was sequenced on 
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multiple tumor regions obtained from single EACs. This revealed a homogeneous pattern 
of TP53 mutations, as well as identical patterns of LOH of the TP53 locus in all EACs, i.e. all 
separated tumor regions obtained from one EAC showed exactly the same TP53 muta-
tions and patterns of LOH of the TP53 locus. In addition, in one paired EAC and BE sample 
the identical TP53 mutation and pattern of LOH were detected. Although no mutations 
in P16 were identified, a homogeneous pattern of LOH of the P16 locus was identified in 
the majority of the EACs, as well as in the paired EAC en BE sample. While no mutations in 
SMAD4 and APC were identified, LOH of the SMAD4 and APC locus was observed in a het-
erogeneous pattern within the EACs, and thus not detectable in every sequenced region 
of the tumors. These findings indicate that alterations in both TP53 and P16 are located 
at the trunk of the so-called tree, representative for BE. TP53 alterations precede LOH 
of P16 in the malignant progression of EAC, however both are homogeneously present 
in the entire tumor. Alterations of SMAD4 and APC seem to be located at the branches, 
representing intratumor heterogeneity of EACs. 
The clonal evolution of BE has been studied before with interesting and conflicting 
interpretations of the data.  Maley et al. proposed that a P16 alteration clonally expands 
throughout the majority of cells of a Barrett segment, and subsequently TP53 alterations 
occur on top of these and also expand.11 Leedham et al. suggested a genetically hetero-
geneous BE, however with a strong selective advantage of cells with the inactivation of 
TP53.12 The data presented in this thesis suggests, although based on the tumor biopsies 
and not BE, a full clonal expansion of TP53 inactivation, followed by the inactivation of 
P16. This is in line with a recent study on the clonal architecture of BE and EAC obtained 
by paired exome sequencing. The data suggests that TP53 mutations are present early 
in BE progression relative to other alterations including inactivation of P16, followed by 
a genome doubling, resulting in a heterogeneous tumor.13 EACs mirror spatial and tem-
poral heterogeneity, although the study in this thesis revealed homogeneous alterations 
of TP53 and P16, which are the most frequently altered genes in EACs, on top of these 
heterogeneous alterations (APC, SMAD4) in the original EACs differ among tumor regions 
and distinct disease site (BE and lymph node metastasis). This mandates taking biopsies 
at multiple time points from the premalignant lesion, the primary tumor and, although 
not studied in this thesis, the metastatic sites. Reconstructing clonal architectures of EAC 
in more detail is necessary to obtain key insight into the etiology of BE and EAC. Our 
attempt of a representation of the mutational landscape of EAC, although in a limited 
number of cases and a relatively small number of genes, has revealed a considerable 
level of heterogeneity that likely affects the identification of oncological biomarkers that 
could serve as markers for risk stratification or as targets for therapy. 
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Somatic hotspot mutations in the promoter of the gene coding for telomerase reverse 
transcriptase (TERT) catalytic subunit have recently been described in bladder cancers14, 
melanomas,15 gliomas,16 and thyroid cancers,17 but not in breast, colorectal and prostate 
cancer. In addition, TERT promoter mutations could not be detected in esophageal SCC.18 
In chapter 3 of this thesis, for the first time, the occurrence of TERT promoter mutations 
in EAC was evaluated with the use of a multiplex SNaPShot assay. Telomerase increases 
telomere length at chromosome ends. It is active in stem cells to prevent chromosome 
shortening, replicative senescence and genomic instability. In differentiated cells of 
somatic tissues, telomerase becomes downregulated, however in cancer cells it can 
become reactivated.19 However, since TERT promoter mutations were not detected in 
EACs, these tumors might have alternative mechanisms to maintain telomere length, and 
therefore would be less likely to benefit from activating mutations in TERT.
Many studies have focussed on the molecular biology of EACs using the tumor as a start-
ing point, by which tumor-specific (somatic) mutations in the genes TP53, P16, SMAD4, 
PIK3CA, ARID1A were identified.8-10 However, research into the genetic alterations of BE 
developing into EAC is important as well. Assessing an individual’s genetic susceptibil-
ity, based on common genetic variants in the population, may identify patients with BE, 
who have a high risk for malignant progression. Single nucleotide polymorphisms (SNPs) 
are the most common type of genetic variations and represent differences of single 
nucleotides at specific positions in the DNA sequence. Each variation is present to some 
appreciable degree in a population. SNPs within the coding sequences of genes, i.e. ex-
ons, can change the amino-acid sequences of a protein and therefore the activity of the 
protein. SNPs located upstream or downstream from a gene may affect gene expression, 
when located in the promotor region. SNPs located in the non-coding regions of a gene, 
i.e. introns, do not affect the amino-acid sequence but, can still be related to variants 
located in an exon. However, the vast majority of the SNPs are located outside the genes 
and functional consequences of these genomic variations are mostly unknown (www.
nature.com). Genome-wide association studies (GWAS) screen thousands of unrelated 
cases (diagnosed with the disease of interest) and controls to identify common genetic 
variants that have an association with a specific disease. The first GWAS on BE and EAC 
revealed several associated SNPs: rs10419226 (CRTC1), rs11789015 (BARX1), rs2687201 
(FOXP1), rs9936833 (FOXF1), rs2178146 (FOXF1) and rs3111601 (FOXF1).20 
In chapter 4 of this thesis the association between these six SNPs and the risk of EAC was 
validated in an independent and large case–control study. The SNPs rs10419226 (CRTC1) 
and rs11789015 (BARX1), were associated with EAC, based on a significantly increased 
risk of EAC for the minor allele T of rs10419226 (CRTC1) and a significantly decreased risk 
of EAC for the minor allele G of rs11789015 (BARX1). In addition, both SNPs showed a 
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dose-effect in the genotypic analysis: homozygosity for two minor alleles gave a stronger 
effect than heterozygous genotypes. Rs10419226 as well as rs11789015 are located in 
the first intron of the genes CRTC1 and BARX1, respectively. Both variants have no obvious 
effect on the coding sequence of the gene but could be linked to an associated variant 
located in an exon. Alternatively, since the SNPs are both located in the first intron of the 
gene, they might affect the promoter and cause up- or downregulation of the expression 
of the gene. 
A more recent GWAS17 supported the association of rs11789015 (BARX1) and rs2687201 
(FOXP1) with the risk BE (not EAC), as previously reported by Levine et al.,20 but not 
replicated by our study. In addition, two new SNPs were identified: rs3072 (GDF7) and 
rs2701108 (TBX5).21 The impact of SNPs on the function of the genes must be interpreted 
with caution. Functional studies are required to determine whether the SNPs cause 
up- or downregulation of gene expression and impact on cell behaviour. In addition, 
the effect of the SNPs can be cell type specific or stage specific or can be influenced by 
environmental factors. These results provide evidence that the risks of BE and EAC are 
influenced by genetic variants that are common in the population, and therefore the 
susceptibility to BE and EAC is not equally distributed among individuals in the popu-
lation. Clearly, some people have a higher susceptibility than others because of their 
genetic load, which in the context of changing environmental conditions may increase 
their absolute risk of cancer. Although the individual effect size of any given SNP is small, 
collectively these SNPs could still account for a substantial proportion of variation in risk.
familial clustering of EAc
Chapter 5 of this thesis consist of a review about familial EAC. Since 1978 several families 
have been described with clustering of BE and EAC.22-27 Families consisting of two or 
more first- or second-degree family members diagnosed with BE and/or EAC are termed 
familial Barrett’s esophagus (FBE). This group comprises approximately seven percent 
of all patients diagnosed with BE or EAC.28-30 The majority of the patients meeting the 
criteria of FBE are diagnosed at a younger age compared to sporadic cases.29-31 In addi-
tion, a segregation analysis of 881 pedigrees of FBE supports an incompletely dominant 
inheritance model with a polygenic component,32 i.e. a trait influenced by many genes. 
Moreover the presence of BE and EAC cases among multiple generations of one family 
also suggests a phenotypic autosomal dominant pattern of inheritance. 24,33 Orloff et al. 
identified germline mutations in the genes MSR1, ASCC1, and CTHRC1 with the use of a 
linkage analysis on affected siblings diagnosed with BE or EAC.34 However, information 
about the presence of identical germline mutations in affected siblings is lacking and the 
role of these genes in the development of FBE is unknown. The presence of several cases 
of BE and EAC among one family can be based on a coincidence, can be explained by 
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shared environmental factors between family members or is caused by the presence of 
a genetic defect concerning a rare variant, of which the importance is not elucidate yet. 
Extensive candidate gene and linkage research has been unsuccessful to date in identify-
ing genetic variants that are associated with FBE. 
In chapter 6 of this thesis a family fulfilling the criteria of FBE was investigated by whole 
-exome sequencing on germline DNA of the proband diagnosed with BE (LGD). Germline 
and tumor DNA of affected relatives diagnosed with EAC was investigated successively. 
A rare heterozygous germline missense variant in the MSX1 gene was identified in all but 
one family member. In addition somatic loss of the wild type allele of the MSX1 gene was 
identified in the tumor DNA, indicating a potential role of this germline variant in the 
development of BE and EAC in this particular family. 
MSX1 encodes a homeobox protein and interacts with bone morphogenetic proteins 
(BMPs) 2 and 4. Recent studies established BMP4 signalling as an important intercon-
nected regulatory pathway that contributes to transformation of the epithelial cells 
from the normal stratified squamous mucosa to an intestinal columnar cell type. BMP4 
was found to be present in inflamed squamous epithelium but not in normal squamous 
mucosa.35,36 In addition, MSX1 has been proposed as a gene in which mutations may con-
tribute to tooth agenesis as well as non-syndromic forms of cleft lip and/or cleft palate. 
37-40
The presence of this genetic variant in this family with clustering of BE and EAC can be 
specific for this particular family. However, other families fulfilling the criteria of FBE 
should be screened for the presence of MSX1 variants, while it might also be common 
a mutation in families with clustering of BE and EAC. Although this MSX1 variant can be 
exclusive for this particular family, when demonstrated to be pathogenic it potentially 
elucidates a more common pathogenic pathway in EAC.
Young patients with EAc
Treatment for cancers has substantially improved over the past few decades, resulting in 
increased survival. Unfortunately, the outcome of young adults diagnosed with cancer 
including melanoma, colorectal cancer, breast cancer, and thyroid cancer remains poor.41 
EAC is most commonly diagnosed at the age of 70 years.42 However, the incidence of EAC 
in young adults (aged ≤50 years) has been rising  (www.cijfersoverkanker.nl).
Chapter 7 and chapter 8 of this thesis show that more than 10% of patients diagnozed 
with EAC in the Netherlands are aged ≤50 years. This is in accordance with a study from 
the USA.43 Patients with advanced EAC often present with dysphagia. Young patients 
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report a longer period of dysphagia prior to diagnosis, as has been found by others.43-46 
Upper gastrointestinal symptoms in younger patients might often be ascribed to be-
nign conditions instead of being recognized as cancer symptoms. In addition, current 
guidelines do not indicate an endoscopy for younger patients (age ≤50 years) presenting 
with dysphagia without other alarming signs or symptoms. 47 This may cause a delay in 
diagnosis. 
In chapter 7 some 1,314 patients with EAC, who underwent esophagectomy were 
studied. There were no differences in tumor grade, TNM-stage, and survival between 
patients aged ≤50 years and their older counterparts. This is in agreement with the study 
of Markar et al.43 The similarity in pathology and outcome after surgery of the two age 
groups can be explained by the applied selection criteria resulting in a homogeneous 
cohort of patients eligible for surgery based on TNM-stage and adequate performance 
status. In chapter 8, 13,331 patients diagnosed with EAC were selected, including patient 
with locally advanced tumors, patients with distant metastasis, and patients who were 
not fit for surgery. This revealed that younger patients presented with positive lymph 
nodes and distant metastasis more often. However, despite a more advanced tumor 
stage, younger patients underwent surgery more often (with or without neoadjuvant 
therapy) as compared to older patients. In patients that did not undergo surgery the 
younger group received more often chemotherapy, while radiotherapy, which is less 
toxic, was applied more often in older patients. A possible explanation might be the 
higher prevalence of co-morbidities in older patients,48-51 whilst younger patients have a 
better physical condition. Hence, more aggressive treatments are offered to the younger 
patients. Nonsurgical complications were seen less often and in-hospital mortality was 
lower in younger age groups. This could explain the finding of a better overall survival in 
the younger patients. It can be expected that medical specialists treat younger patients 
with more aggressive and potentially toxic therapies to obtain improved survival rates. As 
expected, considering the higher prevalence of co-morbidities and incidence of compli-
cations among older patients, the overall survival for the younger patients was higher as 
compared to their older counterparts. This was true for overall survival after surgical and 
nonsurgical treatments. After adjustment for the survival in the general population with 
the same structure for age and gender, the relative survival rates were similar between 
both age groups. Despite the more advanced disease stage in younger patients present 
with at the time of diagnosis, they obtain relative survival rates similar to that of the 
elderly patients, most likely due to application of more aggressive treatment strategies. 
There is a relative lack of clinical trials including young adults with cancer. If biological dif-
ferences exist between younger and older patients with EAC optimal treatment may also 
be different for the two age groups. It has been described that the oncogenic pathways 
153
General discussion
10
in colorectal cancer, breast cancer and melanoma are different between younger and 
old patients.52,53 From a molecular point of view individuals can be predisposed to early 
onset cancer through hereditary factors, including EAC as discussed in chapter 5 and 
chapter 6. However, the majority of early onset cancers are probably sporadic without a 
genetic predisposition. 
In chapter 9 of this thesis the molecular spectrum, i.e. mutational load and mutational 
profile, of patients diagnosed with EAC aged ≤40 years (early onset EACs) was deter-
mined and compared with patient diagnosed with EAC at the average age of ≥68 years. 
In order to ensure a clear segregation of the two entities and to avoid any overlap, 
patients between 41 and 67 years were excluded. Conceptually, in tumors originating 
from self-renewing tissues, the number of mutations is correlated with age. More than 
half of the mutations in tumors occur during the pre-neoplastic phase, which is evidently 
longer for older patients.54 In chapter 9 no difference in mutational load was observed 
between the EAC patients aged ≤40 years and the patients aged ≥68 years, which can 
probably be explained by the presence of an increased mutator phenotype in the young 
adults, i.e. cancer progression in which mutations develop in a rapid burst resulting in an 
accelerated accumulation of mutations. Hence, young adults with early onset EAC have a 
comparable mutational load as their older counterparts.55 
With regard to the molecular profile, others have found as previously, TP53 is the most 
commonly mutated gene in EACs,8-10,56 followed by P16.9 This mutation pattern was ob-
served in chapter 9 as well: TP53 was altered in 75% and P16 in 16% of the patients with 
EAC. Although the percentage of TP53 and P16 mutations was comparable between the 
patients aged ≤40 years and the patients aged ≥68 years, the profile of additional muta-
tions found in early onset EACs includes different genes compared to the older patients 
with EACs. Moreover, the genes mutated in the young EAC patients were mostly classified 
to cell fate pathways (APC, CDH1, CTNNB1, FGFR2, and STK11), while the genes mutated 
in the conventional EACs were classified to cell survival pathways (ABL1, FBXW7, GNA11, 
GNAS, KRAS, MET, SMAD4, and VHL).57 These findings indicate that the development of 
EAC requires, regardless of the age of onset, a TP53 mutation mostly accompanied by a 
P16 mutation. However, the additional mutations needed to probably induce the malig-
nant transformation in young patients with early onset EACs seem to occur in different 
genes, related to different pathways, as compared to the additional mutated genes in 
older EACs patients. Different pathways underlining the possible different genetic make 
up of EAC between young and older patients could indicate that (targeted) treatment 
may have to be adapted. 
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Observations from the clinical and molecular studies suggest that there might be a 
distinct biology of EAC affecting young patients. With molecular profiling and NGS 
technology including whole genome and exome sequencing, becoming widely avail-
able, this may improve the molecular classification of EAC and help to identify specific 
biological entities, and refine our understanding of the impact of age on cancer biology, 
and impact on patient management.
fUTUrE PErsPEcTiVEs
cell free tumor DnA
Molecular testing on tissue samples derived from surgical resection specimens or 
small tumor biopsies remains the standard of care. However, intratumor heterogeneity 
in EAC would mandate multiple biopsies from a tumor, it surrounding premalignant 
BE and the metastatic sites at multiple time points. This is neither feasible nor ethical 
given the invasiveness of the procedure, risk of complications, and economic and logistic 
consequences. Molecular analysis of circulating cell-free tumor DNA (ctDNA) derived 
from blood samples is a novel method, which can be performed at multiple time-points 
and possibly better represents the dominant molecular profile of EAC than a single site 
biopsy, since the fragments of ctDNA are released in the blood from diverse tumor sites. 
This technique is also known as “liquid biopsy” and could also be used for monitoring the 
molecular profile of EACs over time. Possible clinical applications might be the analysis 
of ctDNA to evaluate the response to nCRT, to identify the complete responders prior to 
surgery to prevent them of having an esophagectomy. In addition it may be used as a 
biomarker to monitor disease progression or recurrence. 
familial EAc
It is been estimated that five percent of all human cancers are caused by an inherited 
factor. The patterns of inheritance in most familial cancer syndromes are consistent with 
an autosomal dominant inheritance pattern with a high penetrance. This means that 
offspring of patients have a 50% risk to inherit the disease and most of the individuals, 
who are susceptible will develop symptoms. Cancers diagnosed before the age of 50 
years have relatively high chance to have been caused by an inherited factor.
Seven percent of patients diagnosed with BE and EAC is considered familial, and the 
pattern of inheritance of families with clustering of BE and EAC is consistent with a phe-
notypic autosomal dominant inheritance. The definition of FBE suggests familial BE and 
familial EAC to be part of the same genetic trait. However, BE is much more prevalent 
among the common population and familial BE does not necessarily have to be the 
155
General discussion
10
underlying condition of familial EAC. Although familial EAC might be the result of accel-
erated malignant progression from familial BE, it might also be distinct from most familial 
BE. The possibility of familial EAC as a distinct entity should be considered. A (inter)na-
tional consortium for familial EAC should be established to enlarge our knowledge about 
familial EAC, to set up and coordinate research, and improve the care for patients with 
familial EAC. Most important is to find consensus about an accepted definition of familial 
EAC. Criteria that warrant further testing could be based on the criteria as defined for 
hereditary diffuse gastric cancer: 58
- Gastric cancer diagnosed in one family member before the age of 40 year or
- Gastric cancer diagnosed in two first- or second-degree relatives, of whom one was 
diagnosed before the age of 50 years or
- Gastric cancer diagnosed in three first- or second-degree relatives, regardless of the 
ages.
A clear and scientifically valid definition of familial EAC creates the opportunity to start 
a wide search for the identification of germline defects in these families, with the aid of 
new techniques e.g. genome/exome sequencing, enables testing of unaffected family 
members for the presence of the specific germline defect in order to counsel predisposed 
individuals at an early stage in their life.
Young patients with EAc
Over the last decades it has become apparent that patients diagnosed with cancer aged 
≤40 years have not obtained the same improvements in survival as their older counter-
parts. In addition, it is striking that in terms of long-term survival expectations the most 
favourable ages are >40 years. Reasons for this deficit in survival improvements are the 
lack of awareness of cancer in younger patients and the lack of clinical trial activity and 
participation among younger patients with cancer.59 When focussing on EAC, although 
survival rates are comparable between the younger and the older patients, clinical trials 
barely include younger patients. It should be recommended to include younger patients 
into clinical trials. In addition, more biological studies should be performed in order to 
obtain more knowledge about how tumors from younger patients differ from those 
of older patients on a molecular level to produce new targets for intervention, so that 
survival rates for younger patient can be improved. 
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sUMMArY
This thesis highlighted that the population of EAC patients appears to be relatively 
heterogeneous, including patients with sporadic cancers, patients with a positive family 
history for EAC and BE, and young aged patients.  The aim of this thesis was to elucidate 
the molecular biology of EAC by performing standard molecular analysis, i.e. whole- 
exome sequencing, targeted sequencing and Sanger sequencing on sporadic, familial 
and young EAC cases. In addition, clinicopathological features of families with clustering 
of EAC and BE and young individuals with EAC were studied.
The introduction to this thesis (chapter 1) highlights the growing concerns about 
EAC. The incidence of both EAC and the premalignant lesion BE has been rising over 
the last decades. Despite the improvements in multimodality treatment (nCRT followed 
by surgery) the prognosis of EAC remains relatively poor. In addition, there is a lack of 
discriminative oncological biomarkers that might support the rationale for a BE surveil-
lance program, in order to identify BE patients with a high risk of neoplastic progression.
In chapter 2,  a considerable level of genetic intratumor heterogeneity was revealed 
with the aid of multiregional targeted sequencing of a panel of frequently mutated 
genes in EAC. TP53 alterations were found to be present early in the BE progression, 
followed by P16 inactivation, and therefore both these alterations were homogenously 
present  in the entire tumors. However, alterations of SMAD4 and APC differed among 
tumor regions and distinct disease sites (BE and lymph node metastasis), representing 
intratumor heterogeneity of EACs. 
Chapter 3 comprises a short-report, which revealed, with the aid of a multiplex 
SNaPShot essay,  that somatic shotspot mutations in the promoter of the gene coding 
for telomerase reverse transcriptase (TERT) catalytic subunit do not occur in EAC. This 
suggests that EACs might have alternative mechanisms to maintain telomere length, and 
may therefore be less likely to benefit from activating mutations in TERT.
In chapter 4, SNPs as patient specific biomarkers were considered to avoid the pos-
sible consequence of inter- and intratumor heterogeneity in the search for oncological 
biomarkers. The first GWAS on BE and EAC identified, among several others, the SNPs 
rs10419226 (CRTC1) and rs11789015 (BARX1) to be associated with the risk of EAC. This 
association was validated in a case-control study.  These findings suggest that the risk of 
EAC is influenced by genetic variants that are common in the population, and therefore 
the susceptibility to EAC is not equally distributed among the population. 
In chapter 5 the appearance of families with clustering of BE and EAC was described. 
Families consisting of two or more first- or second-degree family members diagnosed 
with BE and/or EAC are termed “familial Barrett’s esophagus” (FBE) and comprise approxi-
mately seven percent of all patients diagnosed with BE or EAC. Most patients meeting the 
criteria for FBE are diagnosed at a younger age than sporadic cases and a (phenotypic) 
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autosomal dominant pattern of inheritance has been suggested. Until today, extensive 
candidate gene and linkage analysis has been unsuccessful in identifying genetic vari-
ants that are associated with FBE.
In chapter 6 a family meeting the criteria for FBE was investigated by whole-exome 
sequencing. A rare variant in the MSX1 gene was identified heterogeneously in the 
germline DNAs of all affected family members, and in addition somatic loss of the wild 
type allele of the MSX1 gene was identified in the tumor DNAs. This suggests a prominent 
role of this germline defect in the development of BE and EAC in this particular family. 
Although this MSX1 variant may be unique for this particular family, it may also indicate 
a more common pathogenic pathway in EAC, when it is demonstrated to be pathogenic. 
Chapter 7 and chapter 8 demonstrated that currently in the Netherlands about ten 
percent of the patients diagnosed with EAC age ≤50 years. Young patients presented with 
positive lymph nodes and distant metastasis more often when compared to their older 
counterparts. However, despite the more advanced tumor stage the younger patients 
underwent surgery more often. With regard to palliative treatment, younger patients 
received chemotherapy more often while in the older patients radiotherapy was applied 
more frequently. This was probably due to the better physical condition and the absence 
of co-morbidities in young patients with EAC. Despite the more advanced disease stage 
younger patients present with at the time of diagnosis, they obtain comparable relative 
survival rates with elderly patients, probably due to application of more aggressive treat-
ment strategies.
In chapter 9 the molecular spectrum, i.e. mutational load and mutational profile, of 
patients diagnosed with EAC aged ≤40 years was determined and compared with pa-
tients diagnosed with EAC at the average age of ≥68 years. No difference in mutational 
load was observed between the EAC patients aged ≤40 years and the patients aged 
≥68 years. The amount of TP53 and P16 mutations in the young and older patients was 
comparable, while the profile of additional mutations was different between the two age 
groups. The genes mutated in the young EAC patients were mostly classified to cell fate 
pathways (APC, CDH1, CTNNB1, FGFR2, and STK11), while the genes mutated in the older 
EACs patients were classified to cell survival pathways (ABL1, FBXW7, GNA11, GNAS, KRAS, 
MET, SMAD4, and VHL). From a treatment perspective, different pathways could indicate 
different inhibitors for targeted therapy.
Chapter 10, the general discussion of this thesis, comprises brief summaries of all 
previous chapters, the main conclusions and points of discussion. Overall it is concluded 
that the search for oncological biomarkers is hampered by the extent of intratumor 
heterogeneity of EACs. To avoid the consequences of intratumor heterogeneity, com-
mon genetic variants in the population (SNPs) can be used to asses individual genetic 
susceptibility for BE and EAC.
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Seven percent of all patients diagnosed with BE or EAC has at least one other first- or 
second-degree family member diagnosed with BE or EAC, defined as FBE. In the search 
for genetic variants associated with FBE, a mutation in the MSX1 gene was identified by 
whole-exome sequencing in a family consistent with the criteria for FBE. Approximately 
ten percent of the EAC patients aged ≤50 years. They present with more advanced dis-
ease stage, however obtain relative survival rates similar to the elderly patients, most 
likely due to application of more aggressive treatment strategies. In addition, although 
the mutational load between tumors from young and older patients is comparable, the 
mutational spectrum is different besides the frequent mutations in TP53 and P16. 
future recommendations arising from this thesis are:
•	 Molecular analysis of circulating cell-free tumor DNA (ctDNA) derived from blood 
samples is a novel method, which can be performed at multiple time-points and 
possibly represents the dominant molecular profile of EAC better than a single site 
biopsy. Possible clinical applications might be the analysis of ctDNA to evaluate the 
response to nCRT, there by identifying the complete responders prior to surgery to 
prevent them from undergoing  an esophagectomy
•	 Familial EAC should be considered a distinct entity . A (inter)national consortium for 
familial EAC should be established to enlarge our knowledge about familial EAC, to 
set up and coordinate research, and toimprove the care for patients with familial EAC. 
It is highly important is to reach consensus about an accepted definition of familial 
EAC.
•	 It should be recommended to include younger patients into clinical trials. In addition, 
more biological studies should be performed in order to obtain more knowledge 
about how tumors from younger patients differ from those of older patients on a 
molecular level to produce new targets for intervention, so that survival rates for 
younger patient can be improved.
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nEDErlAnDsE sAMEnVATTinG
De incidentie van slokdarmkanker is de laatste decennia sterk toegenomen in Nederland 
en andere Westerse landen. Deze stijging is met name te wijten aan een toename van 
het adenocarcinoom. Barrett epitheel is het premaligne voorstadium van het adenocar-
cinoom. De kans om vanuit Barrett epitheel een adenocarcinoom te ontwikkelen wordt 
geschat op minder dan één procent per jaar.
Doordat de diagnose slokdarmkanker veelal in een laat stadium van de ziekte wordt 
gesteld, komt slechts minder dan de helft van de patiënten in aanmerking voor een in 
opzet curatieve behandeling. Dit resulteert in een 5-jaars overleving van ongeveer 50%. 
De overige patiënten worden palliatief behandeld, waarmee een 2-jaars overleving van 
negen procent wordt behaald.
Gezien de slechte prognose van slokdarmkanker worden patiënten met Barrett epi-
theel onderworpen aan een endoscopisch onderzoek. Dit onderzoek wordt, afhankelijk 
van de aanwezigheid van laaggradige dysplasie, om de 6 maanden, 12 maanden, 3 jaar 
of 5 jaar verricht. De beoordeling van laaggradige dysplasie is sterk afhankelijk van de 
hoeveelheid en de plaats van de biopten en van de patholoog. Echter, momenteel is 
de diagnose laaggradige dysplasie de enige voorspeller voor het ontwikkelen van een 
adenocarcinoom. Het vinden van een moleculaire marker die kan voorspellen welke 
patiënten met Barrett epitheel een hoog risico hebben op het ontwikkelen van een 
adenocarcinoom is noodzakelijk. Daarnaast zou een moleculaire marker, als target voor 
aanvullende therapieën, kunnen bijdragen aan het verbeteren van de prognose van 
slokdarmkanker. 
Tijdens de zoektocht naar moleculaire markers voor slokdarmkanker wordt er vanuit 
gegaan dat het een niet-erfelijke ziekte betreft van de oudere mens. Echter, in dit proef-
schrift wordt de nadruk gelegd op verschillende groepen patiënten met slokdarmkanker, 
zoals patiënten met een positieve familiegeschiedenis voor Barrett epitheel en/of het 
adenocarcinoom en jonge patiënten met slokdarmkanker, naast de grootste groep pati-
enten met een niet-erfelijke tumor. Het doel van dit proefschrift is om door middel van 
standaard moleculaire analyses de moleculaire biologie van het adenocarcinoom van de 
slokdarm te ontrafelen met inachtneming van de verschillende subpopulaties.
Geen twee tumoren, ook al van hetzelfde type, zijn hetzelfde. Zelfs binnen één tumor 
zijn grote verschillen aanwezig, hetgeen intratumor-heterogeniteit wordt genoemd. 
Verschillende delen van een tumor op verschillende tijdstippen laten variatie zien op 
moleculair niveau. Intratumor-heterogeniteit draagt bij aan de tumorgroei via een 
vertakt patroon (Branched evolution), zoals Marco Gerlinger voor het eerst beschreef 
in niertumoren. Als gevolg van intratumor-heterogeniteit worden niet alle mutaties 
van een tumor gedetecteerd in alle biopten, waardoor het aantal mutaties van de 
gehele tumor wordt onderschat. In hoofdstuk 2 werd door middel van het sequensen 
Chapter 11
168
van meerdere biopten van vijf adenocarcinomen van de slokdarm een zekere mate van 
intratumor-heterogeniteit vastgesteld. Mutaties in TP53 en P16 werden in nagenoeg alle 
tumorbiopten aangetroffen en tevens in het bijbehorende Barrett epitheel.  Dit geeft aan 
dat zowel mutaties in TP53 en P16 vroeg in de ontwikkeling van een adenocarcinoom 
van de slokdarm ontstaan, zich klonaal verspreiden en daardoor in alle biopten aanwezig 
zijn. Echter, mutaties in APC en SMAD4 bleken niet aanwezig in alle tumorbiopten en ook 
niet in het Barrett epitheel. Dit betekent dat deze mutaties in een later stadium van de 
ziekte ontstaan en een zekere mate van intratumor-heterogeniteit veroorzaken  in het 
adenocarcinoom van de slokdarm. 
Hoofdstuk 3 betreft een zogeheten ‘short-report’ waarin met behulp van een SNaP-
shot analyse werd aangetoond dat veel voorkomende mutaties in de promotor van 
het gen dat codeert voor telomerase reverse transcriptase (TERT) niet voorkomen in 
het adenocarcinoom van de slokdarm. Dit suggereert dat deze tumoren een alternatief 
mechanisme gebruiken om lengte van de telomeren te behouden. 
Om de consequenties van intratumor-heterogeniteit te vermijden in de zoektocht 
naar moleculaire markers kan gebruik gemaakt worden van patiënt specifieke markers 
in plaats van tumor specifieke markers. Dit kan bijvoorbeeld in de vorm van een SNP 
(een plaatst op het chromosoom bestaande uit een enkel basenpaar (C en G of A en T), 
waarop in minstens één procent van de populatie een variatie in de nucleotide wordt 
gevonden). Recent zijn door middel van een genoomwijde associatiestudie (GWAS) 
enkele SNPs geïdentificeerd die geassocieerd zijn met het risico op Barrett epitheel en 
het adenocarcinoom van de slokdarm.
 In hoofdstuk 4 werd de associatie met SNP rs10419226 in het gen CRTC1 en met SNP 
rs11789015 in het gen BARX1 en het risico op een adenocarcinoom van de slokdarm 
bevestigd door middel van een patiënt-controle studie. Dit zou kunnen betekenen dat 
kwetsbaarheid voor het ontwikkelen van een adenocarcinoom van de slokdarm niet 
evenredig is verdeeld over de populatie en dat bepaalde individuen een hoger risico 
hebben op basis van hun genetische profiel.
Het adenocarcinoom van de slokdarm is in het algemeen een niet-erfelijke vorm van 
kanker. Echter, de laatste jaren zijn er steeds meer aanwijzingen voor een erfelijke vari-
ant van het adenocarcinoom van de slokdarm. Hoofdstuk 5 geeft een overzicht van de 
literatuur die tot op heden bekend is over de erfelijke vorm van het adenocarcinoom 
van de slokdarm. Er wordt gesproken van ”familiaire Barrett’s esophagus” (FBE) indien 
er twee of meer eerste- of tweedegraads familieleden zijn gediagnosticeerd met Barrett 
epitheel of een adenocarcinoom van de slokdarm. De prevalentie hiervan wordt geschat 
op ongeveer zeven procent.  Het merendeel van de patiënten die voldoen aan de criteria 
van FBE krijgen de diagnose op een lagere leeftijd dan patiënten met de niet-erfelijke 
variant. De overerving in deze families lijkt via een (fenotypisch) autosomaal dominant 
patroon te verlopen. Vooralsnog is er geen eenduidig oorzakelijk gendefect bekend voor 
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FBE. In hoofdstuk 6 werd een familie beschreven die voldoet aan de criteria van FBE. 
Deze familie werd tevens onderworpen aan kiembaan DNA onderzoek, waarmee zowel 
gezond weefsel als tumorweefsel van de aangedane familieleden werd onderzocht. 
Een zeldzame mutatie  in het gen MSX1 werd gevonden in de gezonde weefsels van de 
aangedane familieleden en tevens werd er verlies van het wild type allel gevonden in het 
tumorweefsel van twee familieleden. Dit zou kunnen betekenen dat de mutatie in MSX1 
een prominente rol speelt in de ontwikkeling van Barrett epitheel en adenocarcinoom 
van de slokdarm in deze specifieke familie.
In hoofdstuk 7 en hoofdstuk 8 werd beschreven dat in Nederland ongeveer tien 
procent van de patiënten met een adenocarcinoom van de slokdarm ≤50 jaar is. Deze 
jonge patiënten presenteren zich vaker met uitzaaiingen in de lymfeklieren en andere 
organen als ze vergeleken worden met oudere patiënten met een adenocarcinoom van 
de slokdarm. Ondanks dit verder gevorderde ziektestadium ondergingen jonge patiën-
ten vaker een slokdarmresectie en werd vaker chemotherapie gegeven in het kader van 
een palliatieve behandeling, terwijl de oudere patiënten vaker radiotherapie kregen. Het 
krijgen van meer agressieve vormen van therapie voor jonge patiënten kon mogelijk 
verklaard worden door de betere fysieke conditie en de afwezigheid van co-morbidi-
teiten, waardoor ze de therapieën beter tolereerden. Dit resulteerde uiteindelijk in een 
overeenkomstige relatieve overleving tussen de jonge en de oudere patiënten met een 
adenocarcinoom van de slokdarm.
Over het algemeen wordt aangenomen dat kanker een ziekte van de oudere mens 
is. Deze gedachte wordt ondersteund door de aanwijzingen dat de verandering van 
een normale cel in tumor cel en vervolgens een manifeste tumor enkele tientallen jaren 
duurt, en minstens drie mutaties in ‘driver’ genen vereist (genen die de celgroei regelen). 
In hoofdstuk 9 werd onderzocht of adenocarcinomen van de slokdarm afkomstig van 
jonge patiënten (≤40 jaar) op moleculair niveau verschillend zijn van de tumoren afkom-
stig van oudere patiënten  (≥68 jaar). Een panel bestaande uit de meest voorkomende 
kankergerelateerde genen werd onderzocht in het tumorweefsel van een groep jonge 
patiënten en vergeleken met het tumorweefsel van een groep oudere patiënten. De hoe-
veelheid mutaties bleek niet verschillend tussen beide leeftijdsgroepen. De genen TP53 
en P16 bleken evenredig gemuteerd in zowel de jonge als de oudere patiënten.  Echter, 
naast de TP53 en de P16 mutatie bleek het palet aan andere mutaties te verschillen tus-
sen de jonge patiënten en de oudere patiënten. In de jonge patiënten bleken de genen 
APC, CDH1, CTNNB1, FGFR2, en STK11 gemuteerd en in de oudere patiënten de genen 
ABL1, FBXW7, GNA11, GNAS, KRAS, MET, SMAD4  en VHL. Deze bevindingen suggereren 
dat adenocarcinomen van de slokdarm in jonge patiënten, naast de veel voorkomend 
mutaties in TP53 en P16, andere mutaties hebben dan oudere patiënten.  
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Hoofdstuk 10 is de algemene conclusie van dit proefschrift en bevat een korte samen-
vatting van alle voorgaande hoofdstukken met tevens de conclusies en de punten 
van discussie. Geconcludeerd kan worden dat de zoektocht naar moleculaire markers 
verstoord wordt door een zekere mate van intratumor-heterogeniteit, waardoor biopten 
van een adenocarcinoom van de slokdarm een onderschatting geven van de hoeveel-
heid mutaties. Om de gevolgen van intratumor-heterogeniteit te omzeilen kan gebruik 
worden gemaakt van zogeheten SNPs, waarmee de kwetsbaarheid van een individu voor 
het krijgen van een adenocarcinoom van de slokdarm ingeschat kan worden. Zeven 
procent van de patiënten met Barrett epitheel of een adenocarcinoom van de slokdarm 
hebben tenminste nog één eerste- of tweedegraads familielid  met een van deze beide 
aandoeningen. De term ‘familiaire Barrett’s esophagus’ wordt hiervoor gebruikt. In een 
familie met familiaire Barrett’s esophagus werd een zeldzame mutatie in het MSX1 gen 
gevonden. De relevantie van het MSX1 gen in andere families die aan de criteria voldoen 
moet nog onderzocht worden. Tien procent van de patiënten met een adenocarcinoom 
van de slokdarm zijn ≤50 jaar en presenteren zich met een verder gevorderd ziekte sta-
dium. Echter, als gevolg van agressievere therapieën behalen zij een overeenkomstige 
relatieve overleving met de oudere patiënten. Naast de veel voorkomende mutaties in 
de genen TP53 en P16, bezitten de tumoren van jonge patiënten andere mutaties dan die 
van de oudere patiënten. 
Aanbevelingen voor de toekomst:
•	 Moleculaire analyse van circulerend celvrij tumor DNA afkomstig uit bloed bevat het 
volledige moleculaire profiel van een tumor en kan tevens op een minimaal invasieve 
manier op multipele tijdsintervallen worden afgenomen. Het analyseren van circule-
rend celvrij tumor DNA kan klinisch relevant zijn voor het evalueren van de respons 
op neoadjuvante chemoradiotherapie, om te voorkomen dat patiënten die volledig 
responderen  geopereerd worden. 
•	 Familiair adenocarcinoom van de slokdarm zou als een op zichzelf staande entiteit 
moeten worden beschouwd. Men neemt aan dat het familiair voorkomen van zowel 
Barrett epitheel als het adenocarcinoom het gevolg is van eenzelfde erfelijke aan-
legfactor. Echter, gezien de hoge prevalentie van Barrett epitheel in de algemene 
populatie, hoeft dit premaligne voorstadium niet per definitie ook de onderliggende 
conditie te zijn voor het veel zeldzamere familiaire adenocarcinoom.  
•	 Om de overleving van jonge patiënten met een adenocarcinoom van de slokdarm 
te verbeteren, moeten meer jonge patiënten geïncludeerd worden in klinische 
trials. Daarnaast zouden er meer moleculair biologische studies uitgevoerd moeten 
worden om te achterhalen of  tumoren van jonge patiënten op moleculaire niveau 
verschillen van die van oudere patiënten  om zodoende nieuwe aangrijpingspunten 
voor therapieën te ontwikkelen. 
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Presentations
Congres van de Nederlandse Vereniging voor Gastro-
Enterologie (NVGE) – voorjaarsconferentie
The influence of young age on outcome after esophagectomy 
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Veldhoven 2012 1 ECTS
13th World Congress of the International Society for Diseases of 
the Esophagus
The influence of young age on outcome after esophagectomy 
for cancer. (poster)
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26ste Symposium van Experimenteel Onderzoek Heelkundige 
Specialismen (SEOHS)
Early genomic aberrations in esophageal adenocarcinoma as 
potential markers for malignant progression. (oral)
Maastricht 2013 1 ECTS
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Banff, 
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Esophagus
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Congres van de Nederlandse Vereniging voor Gastro-
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enterologie (NVGE) voorjaarsconferentie
Molecular profile of young esophageal adenocarcinoma 
patients. (oral)
Veldhoven 2015 1 ECTS
2. Teaching
2e jaars keuzeonderwijs – Kanker: de arts/onderzoeker in 
relatie tot de patient
2013-2015 3 ECTS
Erasmus anatomy and research project (EARP) – abdomen. 
(assistant)
2013 3 ECTS
Erasmus anatomy and research project (EARP) – abdomen. 
(tutoring)
2014 3 ECTS
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Annemarie was born on November 7th 1988 in Gilze en Rijen, where she grew up as well. 
She attended secondary school (Cambreur College) in Dongen, from which she graduated 
in 2007. The first year after graduation she studied Health Policy & Management at the 
Erasmus University Rotterdam. In 2008 she started her medical training at the Erasmus 
Medical Center Rotterdam. Parallel to her medical study she started a Research Master 
in Clinical research at the Netherlands Institute for Health Sciences, for which she at-
tended Summer school at Johns Hopkins University School of Public Health in Baltimore, 
United States. As part of the Research Master program she started her research project 
at the laboratories of Molecular Diagnostics under the supervision of dr. Dinjens in col-
laboration with the Department of Surgery under supervision of dr. Wijnhoven. After she 
obtained her Master of Science Degree in Clinical Research and finished the theoretical 
part of her medical school, she got the opportunity to proceed with her research project 
as a PhD candidate at the department of Surgery and Pathology (prof. dr. van Lanschot, 
prof. dr. van Kemenade). In order to finish her medical school, she started her clinical 
rotations in March of 2014. In February of 2016 she obtained her medical degree, after 
which she started as a resident (not in training) at the department of Surgery at the Ikazia 
Hospital Rotterdam under the supervision of dr. den Hoed.
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door de Rotterdamse Slokdarmstichting. Ik ben hier enorm dankbaar voor.
Veel dank aan alle co-auteurs, zonder jullie was dit proefschrift er niet geweest.
Beste Conny Vollebregt, bedankt voor de eindeloze sessies eentjes in nullen veranderen 
en vice versa en voor alle kletspraatjes. Vanessa en Carola, hartelijk dank voor jullie hulp 
bij al het andere dat nog komt kijken bij een promotie.
Chirurgen en collega’s uit het Ikazia ziekenhuis. Wat ben ik trots dat ik onderdeel mag 
uitmaken van jullie team. Bedankt voor alle ervaringen tot nu toe en hopelijk volgen 
er nog veel meer. Lieve Inge en Mostafa, jullie hebben binnen 6 uur mijn hart veroverd.
(Oud) collega’s van het Moldiag lab: Erik-Jan, Peggy, Lotte, Ina, Isabel, Ruth, Hein, Gerard, 
Erwin, Hetty, Hester, en natuurlijk Ludo, bedankt voor jullie hulp en uitleg bij alle experi-
menten en uiteraard voor de gezelligheid. Zonder jullie was dit boekje niet geweest wat 
het nu is.
Ronald, mijn constante factor tijdens mijn onderzoekperiode. Wat weet jij ontzettend 
veel, dank dat je een (klein) deel van je kennis met mij hebt willen delen. 
Esther, wat fijn dat ik jou heb leren kennen. Gouden jaren voor de DE en heel veel goede 
en gezellige gesprekken voor ons onder het genot van een lekkere cappuccino. Maar ook 
buiten het Erasmus MC hebben we het gezellig gehad samen, met als kers op de taart 
onze trip naar Canada, wat hebben we gelachen en wat heb jij mij uitgelachen op die 
ski’s.  Dat mijn tijd als onderzoekster erop zit betekent niet dat onze vriendschap voorbij 
is.
Onderzoekers van de Heelkunde en de Pathologie, bedankt voor de gezelligheid tijdens 
koffiepauzes, borrels, etentjes en congressen.
Lieve Emma en Elvira, wat geweldig dat jullie vandaag naast mij willen staan als mijn 
paranimfen. Met jullie aan mijn zijde kan mij niks meer gebeuren.
Elvira, nadat wij eerst wat om elkaar heen draaiden, moesten we er toch aan geloven. 
Het begon als een dansje met een drankje en het groeide uit tot een ware vriendschap, 
waarin we werkelijk alles met elkaar kunnen delen. Wat ben ik trots op jou, prachtige 
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blondine met je ongelofelijke onderzoekskills. Bedankt voor je vriendschap, hopelijk 
worden we heel snel collega’s.
Emma, gelukkig bracht dat ene, net iets minder leuke, jaar ons deze vriendschap. Wij 
zitten altijd op een lijn, kunnen overal over praten en veroordelen elkaar nooit. Jouw car-
rière volgde een ander pad, wat ben je een ambitieuze, harde werker en een ongelofelijk 
goede onderzoekster. Heel veel dank voor jouw vriendschap de afgelopen 10 jaar (we 
worden oud). Ik kijk uit naar jouw twee grote dagen!
Alle fantastische dokters uit mijn co-groepje, bedankt voor de ontzettend leuke tijd 
tijdens de coschappen. 
Wat moet een meisje zonder vriendinnen? Lieve meiden, bedankt voor alle steun, inte-
resse, peptalks, gezelligheid, maar bovenal bedankt voor jullie vriendschap. Een paar van 
jullie wil ik graag in het bijzonder bedanken.
Lieve Marloes, mijn beste vriendin vanaf het eerste moment. Samen groeiden wij op in 
Rijen (of op de Rijen), op de peuterspeelzaal, de Brakken, het Cambreur College altijd 
hand in hand of zij aan zij. Onze wegen splitsten van Rotterdam naar Groningen, Nijme-
gen, Brussel en Maastricht. Dit heeft gelukkig nooit afbreuk gedaan aan onze vriend-
schap en daar ben ik ongelofelijk dankbaar voor. Je bent een prachtige, eerlijke vrouw, 
die iedereen voor vol aanziet en die geen verschil maakt, waarmee je kan lachen, kan 
huilen en een goed gesprek kan voeren. Dit jaar vierden wij ons 25-jarig jubileum en ik 
hoop dat onze vriendschap everlasting is! 
Lieve Nikki (Rollé), ik gun iedereen een vriendin zoals jij. Jij staat werkelijk 24/7 voor mij 
klaar en daar heb ik meerdere malen gebruik van moeten maken. Ik hoop dat ik voor jou 
net zo’n goede vriendin ben als jij voor mij bent geweest. Ik wens je alle geluk van de 
wereld toe. Love you long time lieve snoes!
Lieve Anouk, jij het meisje met de krullen en ik het meisje met de oranje schoenen (what 
was I thinking?). We hebben al veel meegemaakt samen, maar dat maakt onze vriend-
schap alleen maar sterker.
Lieve Kiki, één ding hebben wij gemeen, we zijn gek op elkaar! Ik ben trots op wat jij 
allemaal voor elkaar hebt gekregen, een echte succesvolle Berliner!
Lieve Martine, toen ik jou zag wist ik meteen dat wij vriendinnen zouden worden en 
volgens mij dacht jij precies hetzelfde. Wat heb ik de afgelopen jaren van jou genoten, 
samen studeren, feesten, eten en drinken, vakantie vieren, eindeloos kletsen en nu zelfs 
knuffelen met jouw lieve Valentijn. Ik ben zo blij dat jij mijn vriendin bent!
Lieve Els, ik benijd jouw eindeloze energie, opgewektheid en positieve kijk op het leven. 
Bedankt voor de gezellige tijd.
Lieve Nelleke, die Research Master leverde mij niet alleen dit proefschrift op maar ook 
een mooie vriendschap met jou. Ik ben ontzettend trost op jou en op little princess!
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Lieve Nikki (Hollestelle) a.k.a koninklijke Hollestelle. Soulmate, wij kunnen samen de hele 
wereld aan!
Lieve Pranita, ons huisje op de Abraham Kuyperlaan voelde als een waar thuis. Je bent 
een fijne vriendin.
Lieve tante Ank, wat hebben wij geboft met u en ome Adriaan als buren. Ik heb zo veel 
mooie herinneringen aan de Vucht, de boot, geroosterde boterhammen met suiker, var-
kensvoer, lasagne, spelletjes en worteltrekken. Ik vind het heel jammer dat ome Adriaan 
er vandaag niet bij kan zijn, maar hij zit voor altijd in mijn hart. 
Liefste zus, alleen wij weten wat echte zusterliefde betekent. Ik ga voor jou door het vuur! 
Ik ben zo trots dat jij mijn grote(kleine), mooie en succesvolle zus bent!
Lieve mama en papa, ik mag van geluk spreken met jullie als mijn ouders.
Mama, jij zorgde voor geborgenheid, gezelligheid en een eindeloze zoete inval bij ons 
thuis. Jij overlaadde Margot en mij met liefde en aandacht en maakte van ons de vrouwen 
die wij nu zijn. Ik kan me geen leukere, lievere en zorgzamere moeder voorstellen dan jij.
Lieve papa, harde werker, jij drukte Margot en mij op het hart dat wij het onderste uit de 
kan moesten halen, ons niets van anderen aan moesten aantrekken en onafhankelijke 
vrouwen moesten worden. Dankzij jouw altijd eerlijke en wijze raad is ons dat hopelijk 
gelukt. 
Bedankt lieve mam en pap voor jullie onvoorwaardelijke liefde en steun, dit proefschrift 
is voor jullie!
Lieve, lieve Ran, bedankt voor jouw hulp en liefde de afgelopen periode. Zonder jou was 
het niet gelukt! 
